Multicellular metabolic models and methods

ABSTRACT

The invention provides a computer readable medium or media, having: (a) a first data structure relating a plurality of reactants to a plurality of reactions from a first cell, each of said reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating said substrate and said product; (b) a second data structure relating a plurality of reactants to a plurality of reactions from a second cell, each of said reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating said substrate and said product; (c) a third data structure relating a plurality of intra-system reactants to a plurality of intra-system reactions between said first and second cells, each of said intra-system reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating said substrate and said product; (d) a constraint set for said plurality of reactions for said first, second and third data structures, and (e) commands for determining at least one flux distribution that minimizes or maximizes an objective function when said constraint set is applied to said first and second data structures, wherein said at least one flux distribution is predictive of a physiological function of said first and second cells. The first, second and third data structures also can include a plurality of data structures. Additionally provided is a method for predicting a physiological function of a multicellular organism. The method includes: (a) providing a first data structure relating a plurality of reactants to a plurality of reactions from a first cell, each of said reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating said substrate and said product; (b) providing a second data structure relating a plurality of reactants to a plurality of reactions from a second cell, each of said reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating said substrate and said product; (c) providing a third data structure relating a plurality of intra-system reactants to a plurality of intra-system reactions between said first and second cells, each of said intra-system reactions comprising a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating said substrate and said product; (d) providing a constraint set for said plurality of reactions for said first, second and third data structures; (e) providing an objective function, and (f) determining at least one flux distribution that minimizes or maximizes an objective function when said constraint set is applied to said first and second data structures, wherein said at least one flux distribution is predictive of a physiological function of said first and second cells.

This application is a continuation of U.S. patent application Ser. No.14/572,615, filed Dec. 16, 2014, which is a continuation of U.S. patentapplication Ser. No. 11/188,136, filed Jul. 21, 2005, now U.S. Pat. No.8,949,032, which is a continuation-in-part of U.S. patent applicationSer. No. 10/402,854, filed Mar. 27, 2003, now U.S. Pat. No. 8,229,673,which claims benefit of the filing date of U.S. Provisional ApplicationNo. 601368,588, filed Mar. 29, 2002, the entire contents of each ofwhich is incorporated herein by reference.

BACKGROUND OF THE INVENTION

This invention relates generally to analysis of the activity of chemicalreaction networks and, more specifically, to computational methods forsimulating and predicting the activity of multiple interacting reactionnetworks.

Therapeutic agents, including drugs and gene-based agents, are beingrapidly developed by the pharmaceutical industry with the goal ofpreventing or treating human disease. Dietary supplements, includingherbal products, vitamins and amino acids, are also being developed andmarketed by the nutraceutical industry. Because of the complexity of thebiochemical reaction networks in and between human cells, evenrelatively minor perturbations caused by a therapeutic agent or adietary component in the abundance or activity of a particular target,such as a metabolite, gene or protein, can affect hundreds orbiochemical reactions. These perturbations can lead to desirabletherapeutic effects, such as cell stasis or cell death in the case ofcancer cells or other pathologically hyperproliferative cells. However,these perturbations can also lead to undesirable side effects, such asproduction of toxic byproducts, if the systemic effects of theperturbations are not taken into account.

Current approaches to drug and nutraceutical development do not takeinto account the effect of a perturbation in a molecular target onsystemic cellular behavior. In order to design effective methods ofrepairing, engineering or disabling cellular activities. it is essentialto understand human cellular behavior from an integrated perspective.

Cellular metabolism, which is an example of a process involving a highlyintegrated network of biochemical reactions, is fundamental to allnormal cellular or physiological processes, including homeostatis,proliferation, differentiation, programmed cell death (apoptosis) andmotility. Alterations in cellular metabolism characterize a vast numberof human diseases. For example, tissue injury is often characterized byincreased catabolism of glucose, fatty acids and amino acids, which, ifpersistent, can lead to organ dysfunction. Conditions of low oxygensupply (hypoxia) and nutrient supply, such as occur in solid tumors,result in a myriad of adaptive metabolic changes including activation ofglycolysis and neovascularization. Metabolic dysfunctions alsocontribute to neurodegenerative diseases, cardiovascular disease,neuromuscular diseases, obesity and diabetes. Currently, despite theimportance of cellular metabolism to normal and pathological processes,a detailed systemic understanding of cellular metabolism in human cellsis currently lacking.

Thus, there exists a need for models that describe interacting reactionnetworks within and between cells, including core metabolic reactionnetworks and metabolic reaction networks in specialized cell types,which can be used to simulate different aspects of multicellularbehavior under physiological, pathological and therapeutic conditions.The present invention satisfies this need, and provides relatedadvantages as well.

SUMMARY OF THE INVENTION

The invention provides a computer readable medium or media, having: (a)a first data structure relating a plurality of reactants to a pluralityof reactions from a first cell, each of said reactions comprising areactant identified as a substrate of the reaction, a reactantidentified as a product of the reaction and a stoichiometric coefficientrelating said substrate and said product; (b) a second data structurerelating a plurality of reactants to a plurality of reactions from asecond cell, each of said reactions comprising a reactant identified asa substrate of the reaction, a reactant identified as a product of thereaction and a stoichiometric coefficient relating said substrate andsaid product; (c) a third data structure relating a plurality ofintra-system reactants to a plurality of intra-system reactions betweensaid first and second cells, each of said intra-system reactionscomprising a reactant identified as a substrate of the reaction, areactant identified as a product of the reaction and a stoichiometriccoefficient relating said substrate and said product; (d) a constraintset for said plurality of reactions for said first, second and thirddata structures, and (e) commands for determining at least one fluxdistribution that minimizes or maximizes an objective function when saidconstraint set is applied to said first and second data structures,wherein said at least one flux distribution is predictive of aphysiological function of said first and second cells. The first, secondand third data structures also can include a plurality of datastructures. Additionally provided is a method for predicting aphysiological function of a multicellular organism. The method includes:(a) providing a first data structure relating a plurality of reactantsto a plurality of reactions from a first cell, each of said reactionscomprising a reactant identified as a substrate of the reaction, areactant identified as a product of the reaction and a stoichiometriccoefficient relating said substrate and said product; (b) providing asecond data structure relating a plurality of reactants to a pluralityof reactions from a second cell, each of said reactions comprising areactant identified as a substrate of the reaction, a reactantidentified as a product of the reaction and a stoichiometric coefficientrelating said substrate and said product: (c) providing a third datastructure relating a plurality of intra-system reactants to a pluralityof intra-system reactions between said first and second cells, each ofsaid intra-system reactions comprising a reactant identified as asubstrate of the reaction, a reactant identified as a product of thereaction and a stoichiometric coefficient relating said substrate andsaid product; (d) providing a constraint set for said plurality ofreactions for said first, second and third data structures: (c)providing an objective function, and (f) determining at least one fluxdistribution that minimizes or maximizes an objective function when saidconstraint set is applied to said first and second data structures,wherein said at least one flux distribution is predictive of aphysiological function of said first and second cells.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a schematic representation of a hypothetical metabolicnetwork.

FIG. 2 shows mass balance constraints and flux constraints(reversibility constraints) that can be placed on the hypotheticalmetabolic network shown in FIG. 1.

FIG. 3 shows the stoichiometric matrix (S) for the hypotheticalmetabolic network shown in FIG. 1.

FIG. 4 shows, in Panel A, an exemplary biochemical reaction network andin Panel B, an exemplary regulatory control structure for the reactionnetwork in panel A.

FIGS. 5-1 through 5-9 show a metabolic network of central humanmetabolism.

FIG. 6 shows an example of a gene-protein-reaction association fortrios-phosphate isomerase.

FIGS. 7-1 through 7-35 show a metabolic network of adipocyte metabolism.

FIG. 8 shows muscle contraction in a myocyte metabolic model.

FIGS. 9-1 through 9-35 show a metabolic network of myocyte metabolism.

FIGS. 10-1 through 10-70 show a metabolic network of coupledadipoctye-myocyte metabolism.

FIG. 11 shows triacylglycerol degradation in an adipocyte model.

FIG. 12 shows the impairment of muscle contraction as a result oflactate accumulation during anaerobic exercise. Time is in arbitraryunit. Concentration and yield of lactate production are in mol/molglucose.

FIG. 13 shows glycogen utilization versus (highlighted on the left)glucose utilization (highlighted on the right) in myocyte.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides in silico models that describe theinterconnections between genes in the Homo sapiens genome and theirassociated reactions and reactants. The invention also provides insilica models that describe interconnections between differentbiochemical networks within a cell as well as between cells. Theinterconnections among different biochemical networks between cells candescribe interactions between, for example, groups of cells includingcells within different locations, tissues, organs or between cellscarrying out different functions of a multicellular organism. Therefore,the models can be used to simulate different aspects of the cellularbehavior of a cell derived from a multicellular organism, including ahuman cell, as well as be used to simulate different aspects of cellularbehavioral interactions of groups of cells. Such groups of cellsinclude, for example, eukaryotic cells, such as those of the same tissuetype or colonies of prokaryotic cells, or different types of eukaryoticcells derived from the same or different tissue types from amulticellular organism. The different aspects of cellular behavior,including cellular behavioral interactions, can be simulated underdifferent normal, pathological and therapeutic conditions. therebyproviding valuable information for therapeutic, diagnostic and researchapplications. One advantage of the models of the invention is that theyprovide a holistic approach to simulating and predicting the activity ofmulticellular organisms, cellular interactions and individual cells,including the activity of Homo sapiens cells. Therefore, the models andmethods can be used to simulate the activity of multiple interactingcells, including organs, physiological systems and whole body metabolismfor practical diagnostic and therapeutic purposes.

In one embodiment, the invention is exemplified by reference to ametabolic model of a Homo sapien cell. This in silica model of aneukaryotic cell describes the cellular behavior resulting from two ormore interacting networks because it can contain metabolic, regulatoryand other network interactions, as described below. The models andmethods of the invention applicable to the production and use of acellular model containing two or more interacting networks also areapplicable to the production and use of a multi-network model where thetwo or more networks are separated between compartments such as cells ortissues of a multicellular organism. Therefore. a Homo sapien or othereukaryotic cell model of the invention exemplifies application of themodels and methods of the invention to models that describe theinteraction of multiple biochemical networks between and among cells ofa tissue, organ, physiological system or whole organism.

In another embodiment, the Homo sapiens metabolic models of theinvention can be used to determine the effects of changes from aerobicto anaerobic conditions, such as occurs in skeletal muscles duringexercise or in tumors, or to determine the effect of various dietarychanges. The Homo sapiens metabolic models can also be used to determinethe consequences of genetic defects, such as deficiencies in metabolicenzymes such as phosphofructokinase, phosphoglycerate kinase,phosphoglycerate mutase, lactate dehydrogenase and adenosine deaminase.

In a further embodiment, the invention provides a model of multicellularinteractions that includes the network reconstruction, characteristicsand simulation performance of an integrated two cell model of humanadipocyte and myocyte cells. This multicellular model also included anintra-system biochemical network for extracellular physiologicalsystems. The model was generated by reconstructing each of the componentbiochemical networks within the cells and combining them together withthe addition of the intra-system biochemical network and achievedaccurate predictive performance of the two cell types under differentphysiological conditions. Such multicellular metabolic models can beemployed for the same determinations as described above for the Homosapiens metabolic models. The determinations can be performed at thecellular, tissue, physiological system or organism level.

The multicellular and Homo sapiens metabolic models also can be used tochoose appropriate targets for drug design. Such targets include genes,proteins or reactants, which when modulated positively or negatively ina simulation produce a desired therapeutic result. The models andmethods of the invention can also be used to predict the effects of atherapeutic agent or dietary supplement on a cellular function ofinterest. Likewise, the models and methods can be used to predict bothdesirable and undesirable side effects of the therapeutic agent on aninterrelated cellular function in the target cell, as well as thedesirable and undesirable effects that may occur in other cell types.Thus, the models and methods of the invention can make the drugdevelopment process more rapid and cost effective than is currentlypossible.

The multicellular and Homo sapiens metabolic models also can be used topredict or validate the assignment of particular biochemical reactionsto the enzyme-encoding genes found in the genome, and to identify thepresence of reactions or pathways not indicated by current genomic data.Thus, the models can be used to guide the research and discoveryprocess, potentially leading to the identification of new enzymes,medicines or metabolites of clinical importance.

The models of the invention are based on a data structure relating aplurality of reactants to a plurality of reactions, wherein each of thereactions includes a reactant identified as a substrate of the reaction,a reactant identified as a product of the reaction and a stoichiometriccoefficient relating the substrate and the product. The reactionsincluded in the data structure can be those that are common to all ormost cells or to a particular type or species of cell, including Homosapiens cells, such as core metabolic reactions, or reactions specificfor one or more given cell type.

As used herein, the term “reaction” is intended to mean a conversionthat consumes a substrate or forms a product that occurs in or by acell. The term can include a conversion that occurs due to the activityof one or more enzymes that are genetically encoded by a genome of thecell. The term can also include a conversion that occurs spontaneouslyin a cell. When used in reference to a Homo sapiens reaction, the termis intended to mean a conversion that consumes a substrate or forms aproduct that occurs in or by a Homo sapiens cell. Conversions includedin the term include, for example, changes in chemical composition suchas those due to nucleophilic or electrophilic addition, nucleophilic orelectrophilic substitution, elimination, isomerization, deamination,phosphorylation, methylation, reduction, oxidation or changes inlocation such as those that occur due to a transport reaction that movesa reactant from one cellular compartment to another. In the case of atransport reaction, the substrate and product of the reaction can bechemically the same and the substrate and product can be differentiatedaccording to location in a particular cellular compartment. Thus, areaction that transports a chemically unchanged reactant from a firstcompartment to a second compartment has as its substrate the reactant inthe first compartment and as its product the reactant in the secondcompartment. It will be understood that when used in reference to an insilico model or data structure, a reaction is intended to be arepresentation of a chemical conversion that consumes a substrate orproduces a product.

As used herein, the term “reactant” is intended to mean a chemical thatis a substrate or a product of a reaction that occurs in or by a cell.The term can include substrates or products of reactions performed byone or more enzymes encoded by a genome, reactions occurring in cells ororganisms that are performed by one or more non-genetically encodedmacromolecule, protein or enzyme, or reactions that occur spontaneouslyin a cell. When used in reference to a Homo sapiens reactant, the termis intended to mean a chemical that is a substrate or product of areaction that occurs in or by a Homo sapiens cell. Metabolites areunderstood to be reactants within the meaning of the term. It will beunderstood that when used in reference to an in silico model or datastructure, a reactant is intended to be a representation of a chemicalthat is a substrate or a product of a reaction that occurs in or by acell.

As used herein the term “substrate” is intended to mean a reactant thatcan be convened to one or more products by a reaction. The term caninclude, for example, a reactant that is to be chemically changed due tonucleophilic or electrophilic addition, nucleophilic or electrophilicsubstitution, elimination, isomerization, deamination, phosphorylation,methylation, reduction, oxidation or that is to change location such asby being transported across a membrane or to a different compartment.

As used herein, the term “product” is intended to mean a reactant thatresults from a reaction with one or more substrates. The term caninclude, for example, a reactant that has been chemically changed due tonucleophilic or electrophilic addition, nucleophilic or electrophilicsubstitution, elimination, isomerization, deamination, phosphorylation,methylation, reduction or oxidation or that has changed location such asby being transported across a membrane or to a different compartment.

As used herein, the term “stoichiometric coefficient” is intended tomean a numerical constant correlating the number of one or morereactants and the number of one or more products in a chemical reaction.Typically, the numbers are integers as they denote the number ofmolecules of each reactant in an elementally balanced chemical equationthat describes the corresponding conversion. However, in some cases thenumbers can take on non-integer values, for example, when used in alumped reaction or to reflect empirical data.

As used herein, the term “plurality,” when used in reference toreactions or reactants including Homo sapiens reactions or reactants, isintended to mean at least 2 reactions or reactants. The term can includeany number of reactions or reactants in the range from 2 to the numberof naturally occurring reactants or reactions for a particular of cellor cells. Thus, the term can include, for example, at least 10, 20, 30,50, 100, 150, 200, 300, 400, 500, 600 or more reactions or reactants.The number of reactions or reactants can be expressed as a portion ofthe total number of naturally occurring reactions for a particular cellor cells including a Homo sapiens cell or cells, such as at least 20%,30%, 50%, 60%, 75%, 90%, 95% or 98% of the total number of naturallyoccurring reactions that occur in a particular Homo sapiens cell.

Similarly, the term “plurality,” when used in reference to datastructures, is intended to mean at least 2 data structures. The term caninclude any number of data structures in the range from 2 to the numberof naturally occurring biochemical networks for a particular subsystem,system, intracellular system, cellular compartment, organelle,extra-cellular space, cytosol, mitochondrion, nucleus, endoplasmicreticulum, group of cells, tissue, organ or organism. Therefore. theterm can include, for example, at least about 3, 4, 5, 6, 7, 8, 9, 10,25, 20, 25, 50, 100 or more biochemical networks. The term also can beexpressed as a portion of the total number of naturally occurringnetworks for any of the particular categories above occurring inprokaryotic or eukaryotic cells including Homo sapiens.

As used herein, the term “data structure” is intended to mean a physicalor logical relationship among data elements, designed to supportspecific data manipulation functions. The term can include, for example,a list of data elements that can be added combined or otherwisemanipulated such as a list of representations for reactions from whichreactants can be related in a matrix or network. The term can alsoinclude a matrix that correlates data elements from two or more lists ofinformation such as a matrix that correlates reactants to reactions.Information included in the term can represent, for example, a substrateor product of a chemical reaction, a chemical reaction relating one ormore substrates to one or more products. a constraint placed on areaction, or a stoichiometric coefficient.

As used herein, the term “constraint” is intended to mean an upper orlower boundary for a reaction. A boundary can specify a minimum ormaximum flow of mass, electrons or energy through a reaction. A boundarycan further specify directionality of a reaction. A boundary can be aconstant value such as zero. infinity, or a numerical value such as aninteger. Alternatively, a boundary can be a variable boundary value asset forth below.

As used herein, the term “variable.” when used in reference to aconstraint is intended to mean capable of assuming any of a set ofvalues in response to being acted upon by a constraint function. Theterm “function,” when used in the context of a constraint, is intendedto be consistent with the meaning of the term as it is understood in thecomputer and mathematical arts, A function can be binary such thatchanges correspond to a reaction being off or on. Alternatively,continuous functions can be used such that changes in boundary valuescorrespond to increases or decreases in activity. Such increases ordecreases can also be binned or effectively digitized by a functioncapable of converting sets of values to discreet integer values. Afunction included in the term can correlate a boundary value with thepresence, absence or amount of a biochemical reaction networkparticipant such as a reactant, reaction, enzyme or gene. A functionincluded in the term can correlate a boundary value with an outcome ofat least one reaction in a reaction network that includes the reactionthat is constrained by the boundary limit. A function included in theterm can also correlate a boundary value with an environmental conditionsuch as time, pH, temperature or redox potential.

As used herein, the term “activity,” when used in reference to areaction, is intended to mean the amount of product produced by thereaction, the amount of substrate consumed by the reaction or the rateat which a product is produced or a substrate is consumed. The amount ofproduct produced by the reaction, the amount of substrate consumed bythe reaction or the rate at which a product is produced or a substrateis consumed can also be referred to as the flux for the reaction.

As used herein, the term “activity,” when used in reference to a Homosapiens cell or a multicellular interaction, is intended to mean themagnitude or rate of a change from an initial state to a final state.The term can include, for example, the amount of a chemical consumed orproduced by a cell, the rate at which a chemical is consumed or producedby a cell, the amount or rate of growth of a cell or the amount of orrate at which energy, mass or electrons flow through a particular subsetof reactions.

The invention provides a computer readable medium, having a datastructure relating a plurality of Homo sapiens reactants to a pluralityof Homo sapiens reactions, wherein each of the Homo sapiens reactionsincludes a reactant identified as a substrate of the reaction, areactant identified as a product of the reaction and a stoichiometriccoefficient relating the substrate and the product.

Also provided is a computer readable medium or media having: (a) a firstdata structure relating a plurality of reactants to a plurality ofreactions from a first cell, each of said reactions comprising areactant identified as a substrate of the reaction, a reactantidentified as a product of the reaction and a stoichiometric coefficientrelating said substrate and said product; (b) a second data structurerelating a plurality of reactants to a plurality of reactions from asecond cell, each of said reactions comprising a reactant identified asa substrate oldie reaction, a reactant identified as a product oldiereaction and a stoichiometric coefficient relating said substrate andsaid product; (c) a third data structure relating a plurality ofintra-system reactants to a plurality of intra-system reactions betweensaid first and second cells, each of said intra-system reactionscomprising a reactant identified as a substrate of the reaction, areactant identified as a product of the reaction and a stoichiometriccoefficient relating said substrate and said product; (c) a constraintset for said plurality of reactions for said first, second and thirddata structures, and (d) commands for determining at least one fluxdistribution that minimizes or maximizes an objective function when saidconstraint set is applied to said first and second data structures,wherein said at least one flux distribution is predictive of aphysiological function of said first and second cells.

Depending on the application, the plurality of reactions for any of amulticellular, multi-network or single cell model or method of theinvention, including a Homo sapiens cell model or method, can includereactions selected from core metabolic reactions or peripheral metabolicreactions. As used herein, the term “core,” when used in reference to ametabolic pathway, is intended to mean a metabolic pathway selected fromglycolysis/gluconeogenesis, the pentose phosphate pathway (PPP), thetricarboxylic acid (TCA) cycle, glycogen storage, electron transfersystem (ETS). the malate/aspartate shuttle, the glycerol phosphateshuttle, and plasma and mitochondrial membrane transporters. As usedherein, the term “peripheral,” when used in reference to a metabolicpathway, is intended to mean a metabolic pathway that includes one ormore reactions that are not a part of a core metabolic pathway.

A plurality of reactants can be related to a plurality of reactions inany data structure that represents, for each reactant, the reactions bywhich it is consumed or produced. Thus, the data structure, which isreferred to herein as a “reaction network data structure,” serves as arepresentation of a biological reaction network or system. An example ofa reaction network that can be represented in a reaction network datastructure of the invention is the collection of reactions thatconstitute the core metabolic reactions of Homo sapiens, or themetabolic reactions of a skeletal muscle cell, as shown in the Examples.Further examples of reaction networks that can be represented in areaction network data structure of the invention are the collection ofreactions that constitute the core metabolic reactions and thetriacylglycerol (TAG) biosynthetic pathways of an adipocyte cell; thecore metabolic reactions and the energy and contractile reactions of amyocyte cell, and the intra-system reactions that supply bufferingfunctions of the kidney.

The choice of reactions to include in a particular reaction network datastructure, from among all the possible reactions that can occur inmulticellular organisms or among multicellular interactions, includinghuman cells, depends on the cell type or types and the physiological,pathological or therapeutic condition being modeled, and can bedetermined experimentally or from the literature, as described furtherbelow.

The reactions to be included in a particular network data structure of amulticellular interaction can be determined experimentally using, forexample, gene or protein expression profiles, where the molecularcharacteristics of the cell can be correlated to the expression levels.The expression or lack of expression of genes or proteins in a cell typecan be used in determining whether a reaction is included in the modelby association to the expressed gene(s) and or protein(s). Thus, it ispossible to use experimental technologies to determine which genesand/or proteins are expressed in a specific cell type, and to furtheruse this information to determine which reactions are present in thecell type of interest. In this way a subset of reactions from all ofthose reactions that can occur in human cells are selected to comprisethe set of reactions that represent a specific cell type. cDNAexpression profiles have been demonstrated to be useful., for example,for classification of breast cancer cells (Sorlie et al., Proc. Natl.Acad. Sci. U.S.A. 98(19):10869-10874 (2001)).

The methods and models of the invention can be applied to anymulticellular interaction as well as to any Homo sapiens cell type atany stage of differentiation, including, for example, embryonic stemcells, hematopoietic stein cells, differentiated hematopoietic cells,skeletal muscle cells, cardiac muscle cells, smooth muscle cells, skincells, nerve cells, kidney cells, pulmonary cells, liver cells,adipocytes and endocrine cells (e.g. beta islet cells of the pancreas,mammary gland cells, adrenal cells, and other specialized hormonesecreting cells). Similarly, the methods and models of the invention canbe applied to any interaction between any of these cell types, includingtwo or more of the same cell type or two or more different cell types.Described below in Example IV is an example of the interactions thatoccur between myocyte cells and adipocyte cells during differentphysiological conditions.

The methods and models of the invention can be applied to normal cells,pathological cells as well as to combinations of interactions betweennormal cells, interactions between pathological cells or interactionsbetween normal and pathological cells. Normal cells that exhibit avariety of physiological activities of interest, including homeostasis,proliferation. differentiation, apoptosis, contraction and motility, canbe modeled. Pathological cells can also be modeled, including cells thatreflect genetic or developmental abnormalities, nutritionaldeficiencies, environmental assaults, infection (such as by bacteria,viral, protozoan or fungal agents), neoplasia, aging, altered immune orendocrine function, tissue damage, or any combination of these factors.The pathological cells can be representative of any type of pathology,such as a human pathology, including, for example, various metabolicdisorders of carbohydrate, lipid or protein metabolism, obesity,diabetes, cardiovascular disease, fibrosis, various cancers, kidneyfailure, immune pathologies, neurodegenerative diseases, and variousmonogenetic metabolic diseases described in the Online MendelianInheritance in Man database (Center for Medical Genetics, Johns HopkinsUniversity (Baltimore, Md.) and National Center for BiotechnologyInformation, National Library of Medicine (Bethesda, Md.)).

The methods and models of the invention can also be applied to cells ororganisms undergoing therapeutic perturbations, such as cells treatedwith drugs that target participants in a reaction network or cause aneffect on an interactive reaction network, cells or tissues treated withgene-based therapeutics that increase or decrease expression of anencoded protein, and cells or tissues treated with radiation. As usedherein, the term “drug” refers to a compound of any molecular naturewith a known or proposed therapeutic function, including, for example,small molecule compounds, peptides and other macromolecules,peptidomimetics and antibodies, any of which can optionally be taggedwith cytostatic, targeting or detectable moieties. The term “gene-basedtherapeutic” refers to nucleic acid therapeutics, including, forexample, expressible genes with normal or altered protein activity,antisense compounds, ribozymes, DNAzymes, RNA interference compounds(RNAi) and the like. The therapeutics can target any reaction networkparticipant, in any cellular location, including participants inextracellular, cell surface, cytoplasmic, mitochondrial and nuclearlocations. Experimental data that are gathered on the response of cells,tissues, or interactions thereof, to therapeutic treatment, such asalterations in gene or protein expression profiles, can be used totailor a network or a combination of networks for a pathological stateof a particular cell type.

The methods and models of the invention can be applied to cells, tissuesand physiological systems, including Homo sapiens cells, tissues andphysiological systems, as they exist in any form, such as in primarycell isolates or in established cell lines, or in the whole body, inintact organs or in tissue explants. Accordingly, the methods and modelscan take into account intercellular communications and/or inter-organcommunications, the effect of adhesion to a substrate or neighboringcells (such as a stem cell interacting with mesenchymal cells or acancer cell interacting with its tissue microenvironment, or beta-isletcells without normal stroma), and other interactions relevant tomulticellular systems.

The reactants to be used in a reaction network data structure of theinvention can be obtained from or stored in a compound database. As usedherein, the term “compound database” is intended to mean a computerreadable medium or media containing a plurality of molecules thatincludes substrates and products of biological reactions. The pluralityof molecules can include molecules found in multiple organisms, therebyconstituting a universal compound database. Alternatively, the pluralityof molecules can be limited to those that occur in a particularorganism, thereby constituting an organism-specific compound database.Each reactant in a compound database can be identified according to thechemical species and the cellular compartment in which it is present.Thus, for example, a distinction can be made between glucose in theextracellular compartment versus glucose in the cytosol. Additionallyeach of the reactants can be specified as a metabolite of a primary orsecondary metabolic pathway. Although identification of a reactant as ametabolite of a primary or secondary metabolic pathway does not indicateany chemical distinction between the reactants in a reaction, such adesignation can assist in visual representations of large networks ofreactions.

As used herein, the term “compartment” is intended to mean a subdividedregion containing at least one reactant, such that the reactant isseparated from at least one other reactant in a second region. Asubdivided region included in the term can be correlated with asubdivided region of a cell. Thus, a subdivided region included in theterm can be, for example, the intracellular space of a cell; theextracellular space around a cell; the periplasmic space, the interiorspace of an organelle such as a mitochondrium, endoplasmic reticulum,Golgi apparatus, vacuole or nucleus; or any subcellular space that isseparated from another by a membrane or other physical barrier. Forexample, a mitochondrial compartment is a subdivided region of theintracellular space of a cell, which in turn, is a subdivided region ofa cell or tissue. A subdivided region also can include, for example,different regions or systems of a tissue,organ or physiological systemof an organism. Subdivided regions can also be made in order to createvirtual boundaries in a reaction network that are not correlated withphysical barriers. Virtual boundaries can be made for the purpose ofsegmenting the reactions in a network into different compartments orsubstructures.

As used herein, the term “substructure” is intended to mean a portion ofthe information in a data structure that is separated from otherinformation in the data structure such that the portion of informationcan be separately manipulated or analyzed. The term can include portionssubdivided according to a biological function including, for example,information relevant to a particular metabolic pathway such as aninternal flux pathway. exchange flux pathway, central metabolic pathway,peripheral metabolic pathway, or secondary metabolic pathway. The termcan include portions subdivided according to computational ormathematical principles that allow for a particular type of analysis ormanipulation of the data structure.

The reactions included in a reaction network data structure can beobtained from a metabolic reaction database that includes thesubstrates, products, and stoichiometry of a plurality of metabolicreactions of Homo sapiens, other multicellular organisms or single cellorganisms that exhibit biochemical or physiological interactions. Thereactants in a reaction network data structure can be designated aseither substrates or products of a particular reaction, each with astoichiometric coefficient assigned to it to describe the chemicalconversion taking place in the reaction. Each reaction is also describedas occurring in either a reversible or irreversible direction.Reversible reactions can either be represented as one reaction thatoperates in both the forward and reverse direction or be decomposed intotwo irreversible reactions, one corresponding to the forward reactionand the other corresponding to the backward reaction.

Reactions included in a reaction network data structure can includeintra-system or exchange reactions. Intra-system reactions are thechemically and electrically balanced interconversions of chemicalspecies and transport processes. which serve to replenish or drain therelative amounts of certain metabolites. These intra-system reactionscan be classified as either being transformations or translocations. Atransformation is a reaction that contains distinct sets of compounds assubstrates and products, while a translocation contains reactantslocated in different compartments. Thus a reaction that simplytransports a metabolite from the extracellular environment to thecytosol, without changing its chemical composition is solely classifiedas a translocation, while a reaction that takes an extracellularsubstrate and converts it into a cytosolic product is both atranslocation and a transformation. Further, intra-system reactions caninclude reactions representing one or more biochemical or physiologicalfunctions of an independent cell, tissue, organ or physiological system.For example, the buffering function of the kidneys for the hematopoieticsystem and intra-cellular environments can be represented asintra-system reactions and be included in a multicellular interactionmodel either as an independent reaction network or merged with one ormore reaction networks of the constituent cells.

Exchange reactions are those which constitute sources and sinks,allowing the passage of metabolites into and out of a compartment oracross a hypothetical system boundary. These reactions are included in amodel for simulation purposes and represent the metabolic demands placedon Homo sapiens. While they may be chemically balanced in certain cases,they are typically not balanced and can often have only a singlesubstrate or product. As a matter of convention the exchange reactionsare further classified into demand exchange and input/output exchangereactions.

The metabolic demands placed on a multicellular or Homo sapiensmetabolic reaction network can be readily determined from the dry weightcomposition of the cell, cells, tissue, organ or organism which isavailable in the published literature or which can be determinedexperimentally. The uptake rates and maintenance requirements for Homosapiens cells can also be obtained from the published literature ordetermined experimentally.

Input/output exchange reactions are used to allow extracellularreactants to enter or exit the reaction network represented by a modelof the invention. For each of the extracellular metabolites acorresponding input/output exchange reaction can be created. Thesereactions are always reversible with the metabolite indicated as asubstrate with a stoichiometric coefficient of one and no productsproduced by the reaction. This particular convention is adopted to allowthe reaction to take on a positive flux value (activity level) when themetabolite is being produced or removed from the reaction network and anegative flux value when the metabolite is being consumed or introducedinto the reaction network. These reactions will be further constrainedduring the course of a simulation to specify exactly which metabolitesare available to the cell and which can be excreted by the cell.

A demand exchange reaction is always specified as an irreversiblereaction containing at least one substrate. These reactions aretypically formulated to represent the production of an intracellularmetabolite by the metabolic network or the aggregate production of manyreactants in balanced ratios such as in the representation of a reactionthat leads to biomass formation, also referred to as growth.

A demand exchange reactions can be introduced for any metabolite in amodel of the invention. Most commonly these reactions are introduced formetabolites that are required to be produced by the cell for thepurposes of creating a new cell such as amino acids, nucleotides,phospholipids, and other biomass constituents, or metabolites that areto be produced for alternative purposes. Once these metabolites areidentified. a demand exchange reaction that is irreversible andspecifies the metabolite as a substrate with a stoichiometriccoefficient of unity can be created. With these specifications, if thereaction is active it leads to the net production of the metabolite bythe system meeting potential production demands. Examples of processesthat can be represented as a demand exchange reaction in a reactionnetwork data structure and analyzed by the methods of the inventioninclude, for example, production or secretion of an individual protein;production or secretion of an individual metabolite such as an aminoacid, vitamin. nucleoside, antibiotic or surfactant; production of ATPfor extraneous energy requiring processes such as locomotion or musclecontraction; or formation of biomass constituents.

In addition to these demand exchange reactions that are placed onindividual metabolites, demand exchange reactions that utilize multiplemetabolites in defined stoichiometric ratios can be introduced. Thesereactions are referred to as aggregate demand exchange reactions. Anexample of an aggregate demand reaction is a reaction used to simulatethe concurrent growth demands or production requirements associated withcell growth that are placed on a cell, for example, by simulating theformation of multiple biomass constituents simultaneously at aparticular cellular or organismic growth rate.

A specific reaction network is provided in FIG. 1 to exemplify theabove-described reactions and their interactions. The reactions can berepresented in the exemplary data structure shown in FIG. 3 as set forthbelow. The reaction network, shown in FIG. 1, includes intra-systemreactions that occur entirely within the compartment indicated by theshaded oval such as reversible reaction R₂ which acts on reactants B andG and reaction R₃ which converts one equivalent of B to 2 equivalents ofF. The reaction network shown in FIG. 1 also contains exchange reactionssuch as input/output exchange reactions A_(x1) and E_(x1), and thedemand exchange reaction, which represents growth in response to the oneequivalent of D and one equivalent of F. Other intra-system reactionsinclude R₁ which is a translocation and transformation reaction thattranslocates reactant A into the compartment and transforms it toreactant G and reaction R₆ which is a transport reaction thattranslocates reactant E out of the compartment.

A reaction network can be represented as a set of linear algebraicequations which can be presented as a stoichiometric matrix S, with Sbeing an m x n matrix where m corresponds to the number of reactants ormetabolites and n corresponds to the number of reactions taking place inthe network. An example of a stoichiometric matrix representing thereaction network of FIG. 1 is shown in FIG. 3. As shown in FIG. 3, eachcolumn in the matrix corresponds to a particular reaction n, each rowcorresponds to a particular reactant m, and each S_(mn) elementcorresponds to the stoichiometric coefficient of the reactant m in thereaction denoted n. The stoichiometric matrix includes intra-systemreactions such as R₂ and R₃ which are related to reactants thatparticipate in the respective reactions according to a stoichiometriccoefficient having a sign indicative of whether the reactant is asubstrate or product of the reaction and a value correlated with thenumber of equivalents of the reactant consumed or produced by thereaction. Exchange reactions such as −E_(xt) and −A_(xt) are similarlycorrelated with a stoichiometric coefficient. As exemplified by reactantE, the same compound can be treated separately as an internal reactant(E) and an external reactant (E_(external)) such that an exchangereaction (R₆) exporting the compound is correlated by stoichiometriccoefficients of −1 and 1, respectively. However, because the compound istreated as a separate reactant by virtue of its compartmental location,a reaction, such as R₅, which produces the internal reactant (E) butdoes not act on the external reactant (E_(external)) is correlated bystoichiometric coefficients of 1 and 0, respectively. Demand reactionssuch as V_(growth) can also be included in the stoichiometric matrixbeing correlated with substrates by an appropriate stoichiometriccoefficient.

As set forth in further detail below, a stoichiometric matrix provides aconvenient format for representing and analyzing a reaction networkbecause it can be readily manipulated and used to compute networkproperties, for example, by using linear programming or general convexanalysis. A reaction network data structure can take on a variety offormats so long as it is capable of relating reactants and reactions inthe manner exemplified above for a stoichiometric matrix and in a mannerthat can be manipulated to determine an activity of one or morereactions using methods such as those exemplified below. Other examplesof reaction network data structures that are useful in the inventioninclude a connected graph, list of chemical reactions or a table orreaction equations.

A reaction network data structure can be constructed to include allreactions that are involved in metabolism occurring during theinteraction of two or more cells. Homo sapiens cell metabolism or anyportion thereof. A portion of an organisms metabolic reactions that canbe included in a reaction network data structure of the inventionincludes, for example, a central metabolic pathway such as glycolysis,the TCA cycle, the PPP or ETS; or a peripheral metabolic pathway such asamino acid biosynthesis, amino acid degradation, purine biosynthesis,pyrimidine biosynthesis, lipid biosynthesis, fatty acid metabolism,vitamin or cofactor biosynthesis, transport processes and alternativecarbon source catabolism. Examples of individual pathways within theperipheral pathways are set forth in Table 1. Other examples of portionsof metabolic reactions that can be included in a reaction network datastructure of the invention include, for example, TAG biosynthesis,muscle contraction requirements, bicarbonate buffer system and/orammonia buffer system. Specific examples of these and other reactionsare described further below and in the Examples.

Depending upon a particular application, a reaction network datastructure can include a plurality of Homo sapiens reactions includingany or all of the reactions listed in Table 1, Similarly, a reactionnetwork data structure also can include the reactions set forth inExamples I-IV and include, for example, single reaction networks,multiple reaction networks that interact within a cell as well asmultiple reaction networks that interact between cells or physiologicalsystems.

For some applications, it can be advantageous to use a reaction networkdata structure that includes a minimal number of reactions to achieve aparticular Homo sapiens activity or activity of a multicellularinteraction under a particular set of environmental conditions. Areaction network data structure having a minimal number of reactions canbe identified by performing the simulation methods described below in aniterative fashion where different reactions or sets of reactions aresystematically removed and the effects observed. Accordingly, theinvention provides a computer readable medium, containing a datastructure relating a plurality of Homo sapiens reactants to a pluralityof Homo sapiens reactions, wherein the plurality of Homo sapiensreactions contains at least 65 reactions. For example, the coremetabolic reaction database shown in Tables 2 and 3 contains 65reactions, and is sufficient to simulate aerobic and anaerobicmetabolism on a number of carbon sources, including glucose. Similarly,the invention provides a computer readable medium containing a datastructure relating a plurality of reactants or multicellularinteractions to a plurality of reactions from multicellularinteractions, wherein the reactions contain at least 430 for a two cellinteraction. Such reactions between multicellular interactions areexemplified in Table 11, for example.

Depending upon the particular cell type or types, the physiological,pathological or therapeutic conditions being tested, the desiredactivity and the number of cellular interactions of a model or method ofthe invention, a reaction network data structure can contain smallernumbers of reactions such as at least 200, 150, 100 or 50 reactions. Areaction network data structure having relatively few reactions canprovide the advantage of reducing computation time and resourcesrequired to perform a simulation. When desired, a reaction network datastructure having a particular subset of reactions can be made or used inwhich reactions that are not relevant to the particular simulation areomitted. Alternatively, larger numbers of reactions can be included inorder to increase the accuracy or molecular detail of the methods of theinvention or to suit a particular application. Thus, a reaction networkdata structure can contain at least 300, 350, 400, 450, 500, 550, 600 ormore reactions up to the number of reactions that occur in or bymulticellular interactions, including Homo sapiens, or that are desiredto simulate the activity of the full set of reactions occurring inmulticellular interactions, including Homo sapiens. A reaction networkdata structure that is substantially complete with respect to themetabolic reactions of a multicellular organism, including Homo sapiens,provides an advantage of being relevant to a wide range of conditions tobe simulated, whereas those with smaller numbers of metabolic reactionsare specific to a particular subset of conditions to be simulated.

A Homo sapiens reaction network data structure can include one or morereactions that occur in or by Homo sapiens and that do not occur, eithernaturally or following manipulation, in or by another organism, such asSaccharomyes cerevisiae, it is understood that a Homo sapiens reactionnetwork data structure of a particular cell type can also include one ormore reactions that occur in another cell type. Addition of suchheterologous reactions to a reaction network data structure of theinvention can be used in methods to predict the consequences ofheterologous gene transfer and protein expression, for example, whendesigning in vivo and ex vivo gene therapy approaches. Similarly,reaction networks for a multicellular interactions also can include oneor more reactions that occur entirely within the species of origin ofthe cellular interactions or can contain one or more heterologousreactions from one or more different species.

The reactions included in a reaction network data structure of theinvention can be metabolic reactions. A reaction network data structurecan also be constructed to include other types of reactions such asregulatory reactions, signal transduction reactions, cell cyclereactions, reactions controlling developmental processes, reactionsinvolved in apoptosis, reactions involved in responses to hypoxia,reactions involved in responses to cell-cell or cell-substrateinteractions, reactions involved in protein synthesis and regulationthereof, reactions involved in gene transcription and translation, andregulation thereof, and reactions involved in assembly of a cell and itssubcellular components.

A reaction network data structure or index of reactions used in the datastructure such as that available in a metabolic reaction database, asdescribed above, can be annotated to include information about aparticular reaction. A reaction can be annotated to indicate, forexample, assignment of the reaction to a protein, macromolecule orenzyme that performs the reaction, assignment of a gene(s) that codesfor the protein, macromolecule or enzyme, the Enzyme Commission (EC)number of the particular metabolic reaction, a subset of reactions towhich the reaction belongs, citations to references from whichinformation was obtained, or a level of confidence with which a reactionis believed to occur in Homo sapiens or other organism. A computerreadable medium or media of the invention can include a gene databasecontaining annotated reactions. Such information can be obtained duringthe course of building a metabolic reaction database or model of theinvention as described below.

As used herein, the term “gene database” is intended to mean a computerreadable medium or media that contains at least one reaction that isannotated to assign a reaction to one or more macromolecules thatperform the reaction or to assign one or more nucleic acid that encodesthe one or more macromolecules that perform the reaction. A genedatabase can contain a plurality of reactions, some or all of which areannotated. An annotation can include, for example, a name for amacromolecule; assignment of a function to a macromolecule; assignmentof an organism that contains the macromolecule or produces themacromolecule: assignment of a subcellular location for themacromolecule; assignment of conditions under which a macromolecule isregulated with respect to performing a reaction, being expressed orbeing degraded; assignment of a cellular component that regulates amacromolecule; an amino acid or nucleotide sequence for themacromolecule; a mRNA isoform, enzyme isoform, or any other desirableannotation or annotation found for a macromolecule in a genome databasesuch as those that can he found in Genbank, a site maintained by theNCBI (ncbi.nlm.gov). the Kyoto Encyclopedia of Genes and Genomes (KEGG)(www.genome.ad.jp/kegg/), the protein database SWISS-PROT(ca.expasy.org/sprot/), the LocusLink database maintained by the NCBI(www.ncbi.nlm.nih.gov/LocusLink/), the Enzyme Nomenclature databasemaintained by G.P. Moss of Queen Mary and Westfield College in theUnited Kingdom (www.chem.qmw.ac.uk/iubmb/enzyme/).

A gene database of the invention can include a substantially completecollection of genes or open reading frames in a multicellular organism,including Homo sapiens, or a substantially complete collection of themacromolecules encoded by the organism's genome. Alternatively, a genedatabase can include a portion of genes or open reading frames in anorganism or a portion of the macromolecules encoded by the organism'sgenome, such as the portion that includes substantially all metabolicgenes or macromolecules. The portion can be at least 10%, 15%, 20%, 25%,50%, 75%, 90% or 95% of the genes or open reading frames encoded by theorganism's genome, or the macromolecules encoded therein. A genedatabase can also include macromolecules encoded by at least a portionof the nucleotide sequence for the organism's genome such as at least10%, 15%. 20%, 25%, 50%, 75%, 90% or 95% of the organism's genome.Accordingly, a computer readable medium or media of the invention caninclude at least one reaction for each macromolecule encoded by aportion of an organism's genome, including a Homo sapiens genome.

An in silica model of multicellular interactions, including a Homosapiens model, of the invention can be built by an iterative processwhich includes gathering information regarding particular reactions tobe added to a model, representing the reactions in a reaction networkdata structure, and performing preliminary simulations wherein a set ofconstraints is placed on the reaction network and the output evaluatedto identify errors in the network. Errors in the network such as gapsthat lead to non-natural accumulation or consumption of a particularmetabolite can be identified as described below and simulations repeateduntil a desired performance of the model is attained. An exemplarymethod for iterative model construction is provided in Example I. Formulticellular interactions, an iterative process includes producing oneor more component reaction networks followed by combining the componentsinto a higher order multi-network system, as described in Example IV.For example, components can include the central metabolism reactionnetwork and the cell specific reaction networks such as TAG biosynthesisfor adipocytes or muscle contraction for myocytes. Combination of thecentral metabolism and the cell specific reaction networks into a singlemodel produces, for example, a cell specific reaction network.Components also can include the individual cell types, tissues,physiological systems or intra-system reaction networks that areconstituents of the larger multicellular system. Combining thesecomponents into a larger model produces, for example, a model describingthe relationships and interactions of the multicellular system togetherwith its various interactions.

Thus, the invention provides a method for making a data structurerelating a plurality of reactants to a plurality of reactions in acomputer readable medium or media. The method includes the steps of: (a)identifying a plurality of reactions and a plurality of reactants thatare substrates and products of the reactions; (b) relating the pluralityof reactants to the plurality of Homo sapiens reactions in a datastructure, wherein each of the reactions includes a reactant identifiedas a substrate of the reaction, a reactant identified as a product ofthe reaction and a stoichiometric coefficient relating the substrate andthe product; (c) making a constraint set for the plurality of reactions;(d) providing an objective function; (e) determining at least one fluxdistribution that minimizes or maximizes the objective function when theconstraint set is applied to the data structure, and (f) if the at leastone flux distribution is not predictive of physiology, then adding areaction to or deleting a reaction from the data structure and repeatingstep (e). if the at least one flux distribution is predictive ofphysiology, then storing the data structure in a computer readablemedium or media. The method can be applied to multicellular interactionswithin or among single or multicullar organisms, including Homo sapiens.

Information to be included in a data structure of the invention can begathered from a variety of sources including, for example, annotatedgenome sequence information and biochemical literature.

Sources of annotated human genome sequence information include, forexample, KEGG, SWISS-PROT, LocusLink, the Enzyme Nomenclature database,the International Human Genome Sequencing Consortium and commercialdatabases. KEGG contains a broad range of information, including asubstantial amount of metabolic reconstruction. The genomes of 304organisms can be accessed here, with gene products grouped bycoordinated functions, often represented by a map (e.g., the enzymesinvolved in glycolysis would be grouped together). The maps arebiochemical pathway templates which show enzymes connecting metabolitesfor various parts of metabolism. These general pathway templates arecustomized for a given organism by highlighting enzymes on a giventemplate which have been identified in the genome of the organism.Enzymes and metabolites are active and yield useful information aboutstoichiometry, structure. alternative names and the like, when accessed.

SWISS-PROT contains detailed information about protein function.Accessible information includes alternate gene and gene product names,function, structure and sequence information, relevant literaturereferences, and the like.

LocusLink contains general information about the locus where the gene islocated and, of relevance, tissue specificity, cellular location, andimplication of the gene product in various disease states.

The Enzyme Nomenclature database can be used to compare the geneproducts of two organisms. Often the gene names for genes with similarfunctions in two or more organisms are unrelated. When this is the case,the E.C. (Enzyme Commission) numbers can be used as unambiguousindicators of gene product function. The information in the EnzymeNomenclature database is also published in Enzyme Nomenclature (AcademicPress, San Diego, Calif., 1992) with supplements to date, all found inthe European Journal of Biochemistry (Blackwell Science, Malden, Mass.).

Sources of biochemical information include, for example, generalresources relating to metabolism, resources relating specifically tohuman metabolism, and resources relating to the biochemistry, physiologyand pathology of specific human cell types.

Sources of general information relating to metabolism, which were usedto generate the human reaction databases and models described herein,were J. G. Salway, Metabolism at a Glance. 2^(nd) ed., BlackwellScience. Malden, Mass. (1999) and T. M. Devlin, ed., Textbook ofBiochemistry with Correlations, 4^(th) ed., John Wiley and Sons, NewYork, N.Y. (1997). Human metabolism-specific resources included J. R.Bronk, HumanMetabolism: Functional Diversity and Intregration, AddisonWesley Longman, Essex, England (1999).

The literature used in conjunction with the skeletal muscle metabolicmodels and simulations described herein included R. Maughan et al.,Biochemistry of Exercise and Training, Oxford University Press, Oxford,England (1997), as well as references on muscle pathology such as S.Carpenter et al., Pathology of Skeletal Muscle, 2nd ed., OxfordUniversity Press, Oxford, England (2001), and more specific articles onmuscle metabolism as may be found in the Journal of Physiology(Cambridge University Press, Cambridge, England).

In the course of developing an in silica model of metabolism during orfor multicellular interactions, the types of data that can be consideredinclude, for example, biochemical information which is informationrelated to the experimental characterization of a chemical reaction,often directly indicating a protein(s) associated with a reaction andthe stoichiometry of the reaction or indirectly demonstrating theexistence of a reaction occurring within a cellular extract; geneticinformation, which is information related to the experimentalidentification and genetic characterization of a gene(s) shown to codefor a particular protein(s) implicated in carrying out a biochemicalevent; genomic information, which is information related to theidentification of an open reading frame and functional assignment,through computational sequence analysis, that is then linked to aprotein performing a biochemical event; physiological information. whichis information related to overall cellular physiology, fitnesscharacteristics, substrate utilization, and phenotyping results, whichprovide evidence of the assimilation or dissimilation of a compound usedto infer the presence of specific biochemical event (in particulartranslocations): and modeling information, which is informationgenerated through the course of simulating activity of cells, tissues orphysiological systems using methods such as those described herein whichlead to predictions regarding the status of a reaction such as whetheror not the reaction is required to fulfill certain demands placed on ametabolic network. Additional information relevant to multicellularorganisms that can be considered includes, for example, celltype-specific or condition-specific gene expression information, whichcan be determined experimentally, such as by gene array analysis or fromexpressed sequence tag (EST) analysis, or obtained from the biochemicaland physiological literature.

The majority of the reactions occurring in a multicellular organism'sreaction networks are catalyzed by enzymes/proteins, which are createdthrough the transcription and translation of the genes found within thechromosome in the cell. The remaining reactions occur eitherspontaneously or through non-enzymatic processes. Furthermore, areaction network data structure can contain reactions that add or deletesteps to or from a particular reaction pathway. For example, reactionscan be added to optimize or improve performance of a model formulticellular interactions in view of empirically observed activity.Alternatively, reactions can be deleted to remove intermediate steps ina pathway when the intermediate steps are not necessary to model fluxthrough the pathway. For example, if a pathway contains 3 nonbranchedsteps, the reactions can be combined or added together to give a netreaction, thereby reducing memory required to store the reaction networkdata structure and the computational resources required for manipulationof the data structure.

The reactions that occur due to the activity of gene-encoded enzymes canbe obtained from a genome database which lists genes identified fromgenome sequencing and subsequent genome annotation. Genome annotationconsists of the locations of open reading frames and assignment offunction from homology to other known genes or empirically determinedactivity. Such a genome database can be acquired through public orprivate databases containing annotated nucleic acid or proteinsequences, including Homo sapiens sequences. If desired, a modeldeveloper can perform a network reconstruction and establish the modelcontent associations between the genes, proteins, and reactions asdescribed, for example, in Covert et al. Trends in Biochemical Sciences26:179-186 (2001) and Palsson, WO 00146405.

As reactions are added to a reaction network data structure or metabolicreaction database, those having known or putative associations to theproteins/enzymes which enable/catalyze the reaction and the associatedgenes that code for these proteins can be identified by annotation.Accordingly, the appropriate associations for all of the reactions totheir related proteins or genes or both can be assigned. Theseassociations can be used to capture the non-linear relationship betweenthe genes and proteins as well as between proteins and reactions. Insome cases one gene codes for one protein which then perform onereaction. However, often there are multiple genes which are required tocreate an active enzyme complex and often there are multiple reactionsthat can be carried out by one protein or multiple proteins that cancarry out the same reaction. These associations capture the logic (i.e.AND or OR relationships) within the associations. Annotating a metabolicreaction database with these associations can allow the methods to beused to determine the effects of adding or eliminating a particularreaction not only at the reaction level, but at the genetic or proteinlevel in the context of running a simulation or predicting amulticellular interaction activity, including Homo sapiens activity.

A reaction network data structure of the invention can be used todetermine the activity of one or more reactions in a plurality ofreactions occurring from multicellular interactions, including aplurality of Homo sapiens reactions, independent of any knowledge orannotation of the identity of the protein that performs the reaction orthe gene encoding the protein. A model that is annotated with gene orprotein identities can include reactions for which a protein or encodinggene is not assigned. While a large portion of the reactions in acellular metabolic network are associated with genes in the organism'sgenome, there are also a substantial number of reactions included in amodel for which there are no known genetic associations. Such reactionscan be added to a reaction database based upon other information that isnot necessarily related to genetics such as biochemical or cell basedmeasurements or theoretical considerations based on observed biochemicalor cellular activity. For example, there are many reactions that caneither occur spontaneously or are not protein-enabled reactions.Furthermore, the occurrence of a particular reaction in a cell for whichno associated proteins or genetics have been currently identified can beindicated during the course of model building by the iterative modelbuilding methods of the invention.

The reactions in a reaction network data structure or reaction databasecan be assigned to subsystems by annotation, if desired. The reactionscan be subdivided according to biological criteria, such as according totraditionally identified metabolic pathways (glycolysis, amino acidmetabolism and the like) or according to mathematical or computationalcriteria that facilitate manipulation of a model that incorporates ormanipulates the reactions. Methods and criteria for subdviding areaction database are described in further detail in Schilling et al.,J. Theor. Biol. 203:249-283 (2000), and in Schuster et al.,Bioinformatics 18:351-361 (2002). The use of subsystems can beadvantageous for a number of analysis methods, such as extreme pathwayanalysis, and can make the management of model content easier, Althoughassigning reactions to subsystems can be achieved without affecting theuse of the entire model for simulation, assigning reactions tosubsystems can allow a user to search for reactions in a particularsubsystem which may be useful in performing various types of analyses.Therefore, a reaction network data structure can include any number ofdesired subsystems including, for example, 2 or more subsystems, 5 ormore subsystems, 10 or more subsystems, 25 or more subsystems or 50 ormore subsystems.

The reactions in a reaction network data structure or metabolic reactiondatabase can be annotated with a value indicating the confidence withwhich the reaction is believed to occur in one or more cells of amulticellular interaction or in one or more reaction networks within acell such as a Homo sapiens cell. The level of confidence can be, forexample, a function of the amount and form of supporting data that isavailable. This data can come in various forms including publishedliterature, documented experimental results, or results of computationalanalyses. Furthermore, the data can provide direct or indirect evidencefor the existence of a chemical reaction in a cell based on genetic,biochemical, and/or physiological data.

The invention further provides a computer readable medium, containing(a) a data structure relating a plurality Homo sapiens reactants to aplurality of Homo sapiens reactions, wherein each of the Homo sapiensreactions includes a reactant identified as a substrate of the reaction,a reactant identified as a product of the reaction and a stoichiometriccoefficient relating the substrate and the product, and (b) a constraintset for the plurality of Homo sapiens reactions. Similarly, the computerreadable medium or media can relate a plurality of reactions to aplurality of reactions within first and second cells and for anintra-system between first and second interacting cells.

Constraints can be placed on the value of any of the fluxes in themetabolic network using a constraint set. These constraints can berepresentative of a minimum or maximum allowable flux through a givenreaction, possibly resulting from a limited amount of an enzyme present.Additionally. the constraints can determine the direction orreversibility of any of the reactions or transport fluxes in thereaction network data structure. Based on the in viva environment wheremultiple cells interact, such as in a human organism, the metabolicresources available to the cell for biosynthesis of essential moleculesfor can be determined. Allowing the corresponding transport fluxes to beactive provides the in silica interaction between cells with inputs andoutputs for substrates and by-products produced by the metabolicnetwork.

Returning to the hypothetical reaction network shown in FIG. 1,constraints can be placed on each reaction in the exemplary format shownin FIG. 2, as follows. The constraints are provided in a format that canbe used to constrain the reactions of the stoichiometric matrix shown inFIG. 3. The format for the constraints used for a matrix or in linearprogramming can be conveniently represented as a linear inequality suchas

bj≤vj≤aj:j=1 . . . n   (Eq. 1)

where v_(j) is the metabolic flux vector, b, is the minimum flux valueand a_(j) is the maximum flux value. Thus, a_(j) can take on a finitevalue representing a maximum allowable flux through a given reaction orb_(j) can take on a finite value representing minimum allowable fluxthrough a given reaction. Additionally, if one chooses to leave certainreversible reactions or transport fluxes to operate in a forward andreverse manner the flux may remain unconstrained by setting b_(j) tonegative infinity and a, to positive infinity as shown for reaction R₂in FIG. 2. If reactions proceed only in the forward reaction b_(j) isset to zero while a_(j) is set to positive infinity as shown forreactions R₁, R₃, R₄, R₅, and R₆ in FIG. 2. As an example, to simulatethe event of a genetic deletion or non-expression of a particularprotein, the flux through all of the corresponding metabolic reactionsrelated to the gene or protein in question are reduced to zero bysetting a, and b, to be zero. Furthermore, if one wishes to simulate theabsence of a particular growth substrate one can simply constrain thecorresponding transport fluxes that allow the metabolite to enter thecell to be zero by setting a_(j) and b_(j)to be zero. On the other handif a substrate is only allowed to enter or exit the cell via transportmechanisms, the corresponding fluxes can be properly constrained toreflect this scenario.

The ability of a reaction to be actively occurring is dependent on alarge number of additional factors beyond just the availability ofsubstrates. These factors, which can be represented as variableconstraints in the models and methods of the invention include, forexample, the presence of cofactors necessary to stabilize theprotein/enzyme, the presence or absence of enzymatic inhibition andactivation factors, the active formation of the protein/enzyme throughtranslation of the corresponding mRNA transcript, the transcription ofthe associated gene(s) or the presence of chemical signals and/orproteins that assist in controlling these processes that ultimatelydetermine whether a chemical reaction is capable of being carried outwithin an organism. Of particular importance in the regulation of humancell types is the implementation of paracrine and endocrine signalingpathways to control cellular activities. In these cases a cell secretessignaling molecules that may be carried far afield to act on distanttargets (endocrine signaling), or act as local mediators (paracrinesignaling). Examples of endocrine signaling molecules include hormonessuch as insulin, while examples of paracrine signaling molecules includeneurotransmitters such as acetylcholine. These molecules induce cellularresponses through signaling cascades that affect the activity ofbiochemical reactions in the cell. Regulation can be represented in anin silico Homo sapiens model by providing a variable constraint as setforth below.

Thus, the invention provides a computer readable medium or media,including (a) a data structure relating a plurality of Homo sapiensreactants to a plurality of Homo sapiens reactions, wherein each of thereactions includes a reactant identified as a substrate of the reaction,a reactant identified as a product of the reaction and a stoichiometriccoefficient relating the substrate and the product, and wherein at leastone of the reactions is a regulated reaction; and (b) a constraint setfor the plurality of reactions, wherein the constraint set includes avariable constraint for the regulated reaction. Additionally, theinvention provides a computer readable medium or media including datastructures for two or more cells and for an intra-system and aconstraint set for the plurality of reactions within the data structuresthat includes a variable constraint for a regulated reaction.

As used herein, the term “regulated,” when used in reference to areaction in a data structure, is intended to mean a reaction thatexperiences an altered flux due to a change in the value of a constraintor a reaction that has a variable constraint.

As used herein, the term “regulatory reaction” is intended to mean achemical conversion or interaction that alters the activity of aprotein. macromolecule or enzyme. A chemical conversion or interactioncan directly alter the activity of a protein, macromolecule or enzymesuch as occurs when the protein, macromolecule or enzyme ispost-translationally modified or can indirectly alter the activity of aprotein, macromolecule or enzyme such as occurs when a chemicalconversion or binding event leads to altered expression of the protein,macromolecule or enzyme. Thus, transcriptional or translationalregulatory pathways can indirectly alter a protein, macromolecule orenzyme or an associated reaction. Similarly, indirect regulatoryreactions can include reactions that occur due to downstream componentsor participants in a regulatory reaction network. When used in referenceto a data structure or in silica Homo sapiens model, for example, theterm is intended to mean a first reaction that is related to a secondreaction by a function that alters the flux through the second reactionby changing the value of a constraint on the second reaction.

As used herein, the term “regulatory data structure” is intended to meana representation of an event, reaction or network of reactions thatactivate or inhibit a reaction, the representation being in a formatthat can be manipulated or analyzed. An event that activates a reactioncan be an event that initiates the reaction or an event that increasesthe rate or level of activity for the reaction. An event that inhibits areaction can be an event that stops the reaction or an event thatdecreases the rate or level of activity for the reaction. Reactions thatcan be represented in a regulatory data structure include, for example,reactions that control expression of a macromolecule that in turn,performs a reaction such as transcription and translation reactions,reactions that lead to post translational modification of a protein orenzyme such as phophorylation, dephosphorylation, prenylation,methylation, oxidation or covalent modification, reactions that processa protein or enzyme such as removal of a pre- or pro-sequence, reactionsthat degrade a protein or enzyme or reactions that lead to assembly of aprotein or enzyme.

As used herein, the term “regulatory event” is intended to mean amodifier of the flux through a reaction that is independent of theamount of reactants available to the reaction, A modification includedin the term can be a change in the presence, absence, or amount of anenzyme that performs a reaction, A modifier included in the term can bea regulatory reaction such as a signal transduction reaction or anenvironmental condition such as a change in pH, temperature, redoxpotential or time. It will be understood that when used in reference toan in silica Homo sapiens model or data structure, or when used inreference to a model or data structure for a multicellular interaction,a regulatory event is intended to be a representation of a modifier ofthe flux through a Homo sapiens reaction or reaction occurring in one ormore cells in a multicellular interaction that is independent of theamount of reactants available to the reaction.

The effects of regulation on one or more reactions that occur in Homosapiens can be predicted using an in silica Homo sapiens model ormulticellular model of the invention. Regulation can be taken intoconsideration in the context of a particular condition being examined byproviding a variable constraint for the reaction in an in silica Homosapiens model or multicellular model. Such constraints constitutecondition-dependent constraints. A data structure can representregulatory reactions as Boolean logic statements (Reg-reaction). Thevariable takes on a value of I when the reaction is available for use inthe reaction network and will take on a value of 1 if the reaction isrestrained due to some regulatory feature. A series of Booleanstatements can then be introduced to mathematically represent theregulatory network as described for example in Covert et al. J. Theor.Biol. 213:73-88 (2001). For example, in the case of a transport reaction(A_in) that imports metabolite A, where metabolite A inhibits reactionR2 as shown in FIG. 4, a Boolean rule can state that:

Reg−R2=IF NOT(A_in).   (Eq. 2)

This statement indicates that reaction R2 can occur if reaction A_in isnot occurring (i.e. if metabolite A is not present). Similarly, it ispossible to assign the regulation to a variable A which would indicatean amount of A above or below a threshold that leads to the inhibitionof reaction R2. Any function that provides values for variablescorresponding to each of the reactions in the biochemical reactionnetwork can be used to represent a regulatory reaction or set ofregulatory reactions in a regulatory data structure. Such functions caninclude, for example, fuzzy logic, heuristic rule-based descriptions,differential equations or kinetic equations detailing system dynamics.

A reaction constraint placed on a reaction can be incorporated into anin silico Homo sapiens model or mulicellular model of interacting cellsusing the following general equation:

(Reg−Reaction)*b _(j) ≤v _(j) ≤a _(j)*(Reg−Reaction), ∀=1 . . . n   (Eq.3)

For the example of reaction R2 this equation is written as follows:

(0)*Reg−R2≤R2≤(∞)*Reg−R2.   (Eq. 4)

Thus, during the course of a simulation, depending upon the presence orabsence of metabolite A in the interior of the cell where reaction R2occurs, the value for the upper boundary of flux for reaction R2 willchange from 0 to infinity, respectively.

With the effects of a regulatory event or network taken intoconsideration by a constraint function and the condition-dependentconstraints set to an initial relevant value, the behavior of the Homosapiens reaction network or one or more reaction networks of amulticellular interaction can be simulated for the conditions consideredas set forth below.

Although regulation has been exemplified above for the case where avariable constraint is dependent upon the outcome of a reaction in thedata structure, a plurality of variable constraints can he included inan in silico Homo sapiens model or other model of multicellularinteractions to represent regulation of a plurality of reactions.Furthermore, in the exemplary case set forth above, the regulatorystructure includes a general control stating that a reaction isinhibited by a particular environmental condition. Using a generalcontrol of this type, it is possible to incorporate molecular mechanismsand additional detail into the regulatory structure that is responsiblefor determining the active nature of a particular chemical reactionwithin an organism.

Regulation can also be simulated by a model of the invention and used topredict a Homo sapiens physiological function without knowledge of theprecise molecular mechanisms involved in the reaction network beingmodeled, Thus, the model can be used to predict, in overall regulatoryevents or causal relationships that are not apparent from in vivoobservation of any one reaction in a network or whose in vivo effects ona particular reaction are not known. Such overall regulatory effects caninclude those that result from overall environmental conditions such aschanges in pH, temperature, redox potential, or the passage of time.

As described previously and further below, the models and method of theinvention are applicable to a wide range of multicellular interactions.The multicellular interactions include, for example, interactionsbetween prokaryotic cells such as colony growth and chemotaxis. Themulticellular interactions include, for example, interactions betweentwo or more eukaryotic cells such as the concerted action of two or morecells of the same or different cell type. A specific example of theconcerted action of the same cell type includes the combined output ofthe contractile activity of myocytes. A specific example of theconcerted action of different cell types includes the energy productionof adipocyte cells and the contractile activity of myocyte cells basedon the consumption of energy available from the adipocyte cells.Multicellular interactions also can include, for example, interactionsbetween host cells and a pathogen, such as a bacteria, virus or worm. aswell as symbiotic interactions between host cells and microbes, forexample. A symbiotic microbe can include, for example, E. coli. Furtherexamples of host and microbe interactions include bacterial communitiesthat reside in the skin and mouth and the vagina flora, providing thehost with a defense against infections. Moreover, the models and methodsof the invention also can be used to reconstruction the reactionnetworks between a plurality of dynamic multicellular interactionsincluding, for example, interactions between host cells or tissues,pathogen and symbiotic microbe.

Multicellular interactions also include, for example, interactionsbetween cells of different tissues, different organs and/orphysiological systems as well as interactions between some or all cells,tissues organs and/or physiological systems within a multicellularorganism. Specific examples of such interactions include organismichomeostasis. signal transduction, the endocrine system, the exocrinesystem, sensory transduction, secretion, the hematopoietic system, theimmune system, cell migration, cell adherence, cell invasion andneuronal and synaptic transduction. Numerous other multicellularinteractions are well known in the art and can similarly bereconstructed and simulated to predict an activity thereof using themodels and methods of the invention.

Given the teachings and guidance provided herein with respect to theconstruction and use of multiple reaction networks including, forexample, the regulated and metabolic reaction networks of a Homo sapienscell, those skilled in the art will know how to employ the models andmethods of the invention for the construction and use of anymulticellular interaction. Specific examples of such multicellularinteractions are described above. Other examples of multicellularinteractions include, for example, all interactions occurring betweentwo or more cells such as those cells set forth in Table 5 below. Suchmulticellular interactions can occur between cells within the same ordifferent physiological category or functional characterization.Similarly, such multicellular interactions also can occur between cellswithin the same and between different physiological categories orfunctional characterizations. The number and types of different cellularinteractions will be determined by the multicellular model beingproduced using the methods of the invention.

Models of multicellular interactions also can include, for example,interactions between cells of one or more tissues and organs. The modelsand methods of the invention are applicable to predict the activity ofinteractions between some or all cell types of a tissue or organ. Themodels and methods of the invention also can include reaction networksthat include interactions between some or all cell types of two or moretissues or organs. Specific examples of tissues or organs and theirrespective cell types and functions are shown below in Table 6. Themodels and methods of the invention can include, for example, some orall of these interactions to predict their respective activities.Similarly, Table 7 exemplifies the cell types of a liver. Given theteachings and guidance provided herein, the models and methods of theinvention can be used to construct an in silico reconstruction of thereaction networks for some or all of these cell types to predict some orall of the activities of the liver. Further, an in silico reconstructionof reaction networks for some or all multicellular interactionsexemplified in Tables 5-7, including those within and between tissuesand organs, can be produced that can be used to predict some or allactivities of one or more tissues or of an organism. Therefore, theinvention provides for the in silky) reconstruction of whole organisms,including human organisms, tissues, cells and physical or physiologicalfunctions performed by such cellular systems.

The invention also provides for the in silky reconstruction of aplurality of reaction networks that interact to perform the same ordifferent activity. The plurality can be a small, medium or largeplurality and can reside within the same cell, different cells or indifferent tissues or organisms. Specific examples of such pluralitiesresiding within the same cell include the reaction networks exemplifiedbelow in Example IV for a myocyte or for an adipocyte. Specific examplesof such pluralities residing in different cells or tissues include thereaction networks exemplified below in Example IV for coupledadipocyte-myocyte metabolism. Another example of interactions betweendifferent reaction networks within different networks includesinteractions between pathogen and host cells.

Briefly, and as described previously, a computer readable medium ormedia can be produced that includes a plurality of data structures eachrelating a plurality of reactants to a plurality of reactions from eachcell within the multicellular interaction. The reactions include areactant identified as a substrate of the reaction, a reactantidentified as a product of the reaction and a stoichiometric coefficientrelating the substrate and said product In a two cell interaction,including populations of two cell types, the plurality of datastructures can include a first data structure and a second datastructure corresponding to the reactions within the two cells orpopulations of two cell types. The data structures will describe thereaction networks for each cell.

For optimization of the multicellular interaction containing two cells,a third data structure is particularly useful for relating a pluralityof intra-system reactants to a plurality of intra-system reactionsbetween the first and second cells. Each of the intra-system reactionsincludes a reactant identified as a substrate of the reaction, areactant identified as a product of the reaction and a stoichiometriccoefficient relating the substrate and said product. The inta-systemdata structure can be included in the reconstruction as an independentdata structure or as a component of one or more data structures foreither or both cells within such a two cell interaction model. Aspecific example of intra-system reactions represented by a third datastructure is shown in FIGS. 10-1 through 10-70 for the bicarbonate andammonia buffer systems employed in the two cell model describingadipocyte and myocyte interactions.

As with the models and methods of the invention described above andbelow, a computer readable medium or media describing a multicellularinteraction also will contain a constraint set for the plurality ofreactions for each of the first, second and third data structures aswell as commands for determining at least one flux distribution thatminimizes or maximizes an objective function when said constraint set isapplied to said first and second data structures. The objective functioncan be, for example, those objective functions exemplified previously,those exemplified below or in the Examples as well as various otherobject functions well known to those skilled in the art given theteachings and guidance provided herein. Solving the optimization problemby determining one or more flux distribution will predict aphysiological function of occurring as a result of the interactionbetween the first and second cells of the model.

Each of the first, second or third data structures can include one ormore reaction networks. For example, and with reference to FIGS. 5-1through 5-9, 6, 7-1 through 7-35, 8, 9-1 through 9-35, and 10-1 through10-70, a reaction network for each of the cells exemplified therein canbe defined as the different networks within each cell such as centralmetabolism and the cell specific reactions. Applying this view, theadipocyte and myocyte cells each contain at least two reaction networks.When combined together with the intra-cellular reaction network and theexchange reactions, the interactions of the two cells exemplified inFIG. 6 can be described by at least five different reaction networks.The interactions of this two cell model can therefore be described usingat least five data structures. Alternatively, a reaction network can bedefined as all the networks within each cell. When combined togetherwith the intra-cellular reaction network and the exchange reactions, theinteractions of the exemplified adipocyte and myocyte cells can bedescribed by at least three different reaction networks. One reactionnetwork for each cell and one reaction network for the intra-systemreactions. Therefore, each of the first, second or third data structurescan consist of a plurality of two or more reaction networks including,for example, 2. 3, 4. 5. 10, 20 or 25 or more as well as all integernumbers between and above these exemplary numbers. Similarly. given theteachings and guidance provided herein, the models and methods of theinvention can be generated and used to predict an activity and/orphysiological function of the intercellular network interactions or theintracellular network interaction. The latter interactions, for example,also predict an activity and/or a physiological function of theinteractions between two or more cells including cells of differenttissues, organs of a multicellular organism or of a whole organism.

As with the number of reaction networks within a data structure, themodels and methods of the invention also can employ greater than threedata structures as exemplified above. For example, the models and methodof the invention can comprise one or more fourth data structures havingone or more fourth constraint sets where each fourth data structurerelates a plurality of reactants to a plurality of reactions from a cellalready included in the model or from one or more third cells within themulticellular interaction. Use of one or more fourth data structures isparticularly useful when reconstructing a interactions between three ormore interacting cells including a large plurality of cells such as thecells within a tissue, organ, physiological system or organism. Each ofthe reactions within such fourth data structures include a reactantidentified as a substrate of the reaction, a reactant identified as aproduct of the reaction and a stoichiometric coefficient relating thesubstrate and said product.

The number of fourth data structures can correspond to the number ofcells greater than the first and second cells of the multicellularinteraction and include, for example, a plurality of data structures. Aswith the specific embodiment a two cell interaction, the plurality ofdata structures for three or more interacting cells can correspond todifferent cells within the cellular interaction as well as correspond todifferent cell types within the cellular interaction. The number ofcells can include, for example, at least 4 cells, 5 cells, 6 cells, 7cells, 8 cells, 9 cells, 10 cells, 100 cells, 1000 cells, 5000 cells,10,000 cells or more. Therefore, the number of cells within amulticellular interaction model or used in a method of predicting abehavior of such multicellular interactions can include some or ailcells which constitute a group of interacting cells, a tissue, organ,physiological system or whole organism. The multicellular interactionmodels and methods of the invention also can include some or all cellswhich constitute a group of interacting cells of different types or fromdifferent tissues, organs, physiological systems or organisms. Theorganism can be single cell prokaryotic or eukaryotic organism ormulticellular eukaryotic organisms. Specific examples of different celltypes include a mammary gland cell, hepatocyte, white fat cell, brownfat cell, liver lipocyte, red skeletal muscle cell, white skeletalmuscle cell, intermediate skeletal muscle cell, smooth muscle cell, redblood cell, adipocyte, monocyte, reticulocyte, fibroblast, neuronal cellepithelial cell or one or more cells set forth in Table 5. Specificexamples of physiological functions resulting from multicellularinteractions that can be predicted include metabolite yield, ATP yield,biomass demand, growth, triacylglycerol storage, muscle contraction,milk secretion and oxygen transport capacity.

Intra-system reactions of a multicellular interaction model or method ofthe invention has been exemplified above and below with reference to theextracellular in vivo environment and, in particular, with reference tobuffering this environment by supplying functions of the renal system.Given the teachings and guidance provided herein, those skilled in theart will understand that any extracellular reaction, plurality ofreactions, function of the extracellular space or function supplied intothe extracellular space by another cell, tissue or physiological systemcan be employed as an intra-system reaction network. Such reactions oractivities can represent normal or pathological conditions or bothconditions occurring within this intra-system environment. Specificexamples of intra-system reactions include one or more reactionsperformed in the hematopoietic system, urine, connective tissue,contractile tissue or cells, lymphatic system, respiratory system orrenal system. Reactions or reactants included in one or moreintra-system data structures can be, for example, bicarbonate buffersystem, an ammonia buffer system, a hormone, a signaling molecule, avitamin, a mineral or a combination thereof.

The in silico models of multicellular or multi-network interactions,including Homo sapiens model and methods, described herein can beimplemented on any conventional host computer system, such as thosebased on Intel™. microprocessors and running Microsoft Windows operatingsystems. Other systems, such as those using the UNIX or LINUX operatingsystem and based on IBM™, DECR™. or Motorola™. microprocessors are alsocontemplated. The systems and methods described herein can also beimplemented to run on client-server systems and wide-area networks, suchas the Internet.

Software to implement a method or model of the invention can be writtenin any well-known computer language, such as Java, C, C++, Visual Basic,FORTRAN or COBOL and compiled using any well-known compatible compiler.The software of the invention normally runs from instructions stored ina memory on a host computer system. A memory or computer readable mediumcan be a hard disk, floppy disc, compact disc, magneto-optical disc,Random Access Memory, Read Only Memory or Flash Memory. The memory orcomputer readable medium used in the invention can be contained within asingle computer or distributed in a network. A network can be any of anumber of conventional network systems known in the art such as a localarea network (LAN) or a wide area network (WAN). Client-serverenvironments, database servers and networks that can be used in theinvention are well known in the art. For example, the database servercan run on an operating system such as UNIX, running a relationaldatabase management system, a World Wide Web application and a WorldWide Web server. Other types of memories and computer readable media arealso contemplated to function within the scope of the invention.

A database or data structure of the invention can be represented in amarkup language format including, for example, Standard Generalized.Markup Language (SGML), Hypertext markup language (HTML) or ExtensibleMarkup language (XML). Markup languages can be used to tag theinformation stored in a database or data structure of the invention,thereby providing convenient annotation and transfer of data betweendatabases and data structures. In particular, an XML format can beuseful for structuring the data representation of reactions, reactantsand their annotations; for exchanging database contents, for example,over a network or Internet: for updating individual elements using thedocument object model; or for providing differential access to multipleusers for different information content of a data base or data structureof the invention. XML programming methods and editors for writing XMLcode are known in the art as described, for example, in Ray, “LearningXML” O'Reilly and Associates, Sebastopol, Calif. (2001).

A set of constraints can be applied to a reaction network data structureto simulate the flux of mass through the reaction network under aparticular set of environmental conditions specified by a constraintsset. Because the time constants characterizing metabolic transientsand/or metabolic reactions are typically very rapid, on the order ofmilli-seconds to seconds, compared to the time constants of cell growthon the order of hours to days, the transient mass balances can besimplified to only consider the steady state behavior. Referring now toan example where the reaction network data stucture is a stoichiometricmatrix, the steady state mass balances can be applied using thefollowing system of linear equations

S·v=0   (Eq. 5)

where S is the stoichiometric matrix as defined above and v is the fluxvector. This equation defines the mass, energy, and redox potentialconstraints placed on the metabolic network as a result ofstoichiometry. Together Equations 1 and 5 representing the reactionconstraints and mass balances, respectively, effectively define thecapabilities and constraints of the metabolic genotype and theorganism's metabolic potential. All vectors, v, that satisfy Equation 5are said to occur in the mathematical nullspace of S. Thus, the nullspace defines steady-state metabolic flux distributions that do notviolate the mass, energy, or redox balance constraints. Typically, thenumber of fluxes is greater than the number of mass balance constraints,thus a plurality of flux distributions satisfy the mass balanceconstraints and occupy the null space. The null space, which defines thefeasible set of metabolic flux distributions, is further reduced in sizeby applying the reaction constraints set forth in Equation 1 leading toa defined solution space. A point in this space represents a fluxdistribution and hence a metabolic phenotype for the network. An optimalsolution within the set of all solutions can be determined usingmathematical optimization methods when provided with a stated objectiveand a constraint set. The calculation of any solution constitutes asimulation of the model.

Objectives for activity of a human cell can be chosen. While the overallobjective of a multi-cellular organism may be growth or reproduction,individual human cell types generally have much more complex objectives,even to the seemingly extreme objective of apoptosis (programmed celldeath), which may benefit the organism but certainly not the individualcell. For example, certain cell types may have the objective ofmaximizing energy production, while others have the objective ofmaximizing the production of a particular hormone, extracellular matrixcomponent, or a mechanical property such as contractile force. In caseswhere cell reproduction is slow, such as human skeletal muscle, growthand its effects need not be taken into account. In other cases, biomasscomposition and growth rate could be incorporated into a “maintenance”type of flux, where rather than optimizing for growth, production ofprecursors is set at a level consistent with experimental knowledge anda different objective is optimized.

Certain cell types, including cancer cells, can be viewed as having anobjective of maximizing cell growth. Growth can be defined in terms ofbiosynthetic requirements based on literature values of biomasscomposition or experimentally determined values such as those obtainedas described above. Thus, biomass generation can be defined as anexchange reaction that removes intermediate metabolites in theappropriate ratios and represented as an objective function, In additionto draining intermediate metabolites this reaction flux can be formed toutilize energy molecules such as ATP, NADH and NADPH so as toincorporate any maintenance requirement that must be met. This newreaction flux then becomes another constraint/balance equation that thesystem must satisfy as the objective function. Using the stoichiometricmatrix of FIG. 3 as an example, adding such a constraint is analogous toadding the additional column to the stoichiometric matrix to representfluxes to describe the production demands placed on the metabolicsystem. Setting this new flux as the objective function and asking thesystem to maximize the value of this flux for a given set of constraintson all the other fluxes is then a method to simulate the growth of theorganism.

Continuing with the example of the stoichiometric matrix applying aconstraint set to a reaction network data structure can be illustratedas follows. The solution to equation 5 can be formulated as anoptimization problem, in which the flux distribution that minimizes aparticular objective is found. Mathematically, this optimization problemcan be stated as:

Minimize Z   (Eq. 6)

where z=Σc ₁ ·v _(t)   (Eq. 7)

where Z is the objective which is represented as a linear combination ofmetabolic fluxes v_(i) using the weights c_(i) in this linearcombination. The optimization problem can also be stated as theequivalent maximization problem; i.e. by changing the sign on Z. Anycommands for solving the optimization problem can be used including, forexample, linear programming commands.

A computer system of the invention can further include a user interfacecapable of receiving a representation of one or more reactions. A userinterface of the invention can also be capable of sending at least onecommand for modifying the data structure, the constraint set or thecommands for applying the constraint set to the data representation, ora combination thereof. The interface can be a graphic user interfacehaving graphical means for making selections such as menus or dialogboxes. The interface can be arranged with layered screens accessible bymaking selections from a main screen. The user interface can provideaccess to other databases useful in the invention such as a metabolicreaction database or links to other databases having informationrelevant to the reactions or reactants in the reaction network datastructure or to a multicellular organism's physiology, including Homosapiens physiology. Also, the user interface can display a graphicalrepresentation of a reaction network or the results of a simulationusing a model of the invention.

Once an initial reaction network data structure and set of constraintshas been created, this model can be tested by preliminary simulation.During preliminary simulation, gaps in the network or “dead-ends” inwhich a metabolite can be produced but not consumed or where ametabolite can be consumed but not produced can be identified. Based onthe results of preliminary simulations areas of the metabolicreconstruction that require an additional reaction can be identified.The determination of these gaps can be readily calculated throughappropriate queries of the reaction network data structure and need notrequire the use of simulation strategies, however, simulation would bean alternative approach to locating such gaps.

In the preliminary simulation testing and model content refinement stagethe existing model is subjected to a series of functional tests todetermine if it can perform basic requirements such as the ability toproduce the required biomass constituents and generate predictionsconcerning the basic physiological characteristics of the particularcell type being modeled. The more preliminary testing that is conductedthe higher the quality of the model that will be generated. Typically,the majority of the simulations used in this stage of development willbe single optimizations. A single optimization can be used to calculatea single flux distribution demonstrating how metabolic resources arerouted determined from the solution to one optimization problem. Anoptimization problem can be solved using linear programming asdemonstrated in the Examples below. The result can be viewed as adisplay of a flux distribution on a reaction map. Temporary reactionscan be added to the network to determine if they should be included intothe model based on modeling/simulation requirements.

Once a model of the invention is sufficiently complete with respect tothe content of the reaction network data structure according to thecriteria set forth above, the model can be used to simulate activity ofone or more reactions in a reaction network. The results of a simulationcan be displayed in a variety of formats including, for example, atable, graph, reaction network, flux distribution map or a phenotypicphase plane graph.

Thus, the invention provides a method for predicting a Homo sapiensphysiological function. The method includes the steps of (a) providing adata structure relating a plurality of Homo sapiens reactants to aplurality of Homo sapiens reactions, wherein each of the Homo sapiensreactions includes a reactant identified as a substrate of the reaction,a reactant identified as a product of the reaction and a stoichiometriccoefficient relating said substrate and said product; (b) providing aconstraint set for the plurality of Homo sapiens reactions; (c)providing an objective function, and (d) determining at least one fluxdistribution that minimizes or maximizes the objective function when theconstraint set is applied to the data structure, thereby predicting aHomo sapiens physiological function.

A method for predicting a Homo sapiens physiological function caninclude the steps of (a) providing a data structure relating a pluralityof Homo sapiens reactants to a plurality of Homo sapiens reactions,wherein each of the Homo sapiens reactions includes a reactantidentified as a substrate of the reaction, a reactant identified as aproduct of the reaction and a stoichiometric coefficient relating thesubstrate and the product, and wherein at least one of the reactions isa regulated reaction: (b) providing a constraint set for the pluralityof reactions, wherein the constraint set includes a variable constraintfor the regulated reaction; (c) providing a condition-dependent value tothe variable constraint; (d) providing an objective function, and (e)determining at least one flux distribution that minimizes or maximizesthe objective function when the constraint set is applied to the datastructure, thereby predicting a Homo sapiens physiological function.

Further, a method for predicting a physiological function of amulticellular organism also is provided. The method includes: (a)providing a first data structure relating a plurality of reactants to aplurality of reactions from a first cell, each of said reactionscomprising a reactant identified as a substrate of the reaction, areactant identified as a product of the reaction and a stoichiometriccoefficient relating said substrate and said product; (b) providing asecond data structure relating a plurality of reactants to a pluralityof reactions from a second cell, each of said reactions comprising areactant identified as a substrate of the reaction, a reactantidentified as a product of the reaction and a stoichiometric coefficientrelating said substrate and said product: (c) providing a third datastructure relating a plurality of intra-system reactants to a pluralityof intra-system reactions between said first and second cells, each ofsaid intra-system reactions comprising a reactant identified as asubstrate of the reaction, a reactant identified as a product of thereaction and a stoichiometric coefficient relating said substrate andsaid product: (d) providing a constraint set for said plurality ofreactions for said first, second and third data structures; (e)providing an objective function, and (f) determining at least one fluxdistribution that minimizes or maximizes an objective function when saidconstraint set is applied to said first and second data structures,wherein said at least one flux distribution is predictive of aphysiological function of said first and second cells.

As used herein, the term “physiological function,” when used inreference to Homo sapiens, is intended to mean an activity of anorganism as a whole, including a multicellular organism and/or a Homosapiens organism or cell as a whole. An activity included in the termcan be the magnitude or rate of a change from an initial state of, forexample, two or more interacting cells or a Homo sapiens cell to a finalstate of the two or more interacting cells or the Homo sapiens cell. Anactivity included in the term can be, for example, growth, energyproduction, redox equivalent production, biomass production,development, or consumption of carbon nitrogen, sulfur, phosphate,hydrogen or oxygen. An activity can also be an output of a particularreaction that is determined or predicted in the context of substantiallyall of the reactions that affect the particular reaction in two or moreinteracting cells or a Homo sapiens cell, for example, or substantiallyall of the reactions that occur in a plurality of interacting cells suchas a tissue, organ or organism, or substantially all of the reactionsthat occur in a Homo sapiens cell (e.g., muscle contraction). Examplesof a particular reaction included in the term are production of biomassprecursors, production of a protein, production of an amino acid,production of a purine, production of a pyrimidine, production of alipid, production of a fatty acid, production of a cofactor or transportof a metabolite. A physiological function can include an emergentproperty which emerges from the whole but not from the sum of partswhere the parts are observed in isolation (see for example, Nilsson,Nat. Biotech 18:1147-1150 (2000)),

A physiological function of reactions within two or more interactingcells, including Homo sapiens reactions, can be determined using phaseplane analysis of flux distributions. Phase planes are representationsof the feasible set which can be presented in two or three dimensions.As an example, two parameters that describe the growth conditions suchas substrate and oxygen uptake rates can be defined as two axes of atwo-dimensional space. The optimal flux distribution can be calculatedfrom a reaction network data structure and a set of constraints as setforth above for all points in this plane by repeatedly solving thelinear programming problem while adjusting the exchange fluxes definingthe two-dimensional space. A finite number of qualitatively differentmetabolic pathway utilization patterns can be identified in such aplane, and lines can be drawn to demarcate these regions. Thedemarcations defining the regions can be determined using shadow pricesof linear optimization as described, for example in Chvatal, LinearProgramming New York, W.H. Freeman and Co. (1983). The regions arereferred to as regions of constant shadow price structure. The shadowprices define the intrinsic value of each reactant toward the objectivefunction as a number that is either negative, zero, or positive and aregraphed according to the uptake rates represented by the x and y axes.When the shadow prices become zero as the value of the uptake rates arechanged there is a qualitative shift in the optimal reaction network.

One demarcation line in the phenotype phase plane is defined as the lineof optimality (LO). This line represents the optimal relation betweenrespective metabolic fluxes. The LO can be identified by varying thex-axis flux and calculating the optimal y-axis flux with the objectivefunction defined as the growth flux. From the phenotype phase planeanalysis the conditions under which a desired activity is optimal can bedetermined. The maximal uptake rates lead to the definition of a finitearea of the plot that is the predicted outcome of a reaction networkwithin the environmental conditions represented by the constraint set.Similar analyses can be performed in multiple dimensions where eachdimension on the plot corresponds to a different uptake rate. These andother methods for using phase plane analysis, such as those described inEdwards et al., Biotech Bioeng. 77:27-36(2002), can be used to analyzethe results of a simulation using an in silica Homo sapiens model of theinvention,

A physiological function of Homo sapiens can also be determined using areaction map to display a flux distribution. A reaction map of Homosapiens can be used to view reaction networks at a variety of levels. Inthe case of a cellular metabolic reaction network a reaction map cancontain the entire reaction complement representing a globalperspective. Alternatively, a reaction map can focus on a particularregion of metabolism such as a region corresponding to a reactionsubsystem described above or even on an individual pathway or reaction.

Thus, the invention provides an apparatus that produces a representationof a Homo sapiens physiological function, wherein the representation isproduced by a process including the steps of (a) providing a datastricture relating a plurality of Homo sapiens reactants to a pluralityof Homo sapiens reactions, wherein each of the Homo sapiens reactionsincludes a reactant identified as a substrate of the reaction, areactant identified as a product of the reaction and a stoichiometriccoefficient relating said substrate and said product: (b) providing aconstraint set for the plurality of Homo sapiens reactions; (c)providing an objective function; (d) determining at least one fluxdistribution that minimizes or maximizes the objective function when theconstraint set is applied to the data structure. thereby predicting aHomo sapiens physiological function, and (e) producing a representationof the activity of the one or more Homo sapiens reactions. Similarly,the invention provides an apparatus that produces a representation oftwo or more interacting cells, including a tissue, organ, physiologicalsystem or whole organism wherein data structures are provided relating aplurality o f reactants to a plurality of reactions for each type ofinteracting cell and for one or more intra-system functions. Aconstraint set is provided for the plurality of reactions for theplurality of data structures as well as an objective function thatminimizes or maximizes an objective function when the constraint set isapplied to predict a physiological function of the two or moreinteracting cells. The apparatus produces a representation of theactivity of one more reactions of the two or more interacting cells.

The methods of the invention can be used to determine the activity of aplurality of Homo sapiens reactions including, for example, biosynthesisof an amino acid, degradation of an amino acid, biosynthesis of apurine, biosynthesis of a pyrimidine, biosynthesis of a lipid,metabolism of a fatty acid, biosynthesis of a cofactor, transport of ametabolite and metabolism of an alternative carbon source. In addition,the methods can be used to determine the activity of one or more of thereactions described above or listed in Table 1.

The methods of the invention can be used to determine a phenotype of aHomo sapiens mutant or aberrant cellular interaction between two or morecells. The activity alone or more reactions can be determined using themethods described above, wherein the reaction network data structurelacks one or more gene-associated reactions that occur in Homo sapiensor in a multicellular organism or multicellular interaction.Alternatively, the methods can be used to determine the activity of oneor more reactions when a reaction that does not naturally occur in themodel of multicellular interactions or in Homo sapiens, for example, isadded to the reaction network data structure. Deletion of a gene canalso be represented in a model of the invention by constraining the fluxthrough the reaction to zero, thereby allowing the reaction to remainwithin the data structure. Thus, simulations can be made to predict theeffects of adding or removing genes to or from one or more cells withina multicellular interaction, including Homo sapiens and/or a Homosapiens cell. The methods can be particularly useful for determining theeffects of adding or deleting a gene that encodes for a gene productthat performs a reaction in a peripheral metabolic pathway.

A drug target or target for any other agent that affects a function of amulticellular interaction, including a Homo sapiens function can bepredicted using the methods of the invention. Such predictions can bemade by removing a reaction to simulate total inhibition or preventionby a drug or agent. Alternatively, partial inhibition or reduction inthe activity a particular reaction can be predicted by performing themethods with altered constraints. For example, reduced activity can beintroduced into a model of the invention by altering the a_(j) or b_(j)values for the metabolic flux vector of a target reaction to reflect afinite maximum or minimum flux value corresponding to the level ofinhibition. Similarly, the effects of activating a reaction, byinitiating or increasing the activity of the reaction, can be predictedby performing the methods with a reaction network data structure lackinga particular reaction or by altering the a_(j) or b_(j) values for themetabolic flux vector of a target reaction to reflect a maximum orminimum flux value corresponding to the level of activation. The methodscan be particularly useful for identifying a target in a peripheralmetabolic pathway.

Once a reaction has been identified for which activation or inhibitionproduces a desired effect on a function of a multicellular interaction,including a Homo sapiens function, an enzyme or macromolecule thatperforms the reaction in the multicellular system or a gene thatexpresses the enzyme or macromolecule can be identified as a target fora drug or other agent. A candidate compound for a target identified bythe methods of the invention can be isolated or synthesized using knownmethods. Such methods for isolating or synthesizing compounds caninclude, for example, rational design based on known properties of thetarget (see, for example, DeCamp et al., Protein Engineering Principlesand Practice, Ed. Cleland and Craik, Wiley-Liss, New York, pp. 467-506(1996)), screening the target against combinatorial libraries ofcompounds (see for example. Houghten et al., Nature, 354, 84-86 (1991):Dooley et al., Science 266, 2019-2022 (1994), which describe aniterative approach, or R. Houghten et al. PCT/US91/08694 and U.S. Pat.No. 5,556,762 which describe the positional-scanning approach), or acombination of both to obtain focused libraries. Those skilled in theart will know or will be able to routinely determine assay conditions tobe used in a screen based on properties of the target or activity assaysknown in the art.

A candidate drug or agent, whether identified by the methods describedabove or by other methods known in the art, can be validated using an insilico model or method of multicellular interactions, including a Homosapiens model or method of the invention. The effect of a candidate drugor agent on physiological function can be predicted based on theactivity for a target in the presence of the candidate drug or agentmeasured in vitro or in vivo. This activity can be represented in an insilica model of the multicellular system by adding a reaction to themodel, removing a reaction from the model or adjusting a constraint fora reaction in the model to reflect the measured effect of the candidatedrug or agent on the activity of the reaction. By running a simulationunder these conditions the holistic effect of the candidate drug oragent on the physiological function of the multicellular system,including Homo sapiens physiological function can be predicted.

The methods of the invention can be used to determine the effects of oneor more environmental components or conditions on an activity of, forexample, a multicellular interaction, a tissue, organ. physiologicalfunction or a Homo sapiens cell. As set forth above an exchange reactioncan be added to a reaction network data structure corresponding touptake of an environmental component, release of a component to theenvironment, or other environmental demand. The effect of theenvironmental component or condition can be further investigated byrunning simulations with adjusted a_(j) or b_(j) values for themetabolic flux vector of the exchange reaction target reaction toreflect a finite maximum or minimum flux value corresponding to theeffect of the environmental component or condition. The environmentalcomponent can be, for example an alternative carbon source or ametabolite that when added to the environment of a multicellular system.organism or Homo sapiens cell can be taken up and metabolized. Theenvironmental component can also be a combination of components presentfor example in a minimal medium composition. Thus, the methods can beused to determine an optimal or minimal medium composition that iscapable of supporting a particular activity of a multicellularinteraction or system, including a particular activity of Homo sapiens.

The invention further provides a method for determining a set ofenvironmental components to achieve a desired activity for Homo sapiens.The method includes the steps of (a) providing a data structure relatinga plurality of Homo sapiens reactants to a plurality of Homo sapiensreactions, wherein each of the Homo sapiens reactions includes areactant identified as a substrate of the reaction, a reactantidentified as a product of the reaction and a stoichiometric coefficientrelating the substrate and the product; (b)providing a constraint setfor the plurality of Homo sapiens reactions; (c) applying the constraintset to the data representation, thereby determining the activity of oneor more Homo sapiens reactions (d) determining the activity of one ormore Homo sapiens reactions according to steps (a) through (c), whereinthe constraint set includes an upper or lower bound on the amount of anenvironmental component and (e) repeating steps (a) through (c) with achanged constraint set, wherein the activity determined in step (e) isimproved compared to the activity determined in step (d). Similarly. amethod for determining a set of environmental components to achieve adesired activity for a multicellular interaction also is provided. Themethod includes providing a plurality of data structures relating aplurality of reactants to a plurality of reactions for each type ofinteracting cell and for one or more intra-system functions; providing aconstraint set for the plurality of reactions for the plurality of datastructures as well as providing an objective function that minimizes ormaximizes an objective function when the constraint set is applied topredict a physiological function of the two or more interacting cells;determining the activity of one or more reactions within two or moreinteracting cells using a constraint set having an upper or lower boundon the amount of an environmental component and repeating these stepsuntil the activity is improved.

It is understood that modifications which do not substantially affectthe activity of the various embodiments of this invention are alsoincluded within the definition of the invention provided herein.Accordingly, the following examples are intended to illustrate but notlimit the present invention.

EXAMPLE I

This example shows the construction of a universal Homo sapiensmetabolic reaction database, a Homo sapiens core metabolic reactiondatabase and a Homo sapiens muscle cell metabolic reaction database.This example also shows the iterative model building process used togenerate a Homo sapiens core metabolic model and a Homo sapiens musclecell metabolic model.

A universal Homo sapiens reaction database was prepared from the genomedatabases and biochemical literature. The reaction database shown inTable 1 contains the following information:

-   -   Locus ID—the locus number of the gene found in the LocusLink        website.    -   Gene Ab.—various abbreviations which are used for the gene.    -   Reaction Stoichiometry—includes all metabolites and direction of        the reaction, as well as reversibility,    -   E.C.—The Enzyme Commission number.

Additional information included in the universal reaction database,although not shown in Table 1, included the chapter of Salway, supra(1999), where relevant reactions were found; the cellular location, ifthe reaction primarily occurs in a given compartment the SWISS PROTidentifier, which can be used to locate the gene record in SWISS PROT;the full name of the gene at the given locus; the chromosomal locationof the gene; the Mendelian Inheritance in Man (MIM) data associated withthe gene; and the tissue type, if the gene is primarily expressed in acertain tissue. Overall, 1130 metabolic enzyme- or transporter-encodinggenes were included in the universal reaction database.

Fifty-nine reactions in the universal reaction database were identifiedand included based on biological data as found in Salway supra (1999),currently without genome annotation. Ten additional reactions, notdescribed in the biochemical literature or genome annotation, weresubsequently included in the reaction database following preliminarysimulation testing and model content refinement. These 69 reactions areshown at the end of Table 1.

From the universal Homo sapiens reaction database shown in Table 1, acore metabolic reaction database was established, which included coremetabolic reactions as well as some amino acid and fatty acid metabolicreactions, as described in Chapters 1, 3, 4, 7, 9, 10. 13, 17, 18 and 44of J. G. Salway, Metabolism at a Glance, 2^(nd) ed., Blackwell Science,Malden, Mass. (1999). The core metabolic reaction database included 211unique reactions, accounting for 737 genes in the Homo sapiens genome.The core metabolic reaction database was used, although not in itsentirety, to create the core metabolic model described in Example II.

To allow for the modeling of muscle cells, the core reaction databasewas expanded to include 446 unique reactions, accounting for 889 genesin the Homo sapiens genome. This skeletal muscle metabolic reactiondatabase was used to create the skeletal muscle metabolic modeldescribed in Example II.

Once the core and muscle cell metabolic reaction databases werecompiled, the reactions were represented as a metabolic network datastructure, or “stoichiometric input file.” For example, the coremetabolic network data structure shown in Table 2 contains 33 reversiblereactions. 31 non-reversible reactions, 97 matrix columns and 52 uniqueenzymes. Each reaction in Table 2 is represented so as to indicate thesubstrate or substrates (a negative number) and the product or products(a positive number); the stoichiometry; the name of each reaction (theterm following the zero): and whether the reaction is reversible (an Rfollowing the reaction name). A metabolite that appears in themitochondria is indicated by an “m,” and a metabolite that appears inthe extracellular space is indicated by an “ex.”

To perform a preliminary simulation or to simulate a physiologicalcondition, a set of inputs and outputs has to be defined and the networkobjective function specified. To calculate the maximum ATP production ofthe Homo sapiens core metabolic network using glucose as a carbonsource, a non-zero uptake value for glucose was assigned and ATPproduction was maximized as the objective function, using therepresentation shown in Table 2. The network's performance was examinedby optimizing for the given objective function and the set ofconstraints defined in the input file, using flux balance analysismethods. The model was refined in an iterative manner by examining theresults of the simulation and implementing the appropriate changes.

Using this iterative procedure, two metabolic reaction networks weregenerated, representing human core metabolism and human skeletal musclecell metabolism.

EXAMPLE II

This example shows how human metabolism can be accurately simulatedusing a Homo sapiens core metabolic model.

The human core metabolic reaction database shown in Table 3 was used insimulations of human core metabolism. This reaction database contains atotal of 65 reactions, covering the classic biochemical pathways ofglycolysis, the pentose phosphate pathway, the tricitric acid cycle,oxidative phosphorylation, glycogen storage, the malate/aspartateshuttle, the glycerol phosphate shuttle, and plasma and mitochondrialmembrane transporters. The reaction network was divided into threecompartments: the cytosol, mitochondria, and the extracellular space.The total number of metabolites in the network is 50, of which 35 alsoappear in the mitochondria, This core metabolic network accounts for 250human genes.

To perform simulations using the core metabolic network, networkproperties such as the P/O ratio were specified using Salway. supra(1999) as a reference, Oxidation of NADH through the Electron TransportSystem (ETS) was set to generate 2.5 ATP molecules (i.e. a P/O ratio of2.5 for NADH), and that of FADH₂ was set to 1.5 ATP molecules (i.e. aP/O ratio of 1.5 for FADH₂).

Using the core metabolic network, aerobic and anaerobic metabolisms weresimulated in silico. Secretion of metabolic by-products was in agreementwith the known physiological parameters. Maximum yield of all 12precursor-metabolites (glucose-6-phosphate, fructose-6-phosphate,ribose-5-phosphate, erythrose-4-phosphate, triose phosphate,3-phosphoglycerate, phosphoenolpyruvate, pyruvate, acetyl CoA,α-ketoglutarate, succinyl CoA, and oxaloacetate) was examined and nonefound to exceed the values of its theoretical yield.

Maximum ATP yield was also examined in the cytosol and mitochondria.Salway, supra (1999) reports that in the absence of membraneproton-coupled transport systems, the energy yield is 38 ATP moleculesper molecule of glucose and otherwise 31 ATP molecules per molecule ofglucose. The core metabolic model demonstrated the same values asdescribed by Salway supra (1999). Energy yield in the mitochondria wasdetermined to be 38 molecules of ATP per glucose molecule. This isequivalent to production of energy in the absence of proton-coupletransporters across mitochondrial membrane since all the protons wereutilized only in oxidative phosphorylation. In the cytosol, energy yieldwas calculated to be 30.5 molecules of .ATP per glucose molecule. Thisvalue reflects the cost of metabolite exchange across the mitochondrialmembrane as described by Salway, supra (1999).

EXAMPLE III

This example shows how human muscle cell metabolism can be accuratelysimulated under various physiological and pathological conditions usinga Homo sapiens muscle cell metabolic model.

As described in Example I, the core metabolic model was extended to alsoinclude all the major reactions occurring in the skeletal muscle cell,adding new functions to the classical metabolic pathways found in thecore model, such as fatty acid synthesis and β-oxidation,triacylglycerol and phospholipid formation, and amino acid metabolism.Simulations were performed using the muscle cell reaction database shownin Table 4. The biochemical reactions were again compartmentalized intocytosolic and mitochondrial compartments.

To simulate physiological behavior of human skeletal muscle cells, anobjective function had to be defined. Growth of muscle cells occurs intime scales of several hours to days. The time scale of interest in thesimulation, however, was in the order of several to tens of minutes,reflecting the time period of metabolic changes during exercise. Thus,contraction (defined as, and related to energy production) was chosen tobe the objective function, and no additional constraints were imposed torepresent growth demands in the cell.

To study and test the behavior of the network, twelve physiologicalcases (Table 8) and five disease cases (Table 9) were examined. Theinput and output of metabolites were specified as indicated in Table 8,and maximum energy production and metabolite secretions were calculatedand taken into account.

TABLE 8 Metabolite Exchange 1 2 3 4 5 6 7 8 9 10 11 12 Glucose I I — — II — — — — — — O2 I — I — I — I — I — I — Palmitate I I — — — — — — I I —— Glycogen I I I I — — — — — — — — Phospho- I I — — — — — — — — I Icreatine Triacylglycerol I I — — — — I I — — — — Isoleucine I I — — — —— — — — — — Valine I I — — — — — — — — — — Hydroxy- — — — — — — — — — —— — butyrate Pyruvate O O O O O O O O O O O O Lactate O O O O O O O O OO O O Albumin O O O O O O O O O O O O

TABLE 9 Reaction Disease Enzyme Deficiency Constrained McArdle's diseasephosphorylase GBE1 Tarui's disease phosphofructokianse PFKLPhosphoglycerate kinase phosphoglycerate kinase PGK1R deficiencyPhosphoglycerate mutase phosphoglycerate mutase PGAM3R deficiencyLactate dehydrogenase Lactate dehyrogenase LDHAR deficiency

The skeletal muscle model was tested for utilization of various carbonsources available during various stages of exercise and food starvation(Table 8). The by-product secretion of the network in an aerobic toanaerobic shift was qualitatively compared to physiological outcome ofexercise and found to exhibit the same general features such assecretion of fermentative by-products and lowered energy yield.

The network behavior was also examined for five disease cases (Table 9).The test cases were chosen based on their physiological relevance to themodel's predictive capabilities. In brief, McArdle's disease is markedby the impairment of glycogen breakdown. Tarui's disease ischaracterized by a deficiency in phosphofructokinase. The remainingdiseases examined are marked by a deficiency of metabolic enzymesphosphoglycerate kinase, phosphoglycerate mutase, and lactatedehydrogenase. In each case, the changes in flux and by-productsecretion of metabolites were examined for an aerobic to anaerobicmetabolic shift with glycogen and phosphocreatine as the sole carbonsources to the network and pyruvate, lactate. and albumin as the onlymetabolic by-products allowed to leave the system. To simulate thedisease cases, the corresponding deficient enzyme was constrained tozero. In all cases, a severe reduction in energy production wasdemonstrated during exercise, representing the state of the disease asseen in clinical cases.

EXAMPLE IV

This Example shows the construction and simulation of a multi-cellularmodel demonstrating the interactions between human adipocytes andmonocytes.

The specific examples described above demonstrate the use aconstraint-based approach in modeling metabolism in microbial organismsincluding prokaryotes such as E. coli and eukaryotes such as S.Cerevisiae as well as for complex multicellular organisms requiringregulatory interactions such as humans. Described below is the modelingprocedure, network content, and simulation results including networkcharacteristics and metabolic performance of an integrated two-cellmodel of human adipocyte (fatty cell) and myocyte (muscle cell) usingthe compositions and methods of the invention. Simulations wereperformed to exemplify the coupled function of the two cell types duringdistinct physiological conditions corresponding to the coupled functionof adipocyes and myocytes during sprint and marathon physiologicalconditions.

A human metabolic network model was reconstructed using biochemical,physiological, and genomic data as described previously. Briefly, thecentral metabolic network was used as a template for the construction ofcell-specific models by adding biochemical reactions known to occur inspecific cell-types of interest based on genomic, biochemical, and/orphysiological information. Other methods for reconstructing thecell-specific models included reconstructing all the biochemicalpathways and biochemical reactions that occur in the human metabolismregardless of their tissue specificity and location within the cell in adatabase and then reconstructing cell-, tissue-, organ-specific modelsby separating reactions that occur in specified cells, tissues, and/ororgans based on genomic, physiological, biochemical, and/or highthroughput data such as gene expression. proteomics, metabolomics, andother types of “omic” data. In this latter approach, in addition to thecell-, tissue-, and/or organ-specific reactions, reactions can be addedto balance metabolites and represent the biochemistry, physiology, andgenetics of the cells, tissues, organs, and/or whole human body. In theapproach described below, the initial reconstruction of a centralmetabolic network followed by development of cell-specific models, thereconstruction of a generic central metabolic network is not a necessarystep in reconstructing and modeling human metabolism. Rather, it isperformed to accelerate the reconstruction process.

implementation of the multi-cellular adipocyte-myocyte model isdescribed below with reference to the reconstruction of the constituentcomponents. In this regard, the reconstruction of a central humanmetabolic network is described first followed by the reconstructionprocedures for fatty cell and muscle cell specific networks. Thereconstruction procedure by which the two cell-specific models werecombined to generate a multi-cellular model for human metabolism is thendescribed.

Metabolic Network of Central Human Metabolism

The metabolic network of the central human metabolism was constructed asa template and a starting point for reconstructing more specific cellmodels. To construct a central metabolic network for human metabolism, acompendium of 1557 annotated human genes obtained front KyotoEncyclopedia of Genes and Genomes KEGG, National Center forBiotechnology Information or NCBI, and the Universal Protein Resource orUniProt databases was used. In addition to the genomic and proteomicdata, several primary textbooks and publications on the biochemistry ofhuman metabolism also were used and included the Human Metabolism:Functional Diversity and Integration, Ed. by J. R. Bronk, Harlow,Addison, Wesley, Longman (1999); Textbook of Biochemistry with ClinicalCorrelations, Ed. by Thomas M. Devlin, New York, Wiley-Liss (2002), andMetabolism at a Glance, Ed. by J. G. Salway, Oxford, Maiden, Mass.,Blackwell Science (1999). The network reconstruction of human centralmetabolism included metabolic pathways for glycolysis, glucuneugenesis,citrate cycle (TCA cycle), pentose phosphate pathway, galactose,malonyl-CoA, lactate, and pyruvate metabolism. The methods describedpreviously were similarly used for this reconstruction as well as thosedescribed below. Metabolic reactions were compartmentalized intoextra-cellular space, cytosol, mitochondrion, and endoplasmic reticulum.In addition to the biochemical pathways, exchange reactions wereincluded based on biochemical literature and physiological evidence toprovide the transport of metabolites across different organelles andcytosolic membrane.

The completed central metabolic network for human metabolism is shown inFIGS. 5-1 through 5-9 where dashed lines indicate organelle. cell, orsystem boundary. The large dashed rectangle (black) represents thecytosolic membrane. The large dashed circle (red) represents themitochondrial membrane and small dashed circle (green) represents theendoplasmic reticulum membrane. The human central metabolic networkcontains 80 reactions of which 25 are transporters and 60 uniquemetabolites 5. A representative example of a gene-protein-reactionassociation is shown in FIG. 6 where the open reading frame or ORF(7167) is associated to an mRNA transcript (TPI1). The transcript isthen associated to a translated protein (Tpi1) that catalyzes acorresponding reaction (TPI).

Adipocyte Metabolic Network

Adipocytes are specialized cells for synthesizing and storingtriacylglycerol. Triacylglycerols (TAG's) are synthesized fromdihydroxyacetone phosphate and fatty acids in white adipose tissue.Triacylglycerol synthesized in adipocytes can be hydrolyzed (ordegraded) into fatty acids and glycerol via specialized pathways in thefat cells. The fatty acids that are released from triacylglycerol leavethe cell and are transported to other cell types such as myocytes forenergy production. The fatty acid composition of triacylglycerol inhuman mammary adipose tissue has been experimentally measured (Raclot etal., 324:911-5 (1997)) and includes essential, non-essential, saturated,unsaturated, even-, and odd-chain fatty acids (Table 10).

TABLE 10 Fatty acid composition of fat cell TAG in human, NEFA releasedby these cells in vitro, and relative mobilization (% NEFA/% TAG) offatty acids. TAG NEFA Relative Fatty acid (weight %) (weight %)mobilization C_(12:0) 0.50 ± 0.07 0.45 ± 0.06 0.88 ± 0.02 C_(14:0) 3.08± 0.13 2.94 ± 0.15 0.94 ± 0.01 C_(14:1, n-7) 0.03 ± 0.00 0.03 ± 0.001.07 ± 0.14 C_(14:1, n-5) 0.20 ± 0.01 0.19 ± 0.02 0.96 ± 0.03 C_(15:0)0.33 ± 0.02 0.35 ± 0.02 1.05 ± 0.02 C_(16:0) 22.79 ± 0.56  23.51 ± 0.74 1.02 ± 0.01 C_(16:1, n-9) 0.54 ± 0.01   0.42 ± 0.02*** 0.77 ± 0.01C_(16:1, n-7) 2.77 ± 0.21  3.69 ± 0.34* 1.31 ± 0.02 C_(17:1, n-8) 0.29 ±0.02  0.36 ± 0.02* 1.21 ± 0.03 C_(18:0) 6.67 ± 0.35 6.41 ± 1.39 0.95 ±0.06 C_(18:1, n-9) 40.79 ± 0.52  39.77 ± 0.57  0.96 ± 0.01 C_(18:1, n-7)1.90 ± 0.05 2.12 ± 0.10 1.10 ± 0.03 C_(18:1, n-5) 0.27 ± 0.01 0.31 ±0.03 1.12 ± 0.04 C_(18:2, n-6) 16.23 ± 0.86  16.21 ± 0.62  0.99 ± 0.01C_(18:3, n-6) 0.04 ± 0.00 0.05 ± 0.01 1.27 ± 0.07 C_(18:3, n-3) 0.51 ±0.02   0.75 ± 0.03*** 1.43 ± 0.03 C_(20:0) 0.21 ± 0.02   0.10 ± 0.01***0.47 ± 0.04 C_(20:1, n-11) 0.17 ± 0.01   0.11 ± 0.01*** 0.66 ± 0.03C_(20:1, n-9) 0.84 ± 0.02   0.53 ± 0.02*** 0.62 ± 0.01 C_(20:1, n-7)0.03 ± 0.00  0.02 ± 0.00* 0.67 ± 0.03 C_(20:2, n-9) 0.04 ± 0.00  0.02 ±0.00** 0.63 ± 0.06 C_(20:2, n-6) 0.31 ± 0.02  0.26 ± 0.01* 0.82 ± 0.04C_(20:3, n-6) 0.26 ± 0.03 0.24 ± 0.03 0.90 ± 0.05 C_(20:3, n-3) 0.03 ±0.00 0.03 ± 0.00 0.90 ± 0.06 C_(20:4, n-6) 0.35 ± 0.03   0.57 ± 0.04***1.60 ± 0.04 C_(20:4, n-3) 0.03 ± 0.01 0.04 ± 0.01 1.13 ± 0.16C_(20:5, n-3) 0.04 ± 0.01   0.10 ± 0.01*** 2.25 ± 0.08 C_(22:0) 0.04 ±0.01  0.02 ± 0.01* 0.42 ± 0.05 C_(22:1, n-11) 0.03 ± 0.01  0.01 ± 0.00*0.37 ± 0.02 C_(22:1, n-9) 0.07 ± 0.01  0.03 ± 0.00** 0.45 ± 0.03C_(22:4, n-6) 0.17 ± 0.02  0.10 ± 0.01** 0.58 ± 0.03 C_(22:5, n-6) 0.02± 0.01 0.01 ± 0.00 0.59 ± 0.05 C_(22:5, n-3) 0.20 ± 0.03  0.11 ± 0.01**0.55 ± 0.02 C_(22:6, n-3) 0.21 ± 0.04  0.14 ± 0.02* 0.65 ± 0.04 *P <0.05; **P < 0.01; ***P < 0.001

The adipocyte metabolic model was constructed by adding thenon-essential saturated, unsaturated, even- and odd-chain fatty acidbiosynthetic pathways to the central metabolic network for 21 of thefatty acids listed in Table 10. The remaining 13 essential fatty acidswere supplied to the cell via the extra-cellular space, representing thenutritional intake from the environment. Pathway for biosynthesis oftriacylglycerol (TAG) from all 34 fatty acids was included to accountfor the formation and storage of TAG in adipocytes. Reactions forhydrolysis of TAG into fatty acids were also included to represent TAGdegradation. In addition to fatty acid synthesis and TAG biosynthesisand degradation, transport reactions were included to allow for therelease of fatty acids from intra-cellular space to the environment.

The metabolic model of an adipocyte cell contains a total of 198reactions of which 63 are transporters. The adipocyte cell model isshown in FIGS. 7-1 through 7-35 where dashed lines indicate organelle,cell, or system boundary. The large dashed rectangle (yellow) representsthe adipocyte cytosolic membrane. The two large dashed circles (red)represent the mitochondrial membrane and the small dashed circle at thetop (green) represents the endoplasmic reticulum membrane. As shown,metabolic reactions were compartmentalized into extra-cellular,cytosolic, mitochondrial, and endoplasmic reticulum. As described above,the extra-cellular space represents the environment outside the cell,which can include the space outside the body, connective tissues, andinterstitial space between cells.

Myocyte Metabolic Network

The energy required for muscle contraction is generally supplied byglucose, stored glycogen, phosphocreatine, and fatty acids. The myocytemodel was constructed by adding phosphocreatine kinase reaction,myosin-actin activation mechanism, and β-oxidation pathway to thecentral metabolic network. Muscle contraction was represented by asequential conversion of myoactin to myosin-ATP, myosin-ATP tomyosin-ADP-P, myosin-ADP-P to myosin-actin-ADP-P complex,myosin-actin-ADP-P to myoactin, and subsequently the formation of musclecontraction as shown in FIG. 8.

The conversion of myoactin to myosin-actin-ADP-P complex and musclecontraction results in a net conversion of ATP and H₂O to ADP, H′, andP.

The complete reconstructed metabolic model for myocyte cell metabolismis shown in FIGS. 9-1 through 9-35 where dashed lines indicateorganelle, cell, or system boundary. The large dashed rectangle (brown)represents the myocyte cytosolic membrane. The two large dashed circles(red) represent the mitochondrial membrane. The medium sized dashedcircle (purple) represents the peroxisomal membrane and the small dashedcircle (green) represents the endoplasmic reticulum membrane. Themyocyte network contains a total of 205 reactions of which 46 aretransport reactions. Reactions for utilizing phosphcreatine as well asselected pathways for β-oxidation of saturated, unsaturated, even- andodd-chain fatty acids and their intermediates were also included in themodel and are shown in FIGS. 9-1 through 9-35. As with the previousnetwork models, metabolic reactions were compartmentalized intoextra-cellular, cytosolic, mitochondrial, peroxisomal, and endoplasmicreticulum.

Multi-Cellular Adipocyte-Myocyte Reconstruction

To generate a multi-cellular model for human metabolism, the metabolicfunction of the two models of adipocyte and myocyte were integrated byreconstructing a model that includes all the metabolic reactions in thetwo individual cell types. The interaction of the two cell types werethen represented within an “intra-system” space, which represents theconnective tissues such as blood, urine, and interstitial space, and anoutside environment or “extra-system” space. To represent the uptake ofmetabolites and essential fatty acids from the environment, appropriatetransport reactions were added to exchange metabolites across theextra-system boundary. Additional reactions also were added to balancemetabolites in the intra-system space by including the bicarbonate andammonia buffer systems as they function in the kidneys. These reactionswere initially omitted but were added to improve the model once therequirement for the integrated system to buffer extracellular protons inthe interstitial space became apparent once simulation testing began.The combined adipocyte-myocyte model contains 430 reactions and 240unique metabolites. The complete reconstruction is shown in FIGS. 10-1through 10-70 and a summary of the reactions is set forth in Table I I.A substantially complete listing of all the reactions set forth in FIGS.10-1 through 10-70 is set forth below in Table 15.

TABLE 11 Network properties of central metabolic network, adipocyte,myocyte, and multi-cell adipocyte-myocyte models. Model ReactionsTransporters Compounds Central Metabolism 80 25 60 Adipocyte 198 63 150Myocyte 205 46 167 Adipocyte-Myocyte 430 135 240

In FIGS. 10-1 through 10-70, dashed lines again indicate organelle,cell, or system boundaries. The outer most large dashed rectangle(black) separates the environment inside and outside the human body. Thetwo interior dashed rectangles represents the adipocyte cytosolicmembrane (top, yellow) and the myocyte cytosolic membrane (bottom,brown). The pair of larger dashed circles within the adipocyte andmyocyte cytosol (red) represent the mitochondrial membrane. The mediumsized dashed circle in the myocyte cytosol (purple) represents theperoxisomal membrane and small dashed circle within the adipocyte andmyocyte cytosol (green) represent the endoplasmic reticulum membrane.

Metabolic Simulations

The computational and infrastructure requirements for producing theintegrated multi-cellular model were assessed by examining the networkproperties of first the cell-specific models, and then the integratedmulti-cellular reconstruction.

Metabolic Model of Central Human Metabolism

The metabolic capabilities of the central human model was determinedthrough computation of maximum yield of the 12 precursor metabolites perglucose. The results are shown in Table 12. In all cases, the network'syield was less or equal to the maximum theoretical values except forsuccinyl-CoA. In the case of succinyl-CoA, a higher yield was possibleby incorporating CO₂ via pyruvate carboxylase reaction, PCm. In additionto precursor metabolite yields, the maximum ATP yield per mole ofglucose was computed in the network. The maximum ATP yield for thecentral human metabolism was computed to be 31.5 mol ATP mol glucose,which is consistent with previously calculated values (Vo et al., J.Biol. Chem. 279:39532-40. (2004)).

TABLE 12 Maximum theoretical and central human metabolic network yieldsfor the precursor metabolites per glucose. Units are in mol/mol glucose.Precursor Metabolites Theoretical Central Metabolism Glucose 6-P 1 0.94Fructose 6-P 1 0.94 Ribose 5-P 1.2 1.115 Erythrose 4-P 1.5 1.37Glyceraldehyde 3-P 2 1.775 3-P Glycerate 2 2 Phosphoenolpyruvate 2 2Pyruvate 2 2 Oxaloacetate, mitochondrial 2 1.969 Acetyl-CoA,mitochondrial 2 2 aKeto-glutarate, mitochondrial 1 1 Succinyl-CoA,mitochondrial 1 1.595

The biomass demand in living cells is a requirement for the productionof biosynthetic components such as amino acids, lipids and othermolecules that are needed to provide cell integrity, maintenance, andgrowth. All the biosynthetic components were made from the 12 precursormetabolites in the central metabolism shown in Table 12. The rate ofgrowth and biomass maintenance in mammalian cells however is typicallymuch lower than the rate of metabolic activities. Thus to represent thecells' biosynthetic requirement, a small flux demand was imposed for theproduction of the 12 precursor metabolites while maximizing for ATP. Inthe absence of experimental measurements, the capability of the networkto meet the biosynthetic requirements was examined by constructing areaction in which all the precursor metabolites were made simultaneouslywith stoichiometric coefficients of one as set forth in the reactionbelow:

Precursor Demand:3pg[c]+accoa[m]+akg[m]+e4p[c]+f6p[c]+g3p[c]+g6p[c]oaa[m]+pep[c]+pyr[c]+r5p[c]+succoa[m]→(2)coa[m]

In the absence of quantitative measurement, the above reaction serves todemonstrate the ability of the network to meet both biomass and energyrequirements in the cell simultaneously. The maximum ATP yield for thecentral metabolism with a demand of 0.01 mmol/gDW of precursormetabolites was computed to be 29.0, demonstrating that the energy andcarbon requirements for precursor metabolite generation, as expected,reduce the maximum energy production in the cell and this amount can bequantified using the reconstructed model.

Triacylglycerol Storage and Utilization in Adipocyte Tissue

As described previously, a main function of adipocyte is to synthesize,store, and hydrolyze triacylglycerols. The stored TAG can be used togenerate ATP during starvation or under high-energy demand conditions.TAG hydrolysis results in the formation of fatty acids and glycerol inadipocyte. Fatty acids are transported to other tissues such as themuscle tissue where they can be utilized to generate energy. Glycerol isutilized further by the liver and other tissues where it is convertedinto glycerol phosphate and enters glycolytic pathway.

To simulate the storage of triacylglycerol from glucose in adipocyte,TAG synthesis was simulated by maximizing an internal demand forcytosolic triacylglycerol. The maximum yield of triacylglycerol perglucose was computed to be 0.06 mol TAG/mol glucose, without any biomassdemand. To demonstrate how the stored TAG can he reutilized to producefatty acids, the influx of all other carbon sources including glucosewas constrained to zero and glycerol secretion, which is assumed to betaken up by the liver, was maximized. When 2 mol of cytosolic proton wasallowed to leave the system, a glycerol yield of 1 mol glycerol/mol TAGor 100% was computed. The excess two protons were formed in TAGdegradation pathway. As shown in FIG. 11, degradation of TAG wasperformed in the following three steps: (1) TR1GH_ac_HS_ub; (2)12DGRH_ac_HS_ub, and (3) MGLYCH_ac_HS_ub). Glycerol generated as an endproduct of this pathway was transported out of the cell via aproton-coupled symport mechanism. TAG was hydrolyzed completely to fattyacids and glycerol in three steps and in each step one proton isreleased. Glycerol transport was coupled to one proton. Thus, a netamount of two protons were generated per mol TAG degraded.

To balance protons, an ATPase reaction across the cytosolic membrane wasused. However, since the β-oxidative pathways were not included in thisadipocyte model, this network is unable to use membrane bound ATPase tobalance the internal protons. When oxidative pathways are added to theadipocyte model, the model can completely balance protons.

In addition to triacylglycerol synthesis and hydrolysis, the maximum ATPyield on glucose (YATP/glucose) was computed in the adipocyte model. Asfor the central human metabolic network, YATP/glucose was 31.5 molATP/mol glucose.

Muscle Contraction During Aerobic and Anaerobic Exercise

The required energy in muscle tissue is generally supplied by glucose,stored glycogen, and phosphocreatine. During anaerobic exercise such asa sprint, for example, the blood vessels in the muscle tissue arecompressed and the cells are isolated from the rest of the body (Devlin,supra). This compression restricts the oxygen supply to the tissue andenforces anaerobic energy metabolism in the cell. As a result, lactateis generated to balance the redox potential and must be secreted out ofthe cell. In the liver, lactate is converted into glucose. However,rapid muscle contraction and decreased blood flow to the muscle tissuecause lactate accumulation during anaerobic exercise and quickly impairsmuscle contraction. During starvation or under high-energy demands, theglucose and glycogen storage of the muscle tissue quickly depletes andthe energy storage in triacylglycerol molecules supplied by fatty cellsis used to generate ATP.

To simulate the muscle physiology at steady state, phosphocreatinekinase reaction, myosin-actin activation mechanism, and 0-oxidationpathway were included in the central metabolic network. Thephysiological function of muscle tissue was simulated by determining themaximum amount of contraction that is generated from the energy suppliedby glucose, stored glycogen, phosphocreatine, and supplied fatty acids.

The metabolic capabilities of the myocyte model were assessed by firstcomputing the maximum ATP yield on glucose. As for the central humanmetabolic network, YATP/glucose was 31.5 mol ATP/mol glucose. The musclecontraction was also examined with glucose as the sole carbon source.Maximum muscle contraction with glucose was computed to be 31.5 mol/molglucose in aerobic and 2 mol/mol glucose in anaerobic condition. Lactatewas secreted as a byproduct during anaerobic contraction(Yield/actate/glucose=2 mol/mol).

As lactate accumulates during anaerobic metabolism, its secretion ratequickly fails to meet the demand to release lactate into the blood. Tosimulation the impairment of muscle contraction in anaerobic exercise,the maximum lactate secretion rate was constrained to 75%, 50%, 25%, and0% of its maximum value under anaerobic condition. The results usingthese different constraints are shown in FIG. 12 where the time is shownas an arbitrary unit, rate of contraction and lactate secretion are inmols per cell mass per unit time, r corresponds to rate and laccorresponds to lactate. The results show that as more lactateaccumulates in anaerobic metabolism, the maximum allowable lactatesecretion decreases and maximum muscle contraction decreasedproportionally.

The muscle contraction was simulated also with stored glycogen andphosphocreatine as the energy source. The maximum contraction forglycogen was computed to be 32.5 mol/mol glycogen in aerobic and 3mol/mol glycogen in anaerobic condition. The observed difference betweenthe maximum contraction generated by glycogen in comparison to glucosearises from the absence of the phosphorylation or glucokinase step inthe first step of glycolysis. The results of glycogen versus glucoseutilization are illustrated in FIG. 13 where the glycogen utilizationpathway is shown as the thick bent arrow on the left (red) and theglucose utilization pathway is shown as the thick straight arrow on theright (blue). The dashed circle (green) represents the endoplasmicreticulum membrane. The maximum contraction from phosphocreatine underboth aerobic and anaerobic conditions was computed to be 1 mol/molphosphocreatine. The energy generated from phosphocreatine isindependent of the energy produced through oxidative phosphorylation andthus was computed to be the same in both aerobic and anaerobicconditions.

In addition. β-oxidative pathways in the myocyte tissue were examined bysupplying the network with eicosanoate (n-C20:0), octadecenoate (C18:1,n-9), and pentadecanoate (C15:0) as examples of fatty acid oxidation ofodd- and even-chain, and saturated and unsaturated fatty acids. Theresults are shown in Table 13 and demonstrate that maximum contractionin the myocyte model was 134 mol/mol for eicosanoate, 118.5 mol/mol foroctadecenoate, and 98.5 mol/mol for pentadecanoate. The results alsoshow that on a carbon-mole basis, all the fatty acids yieldedapproximately the same contraction, which was equivalent to ATP yield.Contraction was observed to be larger in terms of carbon yield than thatgenerated from glucose (i.e. ˜6.6 mol ATP/C-mol fatty acid in comparisonto 5.3 mol ATP/C-mol glucose). The maximum ATP yield for palmitate(C16:0) was also computed to be 106 mol ATP/mol palmitate, which wasconsistent with the previously calculated values (Vo et al, supra). Onemol of cytosolic protons per mol of fatty acid was supplied to thenetwork for fatty acid oxidation.

TABLE 13 Maximum contraction in the myocyte model given different fattyacids Maximum Maximum Contraction Contraction Fatty Acid Abbreviation*(mol/mol fatty acid) (mol/C-mol) Eicosanoate C20:0 134 6.7 OctadecenoateC18:1, n-9 118.5 6.6 Palmitate C16:0 106 6.6 Pentadecanoate C15:0 98.56.6 *Abbreviation indicates: number of carbons in the fatty acid, numberof double bonds, carbon number where the 1^(st) double bond appears ifthe fatty acid is unsaturated.

A unit of proton per fatty acid is required in the network to balancefatty acyl CoA formation in the cell as illustrated in the followingreaction:

Fatty Acid Fatty Acid + ATP + CoA → Fatty Acyl-CoA + CoA Ligase: AMP +PPi Adenylate AMP + ATP ↔ (2) ADP Kinase: Inorganic PPi + H₂O → H⁺ + (2)Pi Diphosphatase: Net: Fatty Acid + CoA + (2) ATP + H₂O → FattyAcyl-CoA + (2)O ADP + (2) Pi + H⁺

With respect to ATP balance (i.e. ATP+H₂O→ADP+P_(i)+H^(i)), the netreaction has one mol less H₂O and H′. Water can freely diffuse throughthe membrane. However, cell membrane is impermeable to free protons andthus protons were balanced in all compartments. The proton requirementin the cell can be fulfilled with a proton-coupled fatty acidtransporter. It has been observed that the proton electrochemicalgradient across the inner membrane plays a crucial role in energizingthe long-chain fatty acid transport apparatus in E. coli and the protonelectrochemical gradient across the inner membrane is required foroptimal fatty acid transport (DiRusso et al., Mol. Cell. Biochem.192:41-52 (1999)). Fatty acid transporters in S. cerevisiae have alsobeen studied, however, no evidence is currently available on themechanism of transport. When a proton coupled fatty acid transporter wasused in the model, the requirement for supplying a mol of proton to thesystem was eliminated.

Adipocyte-Myoctye Coupled Functions

Muscle cells largely rely on their stored glycogen and phosphocreatinecontent. During aerobic exercise, however, glucose, glycogen, andphosphcreatine storage of muscle cells are depleted and energygeneration in myocytes is achieved by fatty acid oxidation. Lipolysis orlipid degradation proceeds in muscle cells following the transfer offatty acids from adipocytes to myocytes via blood.

Modeling of multi-cellular metabolism was performed using aconstraint-based approach as described herein where the metabolicnetworks of adipocyte and myocyte were combined into a multi-cellularmetabolic model as shown in FIGS. 10-1 through 10-70. The integratedmodel was assessed by computing the network energy requirements duringanaerobic exercise such as that corresponding to a sprint and aerobicexercise such as that corresponding to a marathon. From a purelyadditive perspective, combining all of the reactions from the adipocytemodel with those from the myocyte model was initially performed as asufficient indicator for the combined network to compute integratedphysiological results. However, with the two models strictly combined inthis manner they were deficient at computing integrated functions suchas those described below and, in particular, the results described inthe “Muscle Contraction in a Marathon” section below. Addition of buffersystems for bicarbonate and ammonia allowed the combined model tofunction more efficiently and predictably. In retrospect, the inclusionof intra-system reactions is consistent with the role that, for example,the kidney plays in integrated metabolic physiology,

Simulation of an Integrated Model for Muscle Contraction During aSprint: The energy requirements of myocytes in a sprint are extremelyhigh and supplied primarily from the fuel present in the muscle. Inaddition, oxygen cannot be transported to the cells fast enough totrigger an aerobic metabolism. It has been estimated that only 5% of theenergy in a sprint is supplied via oxidative phosphorylation and theremaining ATP is generated from anaerobic metabolism from storedglycogen and phosphocreatine (Biochemical and Physiological AspectsHuman Nutrition, Philadelphia, Ed. by M. H. Stipanuk. W. B. Saunders,(2000)).

To simulate the metabolic activity of the muscle in a sprint, themaximum muscle contraction in an aerobic condition was computed bysupplying the multi-cellular model with glucose, glycogen, andphosphocreatine as shown in Table 14. In addition, muscle contractionwas simulated under anaerobic condition by constraining the oxygensupply to zero. Maximum contraction was computed to be the same as inthe isolated myocyte model, as expected, demonstrating that theintegrated model retains the functionalities observed in the single-cellmodel.

TABLE 14 Simulation results in the adipocyte-myocyte integrated model.¹Objective (Cell Aerobic Anaerobic Carbon Source Type) mol/mol carbonsource Glucose Contraction (M) 31.5 2 Glycogen Contraction (M) 32.5 3Phosphocreatine Contraction (M) 1  1 Glucose ATP synthesis (A) 32.5 —Glucose TAG synthesis (A)  0.06 — TAG Glycerol (I)  1* — TAG supplyingC12:0, Contraction (M) 253.9  — C14:0, C15:0, C16:0, C18:0, C18:1 n-9,and C20:0 *Two protons were allowed to leave the cytosol (see section“Triacylglycerol Storage and Utilization in Adipocyte Tissue”) — Notrelevant ¹M, myocyte; A, adipocyte; I, intra-system; TAG,triacylglycerol; C12:0, dodecanoate; C14:0, tetradecanoate; C15:0,pentadecanoate; C16:0, palmitate, C18:0, octadecanoate; C18:1 n-9,octadecenoate; C20:0, eicosanoate

Simulation of an Integrated Model for Muscle Contraction During aMarathon: The total energy expenditure in a marathon is about 12,000 kJor 2868 kcal, which is equivalent to burning about 750 g of carbohydrateor 330 g of fat (Stipanuk, supra). Since the total stored carbohydratein the body is only about 400 to 900 g. the mobilized fatty acids fromadipose tissue provide an important part of the supplied energy to themuscle cells in an aerobic metabolism and especially in a marathon.

To simulate the aerobic oxidation of fatty acid in the muscle cells, theintegrated model was first demonstrated to be able to synthesize andstore triacylglycerol in the adipocyte compartment when supplied byglucose. As for the single cell model, the integrated adipocyte-myocytenetwork was able to store TAG in adipocyte compartment. The results areshown in Table 14. In addition, TAG degradation and fatty acidmobilization to the blood was simulated by maximizing glycerol secretionin the intra-system space generated from the stored TAG in adipocyte. Aswith the single cell model, TAG hydrolysis was simulated with theintegrated adipocyte-myocyte model and maximum glycerol secretion ratewas shown to be the same.

To demonstrate the coupled function of the two cell types, musclecontraction in an aerobic exercise was simulated by constraining allother alternative carbon sources including glucose, stored glycogen, andphosphocreatine to zero and supplying adipocyte with storedtriacylglycerol as an energy source. Exchange fluxes were included toensure the proper transfer of fatty acids between the two models, Themaximum muscle contraction in the network that contains β-oxidativepathways for fatty acids C12:0, C14:0, C15:0, C16:0, C18:0, C18:1 n-9,and C20:0 was simulated and computed to be 253.9 mol/mol TAG. The totalcontraction in this simulation is the sum of maximum contraction that isgenerated if the model was supplied with each fatty acid individually.The results from using the integrated model demonstrated that energygenerated in the muscle cell from triacylglycerol is produced in anadditive fashion and metabolite balance in the two cell types does notreduce the energy production in the cell.

These studies further demonstrate the application of a constraint-basedapproach to modeling multi-cellular integrated metabolic models. Theresults also indicate that modeling multi-cellular networks can beoptimized by incorporating intra-system reactions such as thebicarbonate and ammonia buffer systems into the integratedadipocyte-myocyte model. The reconstructed models and simulation resultsalso demonstrated that metabolic functions of various cell types can bestudied, understood and reproduced using the methods of the invention.Furthermore, coupling of the functions of multiple cell types in asystem was demonstrated through the transport of various metabolites andthe coupled function of different cell types were studied by imposingbiologically appropriate objective function. Finally, the ability topredict further network modifications, such as the transport mechanismof fatty acids into myocyte, using the reconstructed models also wasdemonstrated. These results also indicate that multi-cellular modelingcan be extended to the modeling of more than two cells and whichcorrespond to various cell types including the same specie or amongmultiple different species, tissues, organs, and whole body by includingadditional genomic, biochemical, physiological, and high throughputdatasets.

Throughout this application various publications have been referencedwithin parentheses. The disclosures of these publications in theirentireties are hereby incorporated by reference in this application inorder to more fully describe the state of the art to which thisinvention pertains.

Although the invention has been described with reference to thedisclosed embodiments, those skilled in the art will readily appreciatethat the specific examples and studies detailed above are onlyillustrative of the invention. It should be understood that variousmodifications can be made without departing from the spirit of theinvention. Accordingly, the invention is limited only by the followingclaims.

TABLE 1 Locus ID Gene Ab. Reaction Stoichiometry E.C. 1. CarbohydrateMetabolism 1.1 Glycolysis/Gluconeogenesis [PATH:hsa00010] 3098 HK1 GLC +ATP −> G6P + ADP 2.7.1.1 3099 HK2 GLC + ATP −> G6P + ADP 2.7.1.1 3101HK3 GLC + ATP −> G6P + ADP 2.7.1.1 2645 GCK, HK4, MODY2, NIDDM GLC + ATP−> G6P + ADP 2.7.1.2 2538 G6PC, G6PT G6P + H2O −> GLC + PI 3.1.3.9 2821GPI G6P <−> F6P 5.3.1.9 5211 PFKL F6P + ATP −> FDP + ADP 2.7.1.11 5213PFKM F6P + ATP −> FDP + ADP 2.7.1.11 5214 PFKP, PFK-C F6P + ATP −> FDP +ADP 2.7.1.11 5215 PFKX F6P + ATP −> FDP + ADP 2.7.1.11 2203 FBP1, FBPFDP + H2O −> F6P + PI 3.1.3.11 8789 FBP2 FDP + H2O −> F6P + PI 3.1.3.11226 ALDOA FDP <−> T3P2 + T3P1 4.1.2.13 229 ALDOB FDP <−> T3P2 + T3P14.1.2.13 230 ALDOC FDP <−> T3P2 + T3P1 4.1.2.13 7167 TPI1 T3P2 <−> T3P15.3.1.1 2597 GAPD, GAPDH T3P1 + PI + NAD <−> NADH + 13PDG 1.2.1.12 26330GAPDS, GAPDH-2 T3P1 + PI + NAD <−> NADH + 13PDG 1.2.1.12 5230 PGK1, PGKA13PDG + ADP <−> 3PG + ATP 2.7.23 5233 PGK2 13PDG + ADP <−> 3PG + ATP2.7.2.3 5223 PGAM1, PGAMA 13PDG −> 23PDG 5.4.2.4 23PDG + H2O −> 3PG + PI3.1.3.13 3PG <−> 2PG 5.4.2.1 5224 PGAM2, PGAMM 13PDG <−> 23PDG 5.4.2.423PDG + H2O −> 3PG + PI 3.1.3.13 3PG <−> 2PG 5.4.2.1 669 BPGM 13PDG <−>23PDG 5.4.2.4 23PDG + H2O <−> 3PG + PI 3.1.3.13 3PG <−> 2PG 5.4.2.1 2023EN01, PPH, ENO1L1 2PG <−> PEP + H2O 4.2.1.11 2026 EN02 2PG <−> PEP + H2O4.2.1.11 2027 EN03 2PG <−> PEP + H2O 4.2.1.11 26237 ENOIB 2PG <−> PEP +H2O 4.2.1.11 5313 PKLR, PK1 PEP + ADP −> PYR + ATP 2.7.1.40 5315 PKM2,PK3, THBP1, OIP3 PEP + ADP −> PYR + ATP 2.7.1.40 5160 PDHA1, PHE1A, PDHAPYRm + COAm + NADm −> +NADHm + CO2m + ACCOAm 1.2.4.1 5161 PDHA2, PDHALPYRm + COAm + NADm −> +NADHm + CO2m + ACCOAm 12.4.1 5162 PDHB PYRm +COAm + NADm −> +NADHm + CO2m + ACCOAm 1.2.4.1 1737 DLAT, DLTA, PDC-E2PYRm + COAm + NADm −> +NADHm + CO2m + ACCOAm 2.3.1.12 8050 PDX1, E3BPPYRm + COAm + NADm −> +NADHm + CO2m + ACCOAm 2.3.1.12 3939 LDHA, LDH1NAD + LAC <−> PYR + NADH 1.1.1.27 3945 LDHB NAD + LAC <−> PYR + NADH1.1.1.27 3948 LDHC, LDH3 NAD + LAC <−> PYR + NADH 1.1.1.27 5236 PGM1 G1P<−> G6P 5.4.2.2 5237 PGM2 G1P <−> G6P 5.4.2.2 5238 PGM3 G1P <−> G6P5.4.2.2 1738 DLD, LAD, PHE3, DLDH, E3 DLIPOm + FADm <−> LIPOm + FADH2m1.8.1.4 124 ADH1 ETH + NAD <−> ACAL + NADH 1.1.1.1 125 ADH2 ETH + NAD<−> ACAL + NADH 1.1.1.1 126 ADH3 ETH + NAD <−> ACAL + NADH 1.1.1.1 127ADH4 ETH + NAD <−> ACAL + NADH 1.1.1.1 128 ADH5 FALD + RGT + NAD <−>FGT + NADH 1.2.1.1 ETH + NAD <−> ACAL + NADH 1.1.1.1 130 ADH6 ETH + WAD<−> ACAL + NADH 1.1.1.1 131 ADH7 ETH + NAD <−> ACAL + NADH 1.1.1.1 10327AKR1A1, ALR, ALDR1 1.1.12 97 ACYP1 3.6.1.7 98 ACYP2 3.6.1.7 1.2 Citratecycle (TCA cycle) PATH:hsa00020 1431 CS ACCOAm + OAm + H2Om −> COAm +CITm 4.1.3.7 48 ACO1, IREB1, IRP1 CIT <−> ICIT 4.2.1.3 50 ACO2 CITm <−>ICITm 4.2.1.3 3417 IDH1 ICIT + NADP −> NADPH + CO2 + AKG 1.1.1.42 3418IDH2 ICITm + NADPm −> NADPHm + CO2m + AKGm 1.1.1.42 3419 IDH3A ICITm +NADm −> CO2m + NADHm + AKGm 1,1.1.41 3420 IDH3B ICITm + NADm −> CO2m +NADHm + AKGm 1.1.1.41 3421 IDH3G ICITm + NADm −> CO2m + NADHm + AKGm1.1.1.41 4967 OGOH AKGm + NADm + COAm −> CO2m + NADHm + SUCCOAm 1.2.4.21743 DLST, DLTS AKGm + NADm + COAm −> CO2m + NADHm + SUCCOAm 2.3.1.618802 SUCLG1, SUCLA1 GTPm + SUCCm + COAm <−> GDPm + Plm + SUCCOAm 6.2.1.48603 SUCLA2 ATPm + SUCCm + COAm <−> ADPm + Plm + SUCCOAm 6.2.1.4 2271 FHFUMm + H2Om <−> MALm 4.2.1.2 4190 MDH1 MAl + NAD <−> NADH + OA 1.1.1.374191 MDH2 MALm + NADm <−> NADHm + OAm 1.1.1.37 5091 PC, PCB PYRm +ATPm + CO2m −> ADPm + OAm + Plm 6.4.1.1 47 ACLY, ATPCL, CLATP ATP +CIT + COA + H2O −> ADP + PI + ACCOA + OA 4.1.3.8 3657 5105 PCK1 OA + GTP−> PEP + GDP + CO2 4.1.1.32 5106 PCK2, PEPCK OAm + GTPm −> PEPm + GDPm +CO2m 4.1.1.32 1.3 Pentose phosphate cycle PATH:hsa00030 2539 G6PD, G6PD1G6P + NADP <−> D6PGL + NADPH 1.1.1.49 9563 H6PD 1.1.1.47 D6PGL + H2O −>D6PGC 3.1.1.31 25796 PGLS, 6PGL D6PGL + H2O −> D6PGC 3.1.1.31 5226 PGDD6PGC + NADP −> NADPH + CO2 + RL5P 1.1.1.44 6120 RPE RL5P <−> X5P5.1.3.1 7086 TKT R5P + X5P <−> T3P1 + S7P 2.2.1.1 X5P + E4P <−> F6P +T3P1 8277 TKTL1, TKR, TKT2 R5P + X5P <−> T3P1 + S7P 2.2.1.1 X5P + E4P<−> F6P + T3P1 6868 TALDO1 T3P1 + S7P <−> E4P + F6P 2.2.1.2 5631 PRPS1,PRS I, PRS, I R5P + ATP <−> PRPP + AMP 2.7.6.1 5634 PRPS2, PRS II, PRS,II R5P + ATP <−> PRPP + AMP 2.7.6.1 2663 GDH 1.1.1.47 1.4 Pentose andglucuronate interconversions PATH:hsa00040 231 AKR1B1 , AR, ALDR1, ADR1.1.1.21 7359 UGP1 G1P + UTP −> UDPG + PPI 2.1.7.9 7360 UGP2, UGPP2G1P + UTP−> UDPG + PPI 2.7.7.9 7358 UGDH, UDPGDH 1.1.1.22 10720 UGT2B112.4.1.17 54658 UGT1A1, UGT1A, GNT1, UGT1 2.4.1.17 7361 UGT1A, UGT1,UGT1A 2.4.1.17 7362 UGT2B, UGT2, UGT2B 2.4.1.17 7363 UGT2B4, UGT2B112.4.1.17 7364 UGT2B7, UGT2B9 2.4.1.17 7365 UGT2B10 2.4.1.17 7366UGT2B15, UGT2B8 2.4.1.17 7367 UGT2B17 2.4.1.17 13 AADAC, DAC 3.1.1.—3991 LIPE, LHS, HSL 3.1.1.— 1.5 Fructose and mannose metabolismPATH:hsa00051 4351 MPI, PMI1 MAN6P <−> F6P 5.3.1.8 5372 PMM1 MAN6P <−>MAN1P 5.4.28 5373 PMM2, CDG1, CDGS MAN6P <−> MAN1P 5.4.2.8 2762 GMDS4.2.1.47 8790 FPGT, GFPP 2.7.7.30 5207 PFKFB1, PFRX ATP + F6P −> ADP +F26P 2.7.1.105 F26P −> F6P + PI 3.1.3.46 5208 PFKFB2 ATP + F6P −> ADP +F26P 2.7.1.105 F26P −> F6P + PI 3.1.3.46 5209 PFKF83 ATP + F6P −> ADP +F26P 2.7.1.105 F26P −> F6P + PI 3.1.3.46 5210 PFKFB4 ATP + F6P −> ADP +F26P 2.7.1.105 F26P −> F6P + PI 3.1.3.46 3795 KHK 2.7.1.3 6652 SORDDSOT + NAD −> FRU + NADH 1.1.1.14 2526 FUT4, FCT3A, FUC-TIV 2.4.1.— 2529FUT7 2.4.1.— 3036 HAST HAS 2.4.1.— 3037 HAS2 2.4.1.— 8473 OGT, O-GLCNAC2.4.1.— 51144 LOC51144 1.1.1.— 1.6 Galactose metabolism PATH:hsa000522584 GALK1, GALK, GLAC + ATP −> GAL1P + ADP 2.7.1.6 2585 GALK2, GK2GLAC + ATP −> GAL1P + ADP 2.7.1.6 2592 GALT UTP + GAL1P <−> PPI + UDPGAL2.7.7.10 2582 GALE UDPGAL <−> UDPG 5.1.3.2 2720 GLB1 3.2.1.23 3938 LCT,LAC 3.2.1.62 3.2.1.108 2683 B4GALT1, GGT82, BETA4GAL-T1, 2.4.1.90 GT1,GTB 2.4.1.38 2.4.1.22 3906 LALBA 2.4.1.22 2717 GLA, GALA MELI −> GLC +GLAC 3.2.1.22 2548 GAA MLT −> 2 GLC 3.2.1.20 6DGLC −> GLAC + GLC 2594GANAB MLT −> 2 GLC 3.2.1.20 6DGLC −> GLAC + GLC 2595 GANC MLT −> 2 GLC3.2.1.20 6DGLC −> GLAC + GLC 8972 MGAM, MG, MGA MLT −> 2 GLC 3.2.1.206DGLC −> GLAC + GLC 3.2.1.3 1.7 Ascorbate and aldarate metabolismPATH:hsa00053. 216 ALDH1, PUMB1 ACAL + NAD −> NADH + AC 1.2.1.3 217ALDH2 ACALm + NADm −> NADHm + ACm 1.2.1.3 219 ALDH5, ALDHX 1.2.1.3 223ALDH9, E3 1.2.1.3 1.2.1.19 224 ALDH10, FALDH, SLS 1.2.1.3 8854 RALDH21.2.1.3 1591 CYP24 1.14.—.— 1592 CYP26A1, P450RAI 1.14.—.— 1593 CYP27A1,CTX, CYP27 1.14.—.— 1594 CYP27B1, POOR, VDD1, VDR, CYP1, 1.14.—.— VDDR,I, P450C1 1.8 Pyruvate metabolism PATH:hsa00620 54988 FLJ20581 ATP +AC + COA −> AMP + PPI + ACCOA 6.2.1.1 31 ACACA, ACAC, ACC ACCOA + ATP +CO2 <−> MALCOA + ADP + PI + H 6.4.1.2 6.3.4.14 32 ACACB, ACCB, HACC275,ACC2 ACCOA + ATP + CO2 <−> MALCOA + ADP + PI + H 6.4.1.2 6.6.4.14 2739GLO1, GLYI RGT + MTHGXL <−> LGT 4.4.1.5 3029 HAGH, GLO2 LGT −> RGT + LAC3.1.2.6 2223 FDH FALD + RGT + NAD <−> FGT + NADH 1.2.1.1 9380 GRHPR,GLXR 1.1.1.79 4200 ME2 MALm + NADm −> CO2m + NADHm + PYRm 1.1.1.38 10873ME3 MALm + NADPm −> CO2m + NADPHm + PYRm 1.1.1.40 29897 HUMNDME MAL +NADP −> CO2 + NADPH + PYR 1.1.1.40 4199 ME1 MAL + NADP −> CO2 + NADPH +PYR 1.1.1.40 38 ACAT1, ACAT, T2, THIL, MAT 2 ACCOAm <−> COAm + AACCOAm2.3.1.9 39 ACAT2 2 ACCOAm <−> COAm + AACCOAm 2.3.1.9 1.9 Glyoxylate anddicarboxylate metabolism PATH:hsa00630 5240 PGP 3.1.3.18 2758 GLYD3HPm + NADHm −> NADm + GLYAm 1.1.1.29 10797 MTHFD2, NMDMC METHF <−> FTHF3.5.4.9 METTHF + NAD −> METHF + NADH 1.5.1.15 4522 MTHFD1 METTHF + NADP<−> METHF + NADPH 1.5.1.15 METHF <−> FTHF 3.5.4.9 THF + FOR + ATP −>ADP + PI + FTHF 6.3.4.3 1.10 Propanoate metabolism PATH:hsa00640 34ACADM, MCAD MBCOAm + FADm −> MCCOAm + FADH2m 1.3.99.3 IBCOAm + FADm −>MACOAm + FADH2m IVCOAm + FADm −> MCRCOAm + FADH2m 36 ACADSB MBCOAm +FADm −> MCCOAm + FADH2m 1.3.99.3 IBCOAm + FADm −> MACOAm + FADH2mIVCOAm + FADm −> MCRCOAm + FADH2m 1892 ECHS1, SCEH MACOAm + H2Om −>HIBCOAm 4.2.1.17 MCCOAm + H2Om −> MHVCOAm 1962 EHHADH MHVCOAm + NADm −>MAACOAm + NADHm 1.1.1.35 HIBm + NADm −> MMAm + NADHm MACOAm + H2Om −>HIBCOAm 4.2.1.17 MCCOAm + H2Om −> MHVCOAm 3030 HADHA, MTPA, GBPMHVCOAm + NADm −> MAACOAm + NADHm 1.1.1.35 HIBm + NADm −> MMAm + NADHmMACOAm + H2Om −> HIBCOAm 4.2.1.17 MCCOAm + H2Om −> MHVCOAm C160CARm +COAm + FADm + NADm −> FADH2m + NADHm + 1.1.1.35 C140COAm + ACCOAm4.2.1.17 23417 MLYCD, MCD 4.1.1.9 18 ABAT, GABAT GABA + AKG −> SUCCSAL +GLU 2.6.1.19 5095 PCCA PROPCOAm + CO2m + ATPm −> ADPm + PIm + DMMCOAm6.4.1.3 5096 PCCB PROPCOAm + CO2m + ATPm −> ADPm + PIm + DMMCOAm 6.4.1.34594 MUT, MCM LMMCOAm −> SUCCOAm 5.4.99.2 4329 MMSDH MMAm + COAm + NADm−> NADHm + CO2m + PROPCOAm 1.2.1.27 8523 FACVL1, VLCS, VLACS 6.2.1.—1.11 Butanoate metabolism PATH:hsa00650 3028 HADH2, ERAB C140COAm + 7COAm + 7 FADm + 7 NADm −> 7 FADH2m + 7 1.1.1.35 NADHm + 7 ACCOAm 3033HADHSC, SCHAD 1.1.1.35 35 ACADS, SCAD MBCOAm + FADm −> MCCOAm + FADH2m1.3.99.2 IBCOAm + FADm −> MACOAm + FADH2m 7915 ALDH5A1, SSADH, SSDH1.2.1.24 2571 GAD1, GAD, GAD67, GAD25 GLU −> GABA + CO2 4.1.1.15 2572GAD2 GLU −> GABA + CO2 4.1.1.15 2573 GAD3 GLU −> GABA + CO2 4.1.1.153157 HMGCS1, HMGCS H3MCOA + COA <−> ACCOA + AACCOA 4.1.3.5 3158 HMGCS2H3MCOA + COA <−> ACCOA + AACCOA 4.1.3.5 3155 HMGCL, HL H3MCOAm −>ACCOAm + ACTACm 4.1.3.4 5019 OXCT 2.8.3.5 622 BDH 3HBm + NADm −> NADHm +Hm + ACTACm 1.1.1.30 1629 DBT, BCATE2 OMVALm + COAm + NADm −> MBCOAm +NADHm + CO2m 2.3.1.— OIVALm + COAm + NADm −> IBCOAm + NADHm + CO2mOICAPm + COAm + NADHm −> IVCOAm + NADHm + CO2m 1.13 Inositol metabolismPATH:hsa00031 2. Energy Metabolism 2.1 Oxidative phosphorylationPATH:hsa00190 4535 MTND1 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.34636 MTND2 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 4537 MTND3NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 4538 MTND4 NADHm + Qm + 4Hm −> QH2m + NADm + 4 H 1.6.5.3 4539 MTND4L NADHm + Qm + 4 Hm −> QH2m +NADm + 4 H 1.6.5.3 4240 MIND5 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1.6.5.3 4541 MTND8 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 4694NDUFA1, MWFE NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 4695 NDUFA2,B8 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −>QH2m + NADm + 4 H 1.6.99.3 4696 NDUFA3, B9 NADHm + Qm + 4 Hm −> QH2m +NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4697NDUFA4, MLRQ NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm +4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4698 NDUFA5, UQOR13, 813 NADHm + Qm +4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1.6.99.3 4700 NOUFA6, B14 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4701 NOUFA7, B14.5a,B14.5A NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm−> QH2m + NADm + 4 H 1.6.99.3 4702 NDUFA8, PGIV NADHm + Qm + 4 Hm −>QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1,6.99.3 4704 NDUFA9, NDUFS2L NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4705 NDUFA10NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −>QH2m + NADm + 4 H 1.6.99.3 4706 NDUFAB1, SDAP NADHm + Qm + 4 Hm −>QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1.6.99.3 4707 NDUFB1, MNLL, CI-SGDH NADHm + Qm + 4 Hm −> QH2m + NADm + 4H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4708 NDUFB2,AGGG NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −>QH2m + NADm + 4 H 1.6.99.3 4709 NDUFB3, B12 NADHm + Qm + 4 Hm −> QH2m +NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4710NOUFB4, B15 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm +4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4711 NDUFB5, SGDH NADHm + Qm + 4 Hm−> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1.6.99.3 4712 NDUF86, B17 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4713 NDUFB7, B18 NADHm +Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m +NADm + 4 H 1.6.99.3 4714 NDUFB8, ASHI NADHm + Qm + 4 Hm −> QH2m + NADm +4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4715 NDUFB9,UQOR22, B22 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm +4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4716 NDUFB10, PDSW NADHm + Qm + 4 Hm−> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1.6.99.3 4717 NDUFC1, KFYI NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4718 NDUFC2,B14.5b, B14.58 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm +Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4724 NDUFS4, AQDQ NADHm + Qm + 4Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1.6.99.3 4725 NDUFS5 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4726 NDUFS6 NADHm + Qm +4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1.6.99.3 4731 NDUFV3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 4127NDUFS7, PSST NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm +4 Hm −> QH2m + NADm + 4 H 1.6.99.3 4722 NDUFS3 NADHm + Qm + 4 Hm −>QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1.6.99.3 4720 NDUFS2 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 4729NDUFV2 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm−> QH2m + NADm + 4 H 1.6.99.3 4723 NDUFV1, UQOR1 NADHm + Qm + 4 Hm −>QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1.6.99.3 4719 NDUFS1, PRO1304 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H1.6.99.3 NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 4728 NDUFS8NADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 1.6.5.3 NADHm + Qm + 4 Hm −>QH2m + NADm + 4 H 1.6.99.3 6391 SDHC SUCCm + FADm <−> FUMm + FADH2m1.3.5.1 FADH2m + Qm <−> FADm + QH2m 6392 SDHD, CBT1, PGL, PGL1 SUCCm +FADm <−> FUMm + FADH2m 1.3.5.1 FADH2m + Qm <−> FADm + QH2m 6389 SDHA,SDH2, SDHF, FP SUCCm + FADm <−> FUMm + FADH2m 1.3.5.1 FADH2m + Qm <−>FADm + QH2m 6390 SDHB, SDH1, IP, SDH SUCCm + FADm <−> FUMm + FADH2m1.3.5.1 FADH2m + Qm <−> FADm + QH2m 7386 UQCRFS1, RIS1 O2m + 4 FEROm + 4Hm −> 4 FERIm + 2 H2Om + 4 H 1.10.2.2 4519 MTCYB O2m + 4 FEROm + 4 Hm −>4 FERIm + 2 H2Om + 4 H 1.10.2.2 1537 CYC1 O2m + 4 FEROm + 4 Hm −> 4FERIm + 2 H2Om + 4 H 1.10.2.2 7384 UQCRC1- D3S3191 O2m + 4 FEROm + 4 Hm−> 4 FERIm + 2 H2Om + 4 H 1.10.2.2 7385 UQCRC2 O2m + 4 FEROm + 4 Hm −> 4FERIm + 2 H2Om + 4 H 1.10.2.2 7388 UQCRH O2m + 4 FEROm + 4 Hm −> 4FERIm + 2 H2Om + 4 H 1.10.2.2 7381 UQCRB, QPC, UQBP, QP-C O2m + 4FEROm + 4 Hm −> 4 FERIm + 2 H2Om + 4 H 1.10.2.2 27089 QP-C O2m + 4FEROm + 4 Hm −> 4 FERIm + 2 H2Om + 4 H 1.10.2.2 10975 UQCR O2m + 4FEROm + 4 Hm −> 4 FERIm + 2 H2Om + 4 H 1.10.2.2 1333 COX5BL4 QH2m + 2FERIm + 4 Hm −> Qm + 2 FEROm + 4 H 1.9.3.1 4514 MTCO3 QH2m + 2 FERIm + 4Hm −> Qm + 2 FEROm + 4 H 1.9.3.1 4512 MTCO1 QH2m + 2 FERIm + 4 Hm −>Qm + 2 FEROm + 4 H 1.9.3.1 4513 MTCO2 QH2m + 2 FERIm + 4 Hm −> Qm + 2FEROm + 4 H 1.9.3.1 1329 COX5B QH2m + 2 FERIm + 4 Hm −> Qm + 2 FEROm + 4H 1.9.3.1 1327 COX4 QH2m + 2 FERIm + 4 Hm −> Om + 2 FEROm + 4 H 1.9.3.11337 COX6A1, COX6A QH2m + 2 FERIm + 4 Hm −> Qm + 2 FEROm + 4 H 1.9.3.11339 COX6A2 QH2m + 2 FERIm + 4 Hm −> Qm + 2 FEROm + 4 H 1.9.3.1 1340COX6B QH2m + 2 FERIm + 4 Hm −> Qm + 2 FEROm + 4 H 1.9.3.1 1345 COX6CQH2m + 2 FERIm + 4 Hm −> Qm + 2 FEROm + 4 H 1.9.3.1 9377 COX5A, COX, VA,COX-VA QH2m + 2 FERIm + 4 Hm −> Qm + 2 FEROm + 4 H 1.9.3.1 1346 COX7A1,COX7AM, COX7A QH2m + 2 FERIm + 4 Hm −> Qm + 2 FEROm + 4 H 1.9.3.1 1347COX7A2, COX VIIa-L QH2m + 2 FERIm + 4 Hm −> Om + 2 FEROm + 4 H 1.9.3.11346 COX7A3 QH2m + 2 FERIm + 4 Hm −> Qm + 2 FEROm + 4 H 1.9.3.1 1349COX7B QH2m + 2 FERIm + 4 Hm −> Qm + 2 FEROm + 4 H 1.9.3.1 9167 COX7A2L,COX7RP, EB1 QH2m + 2 FERIm + 4 Hm −> Qm + 2 FEROm + 4 H 1.9.3.1 1350COX7C QH2m + 2 FERIm + 4 Hm −> Qm + 2 FEROm + 4 H 1.9.3.1 1351 COX8, COXVIII QH2m + 2 FERIm + 4 Hm −> Qm + 2 FEROm + 4 H 1.9.3.1 4508 MTATP6ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 4509 MTATP8 ADPm + Pim +3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 499 ATPSA2 ADPm + Pim + 3 H −> ATPm +3 Hm + H2Om 3.6.1.34 507 ATP5BL1, ATPSBL1 ADPm + Pim + 3 H −> ATPm + 3Hm + H2Om 3.6.1.34 508 ATP5BL2, ATPSBL2 ADPm + Pim + 3 H −> ATPm + 3Hm + H2Om 3.6.1.34 519 ATP5H ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om3.6.1.34 537 ATP6S1, ORF, VATPS1, XAP-3 ADPm + Pim + 3 H −> ATPm + 3Hm + H2Om 3.6.1.34 514 ATP5E ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om3.6.1.34 513 ATP5D ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 506ATP5B, ATPSB ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 509 ATP5C1,ATP5C ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 498 ATP5A1, ATP5A,ATPM, OMR, HATP1 ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 539ATP50, ATPO, OSCP ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 516ATP5G1, ATP5G ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 517 ATP5G2ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 518 ATP5G3 ADPm + Pim +3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 515 ATP5F1 ADPm + Pim + 3 H −> ATPm +3 Hm + H2Om 3.6.1.34 521 ATP5I ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om3.6.1.34 522 ATP5J, ATP5A, ATPM, ATP5 ADPm + Pim + 3 H −> ATPm + 3 Hm +H2Om 3.6.1.34 9551 ATP5J2, ATP5JL, F1FO-ATPASE ADPm + Pim + 3 H −>ATPm + 3 Hm + H2Om 3.6.1.34 10476 ATP5JD ADPm + Pim + 3 H −> ATPm + 3Hm + H2Om 3.6.1.34 10632 ATP5JG ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om3.6.1.34 9296 ATP6S14 ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34528 ATP6D ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 523 ATP6A1,VPP2 ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 524 ATP6A2, VPP2ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 525 ATP6B1, VPP3, VATBADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 526 ATP6B2, VPP3 ADPm +Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 523 ATP6E ADPm + Pim + 3 H −>ATPm + 3 Hm + H2Om 3.6.1.34 527 ATP6C, ATPL ADPm + Pim + 3 H −> ATPm + 3Hm + H2Om 3.6.1.34 533 ATP6F ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om3.6.1.34 10312 TdRG1, TIRC7, OC-116, CC-116 kDa, ADPm + Pim + 3 H −>ATPm + 3 Hm + H2Om 3.6.1.34 OC-116 KDA, ATP6N1C 23545 TJ6 ADPm + Pim + 3H −> ATPm + 3 Hm + H2Om 3.6.1.34 50617 ATP6N1B ADPm + Pim + 3 H −>ATPm + 3 Hm + H2Om 3.6.1.34 535 ATP6N1 ADPm + Pim + 3 H −> ATPm + 3 Hm +H2Om 3.6.1.34 51382 VATD ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.348992 ATP6H ADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 9550 ATP6JADPm + Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 51606 LOC51606 ADPm +Pim + 3 H −> ATPm + 3 Hm + H2Om 3.6.1.34 495 ATP4A, ATP6A ATP + H +Kxt + H2O <−> ADP + PI + Hext + K 3.6.1.36 496 ATP4B, ATP6B ATP + H +Kxt + H2O <−> ADP + PI + Hext + K 3.6.1.36 476 ATP1A1 ATP + 3 NA + 2Kxt + H2O <−> ADP + 3 NAxt + 2 K + PI 3.6.1.37 477 ATP1A2 ATP + 3 NA + 2Kxt + H2O <−> ADP + 3 NAxt + 2 K + PI 3.6.1.37 478 ATP1A3 ATP + 3 NA + 2Kxt + H2O <−> ADP + 3 NAxt + 2 K + PI 3.6.1.37 479 ATP1AL1 ATP + 3 NA +2 Kxt + H2O <−> ADP + 3 NAxt + 2 K + PI 3.6.1.37 23439 ATP1B4 ATP + 3NA + 2 Kxt + H2O <−> ADP + 3 NAxt + 2 K + PI 3.6.1.37 481 ATP1B1, ATP1BATP + 3 NA + 2 Kxt + H2O <−> ADP + 3 NAxt + 2 K + PI 3.6.1.37 482ATP1B2, AMOG ATP + 3 NA + 2 Kxt + H2O <−> ADP + 3 NAxt + 2 K + PI3.6.1.37 483 ATP1B3 ATP + 3 NA + 2 Kxt + H2O <−> ADP + 3 NAxt + 2 K + PI3.6.1.37 27032 ATP2C1, ATP2C1A, PMR1 ATP + 2 CA + H20 <−> ADP + PI + 2CAxt 3.6.1.38 487 ATP2A1, SERCA1, ATP2A ATP + 2 CA + H20 <−> ADP + PI +2 CAxt 3.6.1.38 488 ATP2A2, ATP2B, SERCA2, DAR, DD ATP + 2 CA + H20 <−>ADP + PI + 2 CAxt 3.6.1.38 489 ATP2A3, SERCA3 ATP + 2 CA + H20 <−> ADP +PI + 2 CAxt 3.6.1.38 490 ATP2B1, PMCA1 ATP + 2 CA + H20 <−> ADP + PI + 2CAxt 3.6.1.38 491 ATP2B2, PMCA2 ATP + 2 CA + H20 <−> ADP + PI + 2 CAxt3.6.1.38 492 ATP2B3, PMCA3 ATP + 2 CA + H20 <−> ADP + PI + 2 CAxt3.6.1.38 493 ATP2B4, ATP2B2, PMCA4 ATP + 2 CA + H20 <−> ADP + PI + 2CAxt 3.6.1.38 538 ATP7A, MK, MNK, OHS ATP + H2O + Cu2 −> ADP + PI +Cu2xt 3.6.3.4 540 ATP7B, WND ATP + H2O + Cu2 −> ADP + PI + Cu2xt 3.6.3.45464 PP, SID6-8061 PPI −> 2 PI 3.6.1.1 2.2 Photosynthesis PATH:hsa001952.3 Carbon fixation PATH:hsa00710 2805 GOT1 OAm + GLUm <−> ASPm + AKGm2.6.1.1 2806 GOT2 OA + GLU <−> ASP + AKG 2.6.1.1 2875 GPT PYR + GLU <−>AKG + ALA 2.6.1.2 2.4 Reductive carboxyiate cycle (CO2 fixation)PATH:hsa00720 2.5 Methane metabolism PATH:hsa00680 847 CAT 2 H202 −> O21.11.1.6 4025 LPO, SPO 1.11.1.7 4353 MPO 1.11.1.7 8288 EPX, EPX-PEN,EPO, EPP 1.11.1.7 9588 KIAA0106, AOP2 1.11.1.7 6470 SHMT1, CSHMT THF +SER <−> GLY + METTHF 2.1.1.1 6472 SHMT2, GLYA, SHMT THFm + SERm <−>GlYm + METTHFm 2.1.2.1 51004 LOC51004 2OPMPm + O2m −> 2OPMBm 1.14.13.—2OPMMBm + O2m −> 2OMHMBm 9420 CYP7B1 2OPMPm + O2m −> 2OPMBm 1.14.13.—2OPMMBm + O2m −> 2OMHM8m 2.6 Nitrogen metabolism PATH:hsa00910 11238CA5B 4.2.1.1 23632 CA14 4.2.1.1 759 CA1 4.2.1.1 760 CA2 4.2.1.1 761 CA3,CAIII 4.2.1.1 762 CA4, CAIV 4.2.1.1 763 CA5A, CA5, CAV, CAVA 4.2.1.1 765CA6 4.2.1.1 766 CA7 4.2.1.1 767 CA8, CALS, CARP 4.2.1.1 768 CA9, MN4.2.1.1 770 CA11, CARP2 4.2.1.1 771 CA12 4.2.1.1 1373 CPS1 GLUm + CO2m +2 ATPm −> 2 ADPm + 2 Plm + CAPm 6.3.4.16 275 AMT GLYm + THFm + NADm <−>METTHFm + NADHm + CO2m + 2.1.2.10 NH3m 3034 HAL, HSTD, HIS HIS −> NH3 +URO 4.3.1.3 2746 GLUD1, GLUD AKGm + NADHm + NH3m <−> NADm + H2Om + GLUm1.4.1.3 AKGm + NADPHm + NH3m <−> NADPm + H2Om + GLUm 8307 GLUD2 AKGm +NADHm + NH3m <−> NADm + H2Om + GLUm 1.4.1.3 AKGm + NADPHm + NH3m <−>NADPm + H2Om + GLUm 2752 GLUL, GLNS GLUm + NH3m + ATPm −> GLNm + ADPm +Pim 6.3.1.2 22842 KIAA0838 GLN −> GLU + NH3 3.5.1.2 27165 GA GLN −>GLU + NH3 3.5.1.2 2744 GLS GLNm −> GLUm + NH3m 3.5.1.2 440 ASNS ASPm +ATPm + GLNm −> GLUm + ASNm + AMPm + PPIm 6.3.5.4 1491 CTH LLCT + H2O −>CYS + HSER 4.4.1.1 OBUT + NH3 <−> HSER 4.4.1.1 2.7 Sulfur metabolismPATH:hsa00920 9060 PAPSS2, ATPSK2, SK2 APS + ATP −> ADP + PAPS 2.7.1.25SLF + ATP −> PPI + APS 2.7.7.4 9061 PAPSS1, ATPSK1, SK1 APS + ATP −>ADP + PAPS 2.7.1.25 SLF + ATP −> PPI + APS 2.7.7.4 10380 BPNT1 PAP −>AMP + PI 3.1.3.7 6799 SULT1A2 2.8.2.1 6817 SULT1A1, STP1 2.8.2.1 6818SULT1A3, STM 2.8.2.1 6822 SULT2A1, STD 2.8.2.2 6783 STE, EST 2.8.2.46821 SUOX 1.8.3.1 3. Lipid Metabolism 3.1 Fatty acid biosynthesis(path 1) PATH:hsa00061 2194 FASN 2.3.1.85 3.2 Fatty acid biosynthesis(path 2) PATH:hsa00062 10449 ACAA2, DSAEC MAACOAm −> ACCOAm + PROPCOAm2.3.1.16 30 ACAA1, ACAA MAACOA −> ACCOA + PROPCOA 2.3.1.16 3032 HADHBMAACOA −> ACCOA + PROPCOA 2.3.1.16 3.3 Fatty acid metabolismPATH:hsa00071 51 ACOX1, ACOX 1.3.3.6 33 ACADL, LCAD 1.3.99.13 2639 GCDH1.3.99.7 2179 FACL1, LACS ATP + LCCA + COA <−> AMP + PPI + ACOA 6.2.1.32180 FACL2, FACL1, LACS2 ATP + LCCA + COA <−> AMP + PPI + ACOA 6.2.1.32182 FACL4, ACS4 ATP + LCCA + COA <−> AMP + PPI + ACOA 6.2.1.3 1374CPT1A, CPT1, CPT1-L 2.3.1.21 1375 CPT1B, CPT1-M 2.3.1.21 1376 CPT2,CPT1, CPTASE 2.3.1.21 1632 DCI 5.3.3.8 11283 CYP4F8 1.14.14.1 1543CYP1A1, CYP1 1.14.14.1 1544 CYP1A2 1.14.14.1 1545 CYP1B1, GLC3A1.14.14.1 1548 CYP2A6, CYP2A3 1.14.14.1 1549 CYP2A7 1.14.14.1 1551CYP3A7 1.14.14.1 1553 CYP2A13 1.14.14.1 1554 CYP2B 1.14.14.1 1555 CYP2B61.14.14.1 1557 CYP2C19, CYP2C, P450IIC19 1.14.14.1 1558 CYP2C8 1.14.14.11559 CYP2C9, P450IIC9, CYP2C10 1.14.14.1 1562 CYP2C18, P450IIC17,CYP2C17 1.14.14.1 1565 CYP2D6 1.14.14.1 1571 CYP2E, CYP2E1, P450C2E1.14.14.1 1572 CYP2F1, CYP2F 1.14.14.1 1573 CYP2J2 1.14.14.1 1575 CYP3A31.14.14.1 1576 CYP3A4 1.14.14.1 1577 CYP3A5, PCN3 1.14.14.1 1580 CYP4811.14.14.1 1588 CYP19, ARO 1.14.14.1 1595 CYP51 1.14.14.1 194 AHHR, AHH1.14.14.1 3.4 Synthesis and degradation of ketone bodies PATH:hsa000723.5 Sterol biosynthesis PATH:hsa00100 3156 HMGCR MVL + COA + 2 NADP <−>H3MCOA + 2 NADPH 1.1.1.34 4598 MVK, MVLK ATP + MVL −> ADP + PMVL2.7.1.36 CTP + MVL −> CDP + PMVL GTP + MVL −> GDP + PMVL UTP + MVL −>UDP + PMVL 10654 PMVK, PMKASE, PMK, HUMPMKI ATP + PMVL −> ADP + PPMVL2.7.4.2 4597 MVD, MPD ATP + PPMVL −> ADP + PI + IPPP + CO2 4.1.1.33 3422IDI1 IPPP <−> DMPP 5.3.3.2 2224 FDPS GPP + IPPP −> FPP + PPI 2.5.1.10DMPP + IPPP −> GPP + PPI 2.5.1.1 9453 GGPS1, GGPPS DMPP + IPPP −> GPP +PPI 2.5.1.1 GPP + IPPP −> FPP + PPI 2.5.1.10 2.5.1.29 2222 FDFT1, DGPT 2FPP + NADPH −> NADP + SQL 2.5.1.21 6713 SQLE SQL + O2 + NADP −> S23E +NADPH 1.14.99.7 4047 LSS, OSC S23E −> LNST 5.4.99.7 1728 DIA4, NMOR1,NQO1, NMOR1 1.6.99.2 4835 NMOR2, NQO2 1.6.99.2 37 ACADVL, VLCAD, LCACD1.3.99.— 3.6 Bile acid biosynthesis PATH:hsa00120 1056 CEL, BSSL, BAL3.1.1.3 3.1.1.13 3988 LIPA, LAL 3.1.1.13 6646 SOAT1, ACAT, STAT, SOAT,ACAT1, ACACT 2.3.1.26 1581 CYP7A1, CYP7 1.14.13.17 6715 SRD5A1 1.3.99.56716 SRD5A2 1.3.99.5 6718 AKR1D1, SRD5B1, 3o5bred 1.3.99.6 570 BAAT, BAT2.3.1.65 3.7 C21-Steroid hormone metabolism PATH:hsa00140 1583 CYP11A,P450SCC 1.14.15.6 3283 HSD3B1, HSD3B, HSDB3 IMZYMST −> I IMZYMST + CO25.3.3.1 IMZYMST −> IIZYMST + CO2 1.1.1.145 3284 HSD382 IMZYMST −>IIMZYMST + CO2 5.3.3.1 IMZYMST −> IIZYMST + CO2 1.1.1.145 1589 CYP21A2,CYP21, P450C21B, CA21H, CYP21B, P450C21B 1.14.99.10 1586 CYP17, P450C171.14.99.9 1584 CYP11B1, P450C11, CYP11B 1.14.15.4 1585 CYP11B2, CYP11B1.14.15.4 3290 HSD11B1, HSD11, HSD11L, HSD11B 1.1.1.146 3291 HSD1182,HSD11K 1.1.1.146 3.8 Androgen and estrogen metabolism PATH:hsa00150 3292HSD17B1, EDH17B2, EDHB17, 1.1.1.62 HSD17 3293 HSD17B3, EDH17B3 1.1.1.623294 HSD17B2, EDH17B2 1.1.1.62 3295 HSD17B4 1.1.1.62 3296 HSD17BP1,EDH17B1, EDHB17, 1.1.1.62 HSD17 51478 HSD17B7, PRAP 1.1.1.62 412 STS,ARSC, ARSC1, SSDD 3.1.6.2 414 ARSD 3.1.6.1 415 ARSE, CDPX1, CDPXR, CDPX3.1.6.1 11185 INMT 2.1.1.— 24140 JM23 2.1.1.— 29104 N6AMT1, PRED282.1.1.— 29960 FJH1 2.1.1.— 3276 HRMT1L2, HCP1, PRMT1 2.1.1.— 51628LOC51628 2.1.1.— 54743 HASJ4442 2.1.1.— 27292 HSA9761 2.1.1.— 4.Nucleotide Metabolism 4.1 Purine metabolism PATH:hsa00230 11164 NUDT5,HYSAH1, YSA1H 3.6.1.13 5471 PPAT, GPAT PRPP + GLN −> PPI + GLU + PRAM2.4.2.14 2618 GART, PGFT, PRGS PRAM + ATP + GLY <−> ADP + PI + GAR6.3.4.13 FGAM + ATP −> ADP + PI + AIR 6.3.3.1 GAR + FTHF −> THF + FGAR2.1.2.2 5198 PFAS, FGARAT, KIAA0361, PURL FGAR + ATP + GLN −> GLU +ADP + PI + FGAM 6.3.5.3 10606 ADE2H1 CAIR + ATP + ASP <−> ADP + PI +SAICAR 6.3.2.6 CAIR <−> AIR + CO2 4.1.1.21 5059 PAICS, AIRC, PAIS CAIR +ATP + ASP <−> ADP + PI + SAICAR 6.3.2.6 158 ADSL ASUC <−> FUM + AMP4.3.2.2 471 ATIC, PURH AICAR + FTHF <−> THF + PRFICA 2.1.2.3 PRFICA <−>IMP 3.5.4.10 3251 HPRT1, HPRT, HGPRT HYXAN + PRPP −> PPI + IMP 2.4.2.8GN + PRPP −> PPI + GMP 3614 IMPDH1 IMP + NAD −> NAOH + XMP 1.1.1.2053615 IMPDH2 IMP + NAD −> NAOH + XMP 1.1.1.205 8833 GMPS 6.3.5.2 149232987 GUK1 GMP + ATP <−> GDP + ADP 2.7.4.8 DGMP + ATP <−> DGDP + ADPGMP + OATP <−> GDP + DADP 2988 GUK2 GMP + ATP <−> GDP + ADP 2.7.4.8DGMP + ATP <−> DGDP + ADP GMP + DATP <−> GOP + DADP 10621 RPC39 2.7.7.610622 RPC32 2.7.7.6 10623 RPC62 2.7.7.6 11128 RPC155 2.7.7.6 25885DKFZP586M0122 2.7.7.6 30834 2NRD1 2.7.7.6 51082 LOC51082 2.7.7.6 51728LOC51728 2.7.7.6 5430 POLR2A, RPOL2, POLR2, POLRA 2.7.7.6 5431 POLR2B,POL2RB 2.7.7.6 5432 POLR2C 2.7.7.6 5433 POLR2D, HSRBP4, HSRPB4 2.7.7.65434 POLR2E, RPB5, XAP4 2.7.7.6 5435 POLR2F, RPB6, HRBP14.4 2.7.7.6 5436POLR2G, RPB7 2.7.7.6 5437 POLR2H, RPB8, RPB17 2.7.7.6 5438 POLR2I2.7.7.6 5439 POLR2J 2.7.7.6 5440 POLR2K, RP87.0 2.7.7.6 5441 POLR2L,RPB7.6, RPB10 2.7.7.6 5442 POLRMT, APOLMT 2.7.7.6 54479 FLJ10816, Rpo1-22.7.7.6 55703 FLJ10388 2.7.7.6 661 BN51T 2.7.7.6 9533 RPA40, RPA392.7.7.6 10721 POLQ 2.7.7.7 11232 POLG2, MTPOLB, HP55, POLB 2.7.7.7 23649POLR2 2.7.7.7 5422 POLA 2.7.7.7 5423 POLB 2.7.7.7 5424 POLD1, POLD2.7.7.7 5425 POLD2 2.7.7.7 5426 POLE 2.7.7.7 5427 POLE2 2.7.7.7 5428POLG 2.7.7.7 5980 REV3L, POLZ, REV3 2.7.7.7 7498 XDH 1.1.3.22 1.1.1.2049615 GDA, KIAA1258, CYPIN, NEDASIN 3.5.4.3 2766 GMPR 1.6.6.8 51292LOC51292 1.6.6.8 7377 UOX 1.7.3.3 6240 RRM1 ADP + RTHIO −> DADP + OTHIO1.17.4.1 GDP + RTHIO −> DGDP + OTHIO COP + RTHIO −> DCDP + OTHIO UDP +RTHIO −> DUDP + OTHIO 6241 RRM2 ADP + RTHIO −> DADP + OTHIO 1.17.4.1GDP + RTHIO −> DGDP + OTHIO COP + RTHIO −> DCDP + OTHIO UDP + RTHIO −>DUDP + OTHIO 4860 NP, PNP AND + PI <−> AD + R1P 2.4.2.1 GSN + PI <−>GN + R1P DA + PI <−> AD + R1P DG + PI <−> GN + R1P DIN + PI <−> HYXAN +R1P INS + PI <−> HYXAN + R1P XTSINE + PI <−> XAN + R1P 1890 ECGF1,hPD-ECGF DU + PI <−> URA + DR1P 2.4.2.4 DT + PI <−> THY + DR1P 353 APRTAD + PRPP −> PPI + AMP 2.4.2.7 132 ADK ADN + ATP −> AMP + ADP 2.7.1.201633 DCK 2.7.1.74 1716 DGUOK 2.7.1.113 203 AK1 ATP + AMP <−> 2 ADP2.7.4.3 GTP + AMP <−> ADP + GDP ITP + AMP <−> ADP + IDP 204 AK2 ATP +AMP <−> 2 ADP 2.7.4.3 GTP + AMP <−> ADP + GOP ITP + AMP <−> ADP + IDP205 AK3 ATP + AMP <−> 2 ADP 2.7.4.3 GTP + Amp <−> ADP + GOP ITP + AMP<−> ADP + IDP 26289 AK5 ATP + AMP <−> 2 ADP 2.7.4.3 GTP + AMP <−> ADP +GDP ITP + AMP <−> ADP + IDP 4830 NME1, NM23, NM23-H1 UDP + ATP <−> UTP +ADP 2.7.4.6 CDP + ATP <−> CTP + ADP GDP + ATP <−> GTP + ADP IDP + ATP<−> ITP + IDP DGDP + ATP <−> DGTP + ADP DUDP + ATP <−> DUTP + ADP DCDP +ATP <−> DCTP + ADP DTDP + ATP <−> DTTP + ADP DADP + ATP <−> DATP + ADP4831 NME2, NM23-H2 UDP + ATP <−> UTP + ADP 2.7.4.6 CDP + ATP <−> CTP +ADP GDP + ATP <−> GTP + ADP IDP + ATP <−> ITP + IDP DGDP + ATP <−>DGTP + ADP DUDP + ATP <−> DUTP + ADP DCDP + ATP <−> DCTP + ADP DTDP +ATP <−> DTTP + ADP DADP + ATP <−> DATP + ADP 4832 NME3, DR-nm23, DR-NM23UDP + ATP <−> UTP + ADP 2.7.4.6 CDP + ATP <−> CTP + ADP GDP + ATP <−>GTP + ADP IDP + ATP <−> ITP + IDP DGDP + ATP <−> DGTP + ADP DUDP + ATP<−> DUTP + ADP DCDP + ATP <−> DCTP + ADP DTDP + ATP <−> DTTP + ADPDADP + ATP <−> DATP + ADP 4833 NME4 UDPm + ATPm <−> UTPm + ADPm 2.7.4.6CDPm + ATPm <−> CTPm + ADPm GDPm + ATPm <−> GTPm + ADPm IDPm + ATPm <−>ITPm + IDPm DGDPm + ATPm <−> DGTPm + ADPm DUDPm + ATPm <−> DUTPm + ADPmDCDPm + ATPm <−> DCTPm + ADPm DTDPm + ATPm <−> DTTPm + ADPm DADPm + ATPm<−> DATPm + ADPm 22978 NT5B, PNT5, NT5B-PENDING AMP + H2O −> PI + ADN3.1.3.5 GMP −> PI + GSN CMP −> CYTD + PI UMP −> PI + URI IMP −> PI + INSDUMP −> DU + PI DTMP −> DT + PI DAMP −> DA + PI DGMP −> DG + PI DCMP −>DC + PI XMP −> PI + XTSINE 4877 NT3 AMP −> PI + AON 3.1.3.5 GMP −> PI +GSN CMP −> CYTD + PI UMP −> PI + URI IMP −> PI + INS DUMP −> DU + PIDTMP −> DT + PI DAMP −> DA + PI DGMP −> DG + PI DCMP −> DC + PI XMP −>PI + XTSINE 4907 NT5, CD73 AMP −> PI + ADN 3.1.3.5 GMP −> PI + GSN CMP−> CYTD + PI UMP −> PI + URI IMP −> PI + INS DUMP −> DU + PI DTMP −>DT + PI DAMP −> DA + PI DGMP −> DG + PI DCMP −> DC + PI XMP −> PI +XTSINE 7370 UMPH2 AMP −> PI + ADN 3.1.3.5 GMP −> PI + GSN CMP −> CYTD +PI UMP −> PI + URI IMP −> PI + INS DUMP −> DU + PI DTMP −> DT + PI DAMP−> DA + PI DGMP −> DG + PI DCMP −> DC + PI XMP −> PI + XTSINE 10846PDE10A cAMP −> AMP 3.1.4.17 cAMP −> AMP cdAMP −> dAMP cIMP −> IMP cGMP−> GMP cCMP −> CMP 27115 PDE7B cAMP −> AMP 3.1.4.17 cAMP −> AMP cdAMP −>dAMP cIMP −> IMP cGMP −> GMP cCMP −> CMP 5136 PDE1A cAMP −> AMP 3.1.4.17cAMP −> AMP cdAMP −> dAMP cIMP −> IMP cGMP −> GMP cCMP −> CMP 5137PDE1C, HCAM3 cAMP −> AMP 3.1.4.17 cAMP −> AMP cdAMP −> dAMP cIMP −> IMPcGMP −> GMP cCMP −> CMP 5138 PDE2A cAMP −> AMP 3.1.4.17 cAMP −> AMPcdAMP −> dAMP cIMP −> IMP cGMP −> GMP cCMP −> CMP 5139 PDE3A, CGI-PDEcAMP −> AMP 3.1.4.17 cAMP −> AMP cdAMP −> dAMP cIMP −> IMP cGMP −> GMPcCMP −> CMP 5140 PDE3B cAMP −> AMP 3.1.4.17 cAMP −> AMP cdAMP −> dAMPcIMP −> IMP cGMP −> GMP cCMP −> CMP 5141 PDE4A, DPDE2 cAMP −> AMP3.1.4.17 5142 PDE4B, DPDE4, PDEIVB cAMP −> AMP 3.1.4.17 5143 PDE4C,DPDE1 cAMP −> AMP 3.1.4.17 5144 PDE4D, DPDE3 cAMP −> AMP 3.1.4.17 5145PDE6A, PDEA, CGPR-A cGMP −> GMP 3.1.4.17 5146 PDE6C, PDEA2 cGMP −> GMP3.1.4.17 5147 PDE6D cGMP −> GMP 3.1.4.17 5148 PDE6G, PDEG cGMP −> GMP3.1.4.17 5149 PDE6H cGMP −> GMP 3.1.4.17 5152 PDE9A cAMP −> AMP 3.1.4.17cAMP −> AMP cdAMP −> dAMP cIMP −> IMP cGMP −> GMP cCMP −> CMP 5153PDES1B cAMP −> AMP 3.1.4.17 cAMP −> AMP cdAMP −> dAMP cIMP −> IMP cGMP−> GMP cCMP −> CMP 5158 PDE6B, CSN83, PDEB cGMP −> GMP 3.1.4.17 8654PDE5A cGMP −> GMP 3.1.4.17 100 ADA ADN −> INS + NH3 3.5.4.4 DA −> DIN +NH3 270 AMPD1, MADA AMP −> IMP + NH3 3.5.4.6 271 AMPD2 AMP −> IMP + NH33.5.4.6 272 AMPD3 AMP −> IMP + NH3 3.5.4.6 953 ENTPD1, CD39 3.6.1.5 3704ITPA 3.6.1.19 107 ADCY1 ATP −> cAMP + PPI 4.6.1.1 108 ADCY2, HBAC2 ATP−> cAMP + PPI 4.6.1.1 109 ADCY3, AC3, KIAA0511 ATP −> cAMP + PPI 4.6.1.1110 ADCY4 ATP −> cAMP + PPI 4.6.1.1 111 ADCY5 ATP −> cAMP + PPI 4.6.1.1112 ADCY6 ATP −> CAMP + PPI 4.6.1.1 113 ADCY7, KIAA0037 ATP −> cAMP +PPI 4.6.1.1 114 ADCY8, ADCY3, HBAC1 ATP −> cAMP + PPI 4.6.1.1 115 ADCY9ATP −> cAMP + PPI 4.6.1.1 2977 GUCY1A2, GUC1A2, GC-SA2 4.6.1.2 2982GUCY1A3, GUC1A3, GUCSA3, GC- 4.6.1.2 SA3 2983 GUCY1B3, GUC1B3, GUCSB3,GC- 4.6.1.2 SBC 2984 GUCY2C, GUC2C, STAR 4.6.1.2 2986 GUCY2F, GUC2F,GC-F, GUC2DL, 4.6.1.2 RETGC-2 3000 GUCY2D, C0R06, GUC2D, LCA1, 4.6.1.2GUC1M, LCA, retGC 4881 NPR1, ANPRA, GUC2A, NPRA 4.6.12 4882 NPR2, ANPRB,GUC2B, NPRB, NPRBi 4.6.1.2 159 ADSS IMP + GTP + ASP −> GDP + PI + ASUC6.3.4.4 318 NUDT2, APAH1 3.6.1.17 5167 ENPP1, M6S1, LAPPS, PCA1, PC-1,3.6.1.9 PDNP1 5168 ENPP2, ATX, PD-IALPHA, PDNP2 3.6.1.9 5169 ENPP3,PD-IBETA, PDNP3 3.6.1.9 3.1.4.1 2272 FHIT 3.6.1.29 4.2 Pyrimidinemetabolism PATH:hsa00240 790 CAD GLN + 2 ATP + CO2 −> GLU + CAP + 2ADP + PI 6.3.5.5 CAP + ASP −> CAASP + PI 2.1.3.2 CAASP <−> DOROA 3.5.2.31723 DHODH DOROA + 02 <−> H202 + OROA 1.3.3.1 7372 UMPS, OPRT OMP −>CO2 + UMP 4.1.1.23 OROA + PRPP <−> PPI + OMP 2.4.2.10 51727 LOC51727ATP + UMP <−> ADP + UDP 2.7.4.14 CMP + ATP <−> ADP + COP DCMP + ATP <−>ADP + DCDP 50808 AKL3L 2.7.4.10 1503 CTPS UTP + GLN + ATP −> GLU + CTP +ADP + PI 6.3.4.2 ATP + UTP + NH3 −> ADP + PI + CTP 7371 UMPK, TSA903URI + ATP −> ADP + UMP 2.7.1.48 URI + GTP −> UMP + GDP CYTD + GTP −>GDP + CMP 7378 UP URI + PI <−> URA + R1P 2.4.2.3 1806 DPYD, DPD 1.3.1.21807 DPYS, DHPase, DHPASE, DHP 3.5.2.2 51733 LOC51733 3.5.1.6 7296TXNRD1, TXNR OTHIO + NADPH −> NADP + RTHIO 1.6.4.5 1854 DUT DUTP −>PPI + DUMP 3.6.1.23 7298 TYMS, TMS, TS DUMP + METTHF −> DHF + DTMP2.1.1.45 978 CDA, CDD CYTD −> URI + NH3 3.5.4.5 DC −> NH3 + DU 1635 DCTDDCMP <−> DUMP + NH3 3.5.4.12 7083 TK1 DU + ATP −> DUMP + ADP 2.7.1.21DT + ATP −> ADP + DTMP 7084 TK2 DUm + ATPm −> DUMPm + ADPm 2.7.1.21DTm + ATPm −> ADPm + DTMPm 1841 DTYMK, TYMK, CDC8 DTMP + ATP <−> ADP +DTDP 2.7.4.9 4.3 Nucleotide sugars metabolism PATH:hsa00520 23483 TDPGD4.2.1.46 1486 CTBS, CTB 3.2.1.— 5. Amino Acid Metabolism 5.1 Glutamatemetabolism PATH:hsa00251 8659 ALDH4, P5CDH P5C + NAD + H2O −> NADH + GLU1.5.1.12 2058 EPRS, QARS, QPRS GLU + ATP −> GTRNA + AMP + PPI 6.1.1.176.1.1.15 2673 GFPT1, GFA, GFAT, GFPT F6P + GLN −> GLU + GA6P 2.6.1.169945 GFPT2, GFAT2 F6P + GLN −> GLU + GA6P 2.6.1.16 5859 QARS 6.1.1.182729 GLCLC, GCS, GLCL CYS + GLU + ATP −> GC + PI + ADP 6.3.2.2 2730GLCLR CYS + GLU + ATP −> GC + PI + ADP 6.3.2.2 2937 GSS, GSHS GLY + GC +ATP −> RGT + PI + ADP 6.3.2.3 2936 GSR NADPH + OGT −> NADP + RGT 1.6.4.25188 PET112L, PET112 6.3.5.— 5.2 Alanine and aspartate metabolismPATH:hsa00252 4677 NARS, ASNRS ATP + ASP + TRNA −> AMP + PPI + ASPTRNA6.1.1.22 435 ASL ARGSUCC −> FUM + ARG 4.3.2.1 189 AGXT, SPAT SERm + PYRm<−> ALAm + 3HPm 2.6.1.51 ALA + GLX <−> PYR + GLY 2.6.1.44 16 AARS6.1.1.7 1615 DARS 6.1.1.12 445 ASS, CTLN1, ASS1 CITR + ASP + ATP <−>AMP + PPI + ARGSUCC 6.3.4.5 442 ASPA, ASP, ACY2 3.5.1.15 1384 CRAT, CAT12.3.1.7 ACCOA + CAR −> COA + ACAR 8528 DDO 1.4.3.1 5.3 Glycine, serineand threonine metabolism PATH:hsa00260 5723 PSPH, PSP 3PSER + H2O −>PI + SER 3.13.3 29968 PSA PHP + GLU <−> AKG + 3PSER 2.6.1.52 OHB + GLU<−> PHT + AKG 25227 PHGDH, SERA, PGDH, PGD, PGAD 3PG + NAD <−> NADH +PHP 1.1.1.95 23464 GCAT, KBL 2.3.1.29 211 ALAS1, ALAS SUCCOA + GLY −>ALAV + COA + CO2 2.3.1.37 212 ALAS2, ANH1, ASB SUCCOA + GLY −> ALAV +COA + CO2 2.3.1.37 4128 MAOA AMA + H2O + FAD −> NH3 + FADH2 + MTHGXL1.4.3.4 4129 MAOB AMA + H2O + FAD −> NH3 + FADH2 + MTHGXL 1.4.3.4 26ABP1, AOC1, DAO 1.4.3.6 314 AOC2, DA02, RAO 1.4.3.6 8639 AOC3, VAP-1,VAP1, HPAO 1.4.3.6 2731 GLDC GLY + LIPO <−> SAP + CO2 1.4.4.2 1610 DAO,DAMOX 1.4.3.3 2617 GARS 6.1.1.14 2628 GATM 2.1.4.1 2593 GAMT 2.1.1.223761 PISD, PSSC, DKFZP566G2246, PS −> PE + CO2 4.1.1.65 DJ858B16 635BHMT 2.1.1.5 29958 DMGDH 1.5.99.2 875 CBS SER + HCYS −> LLCT + H2O4.2.1.22 6301 SARS, SERS 6.1.1.11 10993 SDS, SDH SER −> PYR + NH3 + H2O4.2.1.13 6897 TARS 6.1.1.3 5.4 Methionine metabolism PATH:hsa00271 4143MAT1A, MATA1, SAMS1, MAT, SAMS MET + ATP + H2O −> PPI + PI + SAM 2.5.1.64144 MAT2A, MATA2, SAMS2, MATII MET + ATP + H2O −> PPI + PI + SAM2.5.1.6 1786 DNMT1, MCMT, DNMT SAM + DNA −> SAH + DNA5MC 2.1.1.37 10768AHCYL1, XPVKONA SAH + H2O −> HCYS + AON 3.3.1.1 191 AHCY, SAHH SAH + H2O−> HCYS + AON 3.3.1.1 4141 MARS, METRS, MTRNS 6.1.1.10 4548 MTR HCYS +MTHF −> THF + MET 2.1.1.13 5.5 Cysteine metabolism PATH:hsa00272 833CARS 6.1.1.16 1036 CDO1 CYS + O2 <−> CYSS 1.13.11.20 8509 NDST2, HSST2,NST2 2.8.2.— 5.6 Valine, leucine and isoleucine degradationPATH:hsa00280 586 BCAT1, BCT1, ECA39, MECA39 AKG + ILE −> OMVAL + GLU2.6.1.42 AKG + VAL −> OIVAL + GLU AKG + LEU −> OICAP + GLU 587 BCAT2,BCT2 OICAPm + GLUm <−> AKGm + LEUm 2.6.1.42 OMVALm + GLUm <−> AKGm +ILEm 5014 OVD1A 1.2.4.4 593 BCKDHA, MSUD1 OMVALm + COAm + NADm −>MBCOAm + NADHm + CO2m 1.2.4.4 OIVALm + COAm + NADm −> IBCOAm + NADHm +CO2m OICAPm + COAm + NADm −> IVCOAm + NADHm + CO2m 594 BCKDHB, E1BOMVALm + COAm + NADm −> MBCOAm + NADHm + CO2m 1.2.4.4 OIVALm + COAm +NADm −> IBCOAm + NADHm + CO2m OICAPm + COAm + NADH −> IVCOAm + NADHm +CO2m 3712 IVD IVCOAm + FADm −> MCRCOAm + FADH2m 1.3.99.10 316 AOX1, AO1.2.3.1 4164 MCCC1 MCRCOAm + ATPm + CO2m + H2Om −> MGCOAm + ADPm +6.4.1.4 Pim 4165 MCCC2 MCRCOAm + ATPm + CO2m + H2Om −> MGCOAm + ADPm +6.4.1.4 Pim 5.7 Valine, leucine and Isoleucine biosynthesisPATH:hsa00290 23395 KIAA0028, LARS2 6.4.1.4 3926 LARS 6.4.1.4 3376 IARS,ILRS 61.1.5 7406 VARS1, VARS 6.1.1.9 7407 VARS2, G7A 6.1.1.9 5.8 Lysinebiosynthesis PATH:hsa00300 3735 KARS, KIAA0070 ATP + LYS + LTRNA −>AMP + PPI + LLTRNA 6.1.1.6 5.9 Lysine degradation PATH:hsa00310 8424BBOX, BBH, GAMMA-BBH, G-BBH 1.14.11.1 5351 PLOD, LLH 1.14.11.4 5352PLOD2 1.14.11.4 8985 PLOD3, LH3 1.14.11.4 10157 LKR/SDH, AASS LYS +NADPH + AKG −> NADP + H2O + SAC 1.5.1.9 SAC + H2O + NAD −> GLU + NADH +AASA 5.10 Arginine and proline metabolism PATH:hsa00330 5009 OTC ORNm +CAPm −> CITRm + Pim + Hm 2.1.3.3 383 ARG1 ARG −> ORN + UREA 3.5.3.1 384ARG2 ARG −> ORN + UREA 3.5.3.1 4842 NOS1, NOS 1.14.13.39 4843 NOS2A,NOS2 1.14.13.39 4846 NOS3, ECHOS 1.14.13.39 4942 OAT ORN + AKG <−>GLUGSAL + GLU 2.6.1.13 5831 PYCR1, P5C, PYCR P5C + NADPH −> PRO + NADP1.5.1.2 P5C + NADH −> PRO + NAD PHC + NADPH −> HPRO + NADP PHC + NADH −>HPRO + NAD 5033 P4HA1, P4HA 1.14.11.2 5917 RARS ATP + ARG + ATRNA −>AMP + PPI + ALTRNA 6.1.1.19 1152 CKB, CKBB PCRE + ADP −> CRE + ATP2.7.3.2 1156 CKBE 2.7.3.2 1158 CKM, CKMM 2.7.3.2 1159 CKMT1, CKMT, UMTCK2.7.3.2 1160 CKMT2, SMTCK 2.7.3.2 6723 SRM, SPS1, SRML1 PTRSC + SAM −>SPRMD + 5MTA 2.5.1.16 262 AMD1, ADOMETDC SAM <−> DSAM + CO2 4.1.1.50 263AMDP1, AMD, AMD2 SAM <−> DSAM + CO2 4.1.1.50 1725 DHPS SPRMD + Qm −>DAPRP + QH2m 1.5.99.6 6611 SMS DSAM + SPRMD −> 5MTA + SPRM 2.5.1.22 4953ODC1 ORN −> PTRSC + CO2 4.1.1.17 6303 SAT, SSAT 2.3.1.57 5.11 Histidinemetabolism PATH:hsa00340 10841 FTCD FIGLU + THF −> NFTHF + GLU 2.1.2.54.3.1.4 3067 HDC 4.1.1.22 1644 DDC, AADC 4.1.1.28 3176 HNMT 2.1.1.8 218ALDH3 ACAL + NAD −> NADH + AC 1.2.1.5 220 ALDH6 ACAL + NAD −> NADH + AC1.2.1.5 221 ALDH7, ALDH4 ACAL + NAD −> NADH + AC 1.2.1.5 222 ALDH8ACAL + NAD −> NADH + AC 1.2.1.5 3035 HARS ATP + HIS + HTRNA −> AMP +PPI + HHTRNA 6.1.1.21 5.12 Tyrosine metabolism PATH:hsa00350 6898 TATAKG + TYR −> HPHPYR + GLU 2.6.1.5 3242 HPD, PPD HPHPYR + O2 −> HGTS +CO2 1.13.11.27 3081 HGD, AKU, HGO HGTS + O2 −> MACA 1.13.11.5 2954GSTZI, MAAI MACA −> FACA 5.2.1.2 2.5.1.18 2184 FAH FACA + H2O −> FUM +ACA 3.7.1.2 7299 TYR, OCA1A 1.14.18.1 7054 TH, TYH 1.14.16.2 1621 DBH1.14.17.1 5409 PNMT, PENT 2.1.1.28 1312 COMT 2.1.1.6 7173 TPO, TPX1.11.1.8 5.13 Phenylalanine metabolism PATH:hsa00360 501 ATQ1 1.2.1.—5.14 Tryptophan metabolism PATH:hsa00380 6999 TDO2, TPH2, TRPO, TDOTRP + O2 −> FKYN 1.13.11.11 8564 KMO KYN + NAD PH + O2 −> HKYN + NADP +H2O 1.14.13.9 8942 KYNU KYN −> ALA + AN 3.7.1.3 HKYN + H2O −> HAN + ALA23498 HAAO, HAO, 3-HAO HAN + O2 −> CMUSA 1.13.11.6 7166 TPH, TPRH1.14.16.4 438 ASMT, HIOMT, ASMTY 2.1.1.4 15 AANAT, SNAT 2.3.1.87 3620INDO, IDO 1.13.11.42 10352 WARS2 ATPm + TRPm + TRNAm −> AMPm + PPIm +TRPTRNAm 6.1.1.2 7453 WARS, IFP53, IF153, GAMMA-2 ATP + TRP + TRNA −>AMP + PPI + TRPTRNA 6.1.1.2 4734 NEDD4, KIAA0093 6.3.2.— 5.15Phenylalanine, tyrosine and tryptophan biosynthesis PATH:hsa00400 5053PAH, PKU1 PHE + THBP + O2 −> TYR + DHBP + H2O 1.14.16.1 10667 FARS16.1.1.20 2193 FARSl, CML33 6.1.1.20 10056 PheHB 6.1.1.20 8565 YARS,TYRRS, YTS, YRS 6.1.1.1 5.16 Urea cycle and metabolism of amino groupsPATH:hsa00220 5832 PYCS 2.7.2.11 GLUP + NADH −> NAD + PI + GLUGSAL1.2.1.41 GLUP + NADPH −> NADP + PI + GLUGSAL 95 ACY1 3.5.1.14 6.Metabolism of Other Amino Acids 6.1 beta-Alanine metabolismPATH:hsa00410 6.2 Taurine and hypotaurine metabolism PATH:hsa00430 2678GGT1, GTG, D22S672, D22S732, RGT + ALA −> CGLY + ALAGLY 2.3.2.2 GGT 2679GGT2, GGT RGT + ALA −> CGLY + ALAGLY 2.3.2.2 2680 GGT3 RGT + ALA −>CGLY + ALAGLY 2.3.2.2 2687 GGTLA1, GGT-REL, DKFZP5660011 RGT + ALA −>CGLY + ALAGLY 2.3.2.2 6.3 Aminophosphonate metabolism PATH:hsa00440 5130PCYT1A, CTPCT, CT, PCYT1 PCHO + CTP −> CDPCHO + PPI 2.7.7.15 9791PTDSS1, KIAA0024, PSSA CDPDG + SER <−> CMP + PS 2.7.8.— 6.4 Selenoaminoacid metabolism PATH:hsa00450 22928 SPS2 2.7.9.3 22929 SPS, SELD 2.7.9.36.5 Cyanoamino acid metabolism PATH:hsa00460 6.6 D-Glutamine andD-glutamate metabolism PATH:hsa00471 6.7 D-Arginine and D-ornithinemetabolism PATH:hsa00472 6.9 Glutathione metabolism PATH:hsa00480 5162PEPB 3.4.11.4 2655 GCTG 2.3.2.4 2876 GPX1, GSHPX1 2 RGT + H2O2 <−> OGT1.11.1.9 2877 GPX2, GSHPX-GI 2 RGT + H2O2 <−> OGT 1.11.1.9 2878 GPX3 2RGT + H2O2 <−> OGT 1.11.1.9 2879 GPX4 2 RGT + H2O2 <−> OGT 1.11.1.9 2880GPX5 2 RGT + H2O2 <−> OGT 1.11.1.9 2881 GPX6 2 RGT + H2O2 <−> OGT1.11.1.9 2938 GSTA1 2.5.1.18 2939 GSTA2, GST2 2.5.1.18 2940 GSTA32.5.1.18 2941 GSTA4 2.5.1.18 2944 GSTM1, GST1, MU 2.5.1.18 2946 GSTM2,GST4 2.5.1.18 2947 GSTM3, GST5 2.5.1.18 2948 GSTM4 2.5.1.18 2949 GSTM52.5.1.18 2950 GSTP1, FAEES3, DFN7, GST3, PI 2.5.1.18 2952 GSTT1 2.5.1.182953 GSTT2 2.5.1.18 4257 MGST1, GST12, MGST, MGST-I 2.5.1.18 4258 MGST2,GST2, MGST-II 2.5.1.18 4259 MGST3, GST-III 2.5.1.18 7. Metabolism ofComplex Carbohydrates 7.1 Starch and sucrose metabolism PATH:hsa005006476 SI 3.2.1.10 3.2.1.48 11181 TREH, TRE, TREA TRE −> 2 GLC 3.2.1.282990 GUSB 3.2.1.31 2632 GBE1 GLYCOGEN + PI −> G1P 2.4.1.18 5834 PYGBGLYCOGEN + PI −> G1P 2.4.1.1 5836 PYGL GLYCOGEN + PI −> G1P 2.4.1.1 5837PYGM GLYCOGEN + PI −> G1P 2.4.1.1 2997 GYS1, GYS UDPG −> UDP + GLYCOGEN2.4.1.11 2998 GYS2 UDPG −> UDP + GLYCOGEN 2.4.1.11 276 AMY1A, AMY13.2.1.1 277 AMY1B, AMY1 3.2.1.1 278 AMY1C, AMY1 3.2.1.1 279 AMY2A, AMY23.2.1.1 280 AMY2B, AMY2 3.2.1.1 178 AGL, GDE 2.4.1.25 3.2.1.33 10000AKT3, PKBG, RAC-GAMMA, PRKBG 2.7.1.— 1017 CDK2 1018 CDK3 2.7.1.— 1019CDK4, PSK-J3 2.7.1.— 1020 CDK5, PSSALRE 2.7.1.— 1021 CDK8, PLSTIRE2.7.1.— 1022 CDK7, CAK1, STK1, CDKN7 2.7.1.— 1024 CDK8, K35 2.7.1.— 1025CDK9, PITALRE, CDC2L4 2.7.1.— 10298 PAK4 2.7.1.— 10746 MAP3K2, MEKK22.7.1.— 1111 CHEK1, CHK1 2.7.1.— 11200 RAD53, CHK2, CDS1, HUCDS1 2.7.1.—1195 CLK1, CLK 2.7.1.— 1326 MAP3K8, COT, EST, ESTF, TPL-2 2.7.1.— 1432MAPK14, CSBP2, CSPB1, PRKM14, PRKM15, CSBP1, P38, MXI2 2.7.1.— 1452CSNK1A1 2.7.1.— 1453 CSNK1D, HCKID 2.7.1.— 1454 CSNK1E, HCKIE 2.7.1.—1455 CSNK1G2 2.7.1.— 1456 CSNK1G3 2.7.1.— 1612 DAPK1, DAPK 2.7.1.— 1760DMPK, DM, DMK, DM1 2.7.1.— 1859 DYRK1A, DYRK1, DYRK, MNB, MNBH 2.7.1.—208 AKT2, RAC-BETA, PRKBB, PKBBETA 2.7.1.— 269 AMHR2, AMHR 2.7.1.— 27330RPS6KA6, RSK4 2.7.1.— 2868 GPRK2L, GPRK4 2.7.1.— 2869 GPRK5, GRK52.7.1.— 2870 GPRK6, GRK6 2.7.1.— 29904 HSU93850 2.7.1.— 30811 HUNK2.7.1.— 3611 ILK, P59 2.7.1.— 3654 IRAK1, IRAK 2.7.1.— 369 ARAF1, PKS2,RAFA1 2.7.1.— 370 ARAF2P, PKS1, ARAF2 2.7.1.— 3984 LIMK1, LIMK 2.7.1.—3985 LIMK2 2.7.1.— 4117 MAK 2.7.1.— 4140 MARK3, KP78 2.7.1.— 4215MAP3K3, MAPKKK3, MEKK3 2.7.1.— 4216 MAP3K4, MAPKKK4, MTK1, MEKK4,KIAA0213 2.7.1.— 4217 MAP3K5, ASK1, MAPKKK5, MEKK5 2.7.1.— 4293 MAP3K9,PRKE1, MLK1 2.7.1.— 4294 MAP3K10, MLK2, MST 2.7.1.— 4342 MOS 2.7.1.—4751 NEK2, NLK1 2.7.1.— 4752 NEK3 2.7.1.— 5058 PAK1, PAKalpha 5062 PAK2,PAK65, PAKgamma 2.7.1.— 5063 PAK3, MRX30, PAK3beta 2.7.1.— 5127 PCTK1,PCTGAIRE 2.7.1.— 5128 PCTK2 2.7.1.— 5129 PCTK3, PCTAIRE 2.7.1.— 5292PIM1, PIM 2.7.1.— 5347 PLK, PLK1 2.7.1.— 5562 PRKAA1 2.7.1.— 5563PRKAA2, AMPK, PRKAA 2.7.1.— 5578 PRKCA, PKCA 2.7.1.— 5579 PRKCB1, PKCB,PRKCB, PRKCB2 2.7.1.— 5580 PRKCD 2.7.1.— 5581 PRKCE 2.7.1.— 5582 PRKCG,PKCC, PKCG 2.7.1.— 5583 PRKCH, PKC-L, PRKCL 2.7.1.— 5584 PRKCl,DXS1179E, PKCl 2.7.1.— 5585 PRKCL1, PAK1, PRK1, DBK, PKN 2.7.1.— 5586PRKCL2, PRK2 2.7.1.— 5588 PRKCQ 2.7.1.— 5590 PRKCZ 2.7.1.— 5594 MAPK1,PRKM1, P41MAPK, P42MAPK, ERK2, ERK, MAPK2, 2.7.1.— PRKM2 5595 MAPK3,ERK1, PRKM3, P44ERK1, P44MAPK 2.7.1.— 5597 MAPK6, PRKM6, P97MAPK, ERK32.7.1.— 5598 MAPK7, BMKI, ERK5, PRKM7 2.7.1.— 5599 MAPK8, JNK, JNK1,SAPK1, PRKM8, 2.7.1.— JNK1A2 5601 MAPK9, JNK2, PRKM9, P54ASAPK, 2.7.1.—JUNKINASE 5602 MAPK10, JNK3, PRKM10, P493F12, P54BSAPK 2.7.1.— 5603MAPK13, SAPK4, PRKM13, P38DELTA 2.7.1.— 5604 MAP2K1, MAPKK1, MEK1, MKK1,PRKMK1 2.7.1.— 5605 MAP2K2, MEK2, PRKMK2 2.7.1.— 5606 MAP2K3, MEK3,MKK3, PRKMK3 2.7.1.— 5607 MAP2K5, MEK5, PRKMK5 2.7.1.— 5608 MAP2K6,MEK6, MKK6, SAPKK3, PRKMK6 2.7.1.— 5609 MAP2K7, MAPKK7, MKK7, PRKMK7,JNKK2 2.7.1.— 5610 PRKR, EIF2AK1, PKR 2.7.1.— 5613 PRKX, PKX1 2.7.1.—5894 RAF1 2.7.1.— 613 BCR CMl, PHL, BCR1 D22S11, D22S662 2.7.1.— 6195RPS6KA1, HU-1, RSK, RSK1, MAPKAPK1A 2.7.1.— 6196 RPS6KA2, HU-2,MAPKAPKIC, RSK, RSK3 2.7.1.— 6197 RPS6KA3, RSK2, HU-2, HU-3, RSK,2.7.1.— MAPKAPK1B, ISPK-1 6198 RPS6KB1, STK14A 2.7.1.— 6199 RPS6KB2,P70-BETA, P70S6KB 2.7.1.— 6300 MAPK12, ERK6, PRKM12, SAPK3, P38GAMMA,SAPK-3 2.7.1.— 6416 MAP2K4, JNKK1, MEK4, PRKMK4, SERK1, MKK4 2.7.1.—6446 SGK 2.7.1.— 658 BMPR1B, ALK-6, ALK6 2.7.1.— 659 BMPR2, BMPR-II,BMPR3, BRK-3 2.7.1.— 673 BRAF 2.7.1.— 6792 STK9 2.7.1.— 6794 STK11,LKB1, PJS 2.7.1.— 6885 MAP3K7, TAK1 2.7.1.— 699 BUB1 2.7.1.— 701 BUB1B,BUBR1, MAD3L 2.7.1.— 7016 TESK1 2.7.1.— 7272 TTK, MPS1L1 2.7.1.— 7867MAPKAPK3, 3PK, MAPKAP3 2.7.1.— 8408 ULK1 2.7.1.— 8558 CDK10, PISSLRE2.7.1.— 8621 CDC2L5, CDC2L, CHED 2.7.1.— 8737 RIPK1, RIP 2.7.1.— 8814CDKL1, KKIALRE 2.7.1.— 8899 PRP4, PR4H 2.7.1.— 9064 MAP3K6, MAPKKK62.7.1.— 9149 DYRK1B 2.7.1.— 92 ACVR2, ACTRII 2.7.1.— 9201 DCAMKL1,KIAA0369 2.7.1.— 93 ACVR2B 2.7.1.— 983 CDC2 2.7.1.— 984 CDC2L1 2.7.1.—5205 FIC1, BRIC, PFIC1, PFIC, ATP8B1 3.6.1.— DHPP −> DHP + PI GTP −>GSN + 3 PI DGTP −> DG + 3 PI 7.2 Glycoprotein biosynthesis PATH:hsa005101798 DPAGT1, DPAGt, UGAT, UAGT, 2.7.8.15 D11S366, DGPT, DPAGT2, GPT29880 ALG5 2.4.1.117 8813 DPM1 GDPMAN + DOLP −> GDP + DOLMANP 2.4.1.831650 DDOST, OST, OST48, KIAA0115 2.4.1.119 6184 RPN1 2.4.1.119 6185 RPN22.4.1.119 10130 P5 5.3.4.1 10954 PDIR 3.3.4.1 11008 PDI 5.3.4.1 2923GRP58, ERp57, ERp60, ERp61, 5.3.4.1 GRP57, P58, PI-PLC, ERP57, ERP60,ERP61 5034 P4HB, PROHB, P04DB, ERBA2L 5.3.4.1 7841 GCS1 3.2.1.106 4121MAN1A1, MAN9, HUMM9 3.2.1.113 4245 MGAT1, GLYT1, GLCNAC-TI, GNT-I,2.4.1.101 MGAT 4122 MAN2A2, MANA2X 3.2.1.114 4124 MAN2A1, MANA23.2.1.114 4247 MGAT2, CDGS2, GNT-II, GLCNACTII, 2.4.1.143 GNT2 4248MGAT3, GNT-III 2.4.1.144 6487 SIAT6, ST3GALII 2.4.99.6 6480 SIAT12.4.99.1 2339 FNTA, FPTA, PGGT1A 2.5.1.— 2342 FNTB, FPTB 2.5.1.— 5229PGGT1B, BGGI, GGTI 2.5.1.— 5875 RABGGTA 2.5.1.— 5876 RABGGTB 2.5.1.—1352 COX10 2.5.1.— 7.3 Glycoprotein degradation PATH:hsa00511 4758 NEU1,NEU 3.2.1.18 3073 HEXA, TSD 3.2.1.52 3074 HEXB 3.2.1.52 4123 MAN2C1,MANA, MANA1, MAN6A8 3.2.1.24 4125 MAN2B1, MANS, LAMAN 3.2.1.24 4126MANBA, MANB1 3.2.1.25 2517 FUCA1 3.2.1.51 2519 FUCA2 3.2.1.51 175 AGA,AGU 3.5.1.26 7.4 Aminosugars metabolism PATH:hsa00530 6675 UAP1, SPAG2,AGX1 UTP + NAGAIP <−> UDPNAG + PPI 2.7.7.23 10020 GNE, GLCNE 5.1.3.1422951 CMAS 2.7.7.43 1727 DIA1 1.6.2.2 4669 NAGLU, NAG 3.2.1.50 7.5Lipopolysaccharide biosynthesis PATH:hsa00540 6485 SIAT5, SAT3, STZ2,4.99.— 7903 SIAT8D, PST, PST1, ST8SIA-IV 2.4.99.— 8128 SIAT8B, STX,STSSIA-II 2.4.99.— 7.7 Glycosaminoglycan degradation PATH:hsa00531 3423IDS, MPS2, SIDS 3.1.6.13 3425 IDUA, IDA 3.2.1.76 411 ARSB 3.1.6.12 2799GNS, G6S 3.1.6.14 2588 GALNS, MPS4A, GALNAC6S, GAS 3.1.6.4 8. Metabolismof Complex Lipids 8.1 Glycerolipid metabolism PATH:hsa00561 10554AGPAT1, LPAAT-ALPHA, G15 AGL3P + 0.017 C100ACP + 0.062 C120ACP + 0.100C140ACP + 2.3.1.51 0.270 C160ACP + 0.169 C161ACP + 0.055 C180ACP + 0.235C181ACP + 0.093 C182ACP −> PA + ACP 10555 AGPAT2, LPAAT-BETA AGL3P +0.017 C100ACP + 0.062 C120ACP + 0.100 C140ACP + 2.3.1.51 0.270 C160ACP +0.169 C161ACP + 0.055 C180ACP + 0.235 C181ACP + 0.093 C182ACP −> PA +ACP 1606 DGKA, OAGK, DAGK1 2.7.1.107 1608 DGKG, DAGK3 2.7.1.107 1609DGKQ, DAGK4 2.7.1.107 8525 DGKZ, DAGK5, HDGKZETA 2.7.1.107 8526 DGKE,DAGK6, DGK 2.7.1.107 8527 DGKD, DGKDELTA, KIAA0145 2.7.1.107 1120 CHKLATP + CHO −> ADP + PCHO 2.7.1.32 EKI1 ATP + ETHM −> ADP + PETHM 2.7.1.821119 CHK, CKI ATP + CHO −> ADP + PC HO 2.7.1.32 43 ACHE, YT 3.1.1.7 1103CHAT 2.3.1.6 5337 PLD1 3.1.4.4 26279 PLA2G2D, SPLA2S 3.1.1.4 30814PLA2G2E 3.1.1.4 5319 PLA2G1B, PIA2, PLA2A, PPLA2 3.1.1.4 5320 PLA2G2A,MOM1, PLA2B, PLA2L 3.1.1.4 5322 PLA2G5 3.1.1.4 8398 PLA2G6, IPLA23.1.1.4 8399 PLA2G10, SPLA2 3.1.1.4 1040 CDS1 PA + CTP <−> CDPDG + PPI2.7.7.41 10423 PIS CDPDG + MYOI −> CMP + PINS 2.7.8.41 2710 GK GL + ATP−> GL3P + ADP 2.7.1.30 2820 GPD2 GL3Pm + FADm −> T3P2m + FADH2m 1.1.99.52819 GPD1 T3P2 + NADH <−> GL3P + NAD 1.1.1.8 248 ALPI AHTD −> DHP + 3 PI3.1.3.1 249 ALPL, HOPS, TNSALP AHTD −> DHP + 3 PI 3.1.3.1 250 ALPP AHTD−> DHP + 3 PI 3.1.3.1 251 ALPPL2 AHTD −> DHP + 3 PI 3.1.3.1 439 ASNA1,ARSA-I 3.6.1.16 8694 DGAT, ARGP1 DAGLY + 0.017 C100ACP + 0.062 C120ACP +0.100 C140ACP + 2.3.1.20 0.270 C160ACP + 0.169 C161ACP + 0.055 C180ACP +0.235 C181ACP + 0.093 C182ACP −> TAGLY + ACP 3989 LIPB 3.1.1.3 3990LIPC, HL 3.1.1.3 5406 PNLIP 3.1.1.3 5407 PNLIPRP1, PLRP1 3.1.1.3 5408PNLIPRP2, PLRP2 3.1.1.3 8513 LIPF, HGL, HLAL 3.1.1.3 4023 LPL, LIPD3.1.1.34 8443 GNPAT, DHAPAT, DAP-AT 2.3.1.42 8540 AGP-S, ADAS, ADHAPS,ADPS, 2.5.1.26 ALDHPSY 4186 MDCR, MDS, US1 3.1.1.47 5048 PAFAH1B1, US1,MDCR, PAFAH 3.1.1.47 5049 PAFAH 1B2 3.1.1.47 5050 PAFAH1B3 3.1.1.47 5051PAFAH2, HSD-PLA2 3.1.1.47 7941 PLA2G7, PAFAH, LDL-PLA2 3.1.1.47 8.2Inositol phosphate metabolism PATH:hsa00562 5290 PIK3CA ATP + PINS −>ADP + PINSP 2.7.1.137 5291 PIK3CB, PIK3C1 ATP + PINS −> ADP + PINSP2.7.1.137 5293 PIK3CD ATP + PINS −> ADP + PINSP 2.7.1.137 5294 PIK3CGATP + PINS −> ADP + PINSP 2.7.1.137 5297 PIK4CA, PI4K-ALPHA ATP + PINS−> ADP + PINS4P 2.7.1.67 5305 PIP5K2A PINS4P + ATP −> D45P1 + ADP2.7.1.68 5330 PLCB2 D45P1−> TPI + DAGLY 3.1.4.11 5331 PLCB3 D45P1−>TPI + DAGLY 3.1.4.11 5333 PLCD1 D45PI −> TPI + DAGLY 3.1.4.11 5335PLCG1, PLC1 D45PI −> TPI + DAGLY 3.1.4.11 5336 PLCG2 D45PI −> TPI +DAGLY 3.1.4.11 3612 IMPA1, IMPA MI1P −> MYO1+ PI 3.1.3.25 3613 IMPA2MI1P −> MYOI + PI 3.1.3.25 3628 INPP1 3.1.3.57 3632 INPP5A 3633 INPP5B3.1.3.56 3636 INPPL1, SHIP2 3.1.3.56 4952 OCRL, LOCR, OCRL1, INPP5F3.1.3.56 8867 SYNJ1, INPP5G 3.1.3.56 3706 ITPKA 2.7.1.127 51477 ISYNA1G6P −> MI1P 5.5.1.4 3631 INPP4A, INPP4 3.1.3.66 6821 INPP4B 3.1.3.66 8.3Sphingophospholipid biosynthesis PATH:hsa00570 6609 SMPD1, NPD 3.1.4.128.4 Phospholipid degradation PATH:hs800580 1178 CLC 3.1.15 5321 PLA2G4A,CPLA2-ALPHA, PLA2G4 3.1.1.5 8.5 Sphingogtycolipid metabolismPATH:hsa00600 10558 SPTLC1, LCB1, SPTI PALCOA + SER −> COA + DHSPH + CO22.3.1.50 9517 SPTLC2, KIAA0526, LCB2 PALCOA + SER −> COA + DHSPH + CO22.3.1.50 427 ASAH, AC, PHP32 3.5.1.23 7357 UGCG, GCS 2.4.1.80 2629 GBA,GLUC 3.2.1.45 2583 GALGT, GALNACT 2.4.1.92 6489 SIAT8A SIAT8, ST8SIA-I2.4.99.8 6481 SIAT2 2.4.99.2 4668 NAGA, D22S674, GALB 3.2.1.49 9514 CST2.8.2.11 410 ARSA, MLD 3.1.6.8 8.6 Blood group glycolipid biosynthesis -lact series PATH hsa00601 28 ABO 2.4.1.40 2.4.1.37 2525 FUT3, LE2.4.1.65 2527 FUT5, FUC-TV 2.4.1.65 2528 FUT6 2.4.1.65 2523 FUT1, H, HH2.4.1.69 2524 FUT2, SE 2.4.1.69 8.7 Blood group glycolipidbiosynthesis - neolact series PATH:hsa00602 2651 GCNT2, IGNT, NACGT1,NAGCT1 2.4.1.1.50 8.8 Prostaglandin and leukotriene metabolismPATH:hsa00590 239 ALOX12, LOG12 1.13.11.31 246 ALOX15 1.13.11.33 240ALOX5 1.13.11.34 4056 LTC4S 2.5.1.37 4048 LTA4H 3.3.2.6 4051 CYP4F3,CYP4F, LTB4H 1.14.13.30 8529 CYP4F2 1.14.13.30 5742 PTGS1, PGHS-11.14.99.1 5743 PTGS2, COX-2, COX2 1.14.99.1 27306 PGDS 5.3.99.2 5730PTGDS 5.3.99.2 5740 PTGIS, CYP8, PGIS 5.3.99.4 6916 TBXAS1, CYP55.3.99.5 873 CBR1, CBR 1.1.1.184 1.1.1.189 1.1.1.197 874 CBR3 1.1.1.1849. Metabolism of Cofactors and Vitamins 9.2 Riboflavin metabolismPATH:hsa00740 52 ACP1 3.1.3.48 FMN −> RIBOFLAV + PI 3.1.3.2 53 ACP2 FMN−> RIBOFLAV + PI 3.1.3.2 54 ACP5, TRAP FMN −> RIBOFLAV + PI 3.1.3.2 55ACPP, PAP FMN −> RIBOFLAV + PI 3.1.3.2 9.3 Vitamin B6 metabolismPATH:hsa00750 8566 PDXK, PKH, PNK PYRDX + ATP −> P5P + ADP 2.7.1.35PDLA + ATP −> POLA5P + ADP PL + ATP −> PL5P + ADP 9.4 Nicotinate andnicotinamide metabolism PATH:hsa00760 23475 QPRT QA + PRPP −> NAMN +CO2 + PPI 2.4.2.19 4837 NNMT 2.1.1.1 683 BST1, CD157 NAD −> NAM + ADPRIB3.2.2.5 952 CD38 NAD −> NAM + ADPRIB 3.2.2.5 23530 NNT 1.6.1.2 9.5Pantothenate and CoA biosynthesis PATH:hsa00770 9.6 Biotin metabolismPATH:hsa00780 3141 HLCS, HCS 6.3.4.— 6.3.4.9 6.3.4.10 6.3.4.11 6.3.4.153.5.1.12 686 BTD 9.7 Folate biosynthesis PATH:hsa00790 2643 GCH1, DYT5,GCH, GTPCH1 GTP −> FOR + AHTD 3.5.4.16 1719 DHFR DHF + NADPH −> NADP +THF 1.5.1.3 2356 FPGS THF + ATP + GLU <−> ADP + PI + THFG 6.3.2.17 8836GGH, GH 3.4.19.9 5805 PTS 4.6.1.10 6697 SPR 1.1.1.153 5860 QDPR, DHPR,PKU2 NADPH + DHBP −> NADP + THBP 1.6.99.7 9.8 One carbon pool by folatePATH:hsa00670 10840 FTHFD 1.5.1.6 10588 MTHFS ATP + FTHF −> ADP + PI +MTHF 6.3.3.2 9.10 Porphyrin and chlorophyll metabolism PATH:hsa00860 210ALAD 2 ALAV −> PBG 4.2.1.24 3145 HMBS, PBGD, UPS 4 PBG −> HMB + 4 NH34.3.1.8 7390 UROS HMB −> UPRG 4.2.1.75 7389 UROD UPRG −> 4 CO2 + CPP4.1.1.37 1371 CPO, CPX O2 + CPP −> 2 CO2 + PPHG 1.3.3.3 5498 PPOX, PPOO2 + PPHGm −> PPIXm 1.3.3.4 2235 FECH, FCE PPIXm −> PTHm 4.99.1.1 3162HMOX1, HO-1 1.14.99.3 3163 HMOX2, HO-2 1.14.99.3 644 BLVRA, BLVR1.3.1.24 645 BLVRB, FLR 1.3.1.24 2232 FDXR, ADXR 1.6.99.1 1.18.1.2 3052HCCS, CCHL 4.4.1.17 1356 CP 1.16.3.1 9.11 Ubiquinone biosynthesisPATH:hsa00130 4938 OAS1, IFI-4, OIAS 2.7.7.— 4939 OAS2, P69 2.7.7.— 5557PRIM1 2.7.7.— 5558 PRIM2A, PRIM2 2.7.7.— 5559 PRIM2B, PRIM2 2.7.7.— 7015TERT, EST2, TCS1, TP2, TRT 2.7.7.— 8638 OASL, TRIP14 2.7.7.— 10.Metabolism of Other Substances 10.1 Terpenoid biosynthesis PATH:hsa0090010.2 Flavonoids, stilbene and lignin biosynthesis PATH:hsa00940 10.3Alkaloid biosynthesis I PATH:hsa00950 10.4 Alkaloid biosynthesis IIPATH:hsa00960 10.6 Streptomycin biosynthesis PATH:hsa00521 10.7Erythromycin biosynthesis PATH:hsa00522 10.8 Tetracycline biosynthesisPATH:hsa00253 10.14 gamma-Hexachlorocyclohexane degradationPATH:hsa00361 5444 PON1, ESA, PON 3.1.8.1 3.1.1.2 5445 PON2 3.1.1.23.1.8.1 10.18 1,2-Dichloroethane degradation PATH:hsa00631 10.20Tetrachloroethene degradation PATH:hsa00625 2052 EPHX1, EPHX, MEH3.3.2.3 2053 EPHX2 3.3.2.3 10.21 Styrene degradation PATH:hsa00643 11.Transcription (condensed) 11.1 RNA polymerase PATH:hsa03020 11.2Transcription factors PATH:hsa03022 12. Translation (condensed) 12.1Ribosome PATH:hsa03010 12.2 Translation factors PATH:hsa03012 1915EEF1A1, EF1A, ALPHA, EEF-1, EEF1A 3.6.1.48 1917 EEF1A2, EF1A 3.6.1.481938 EEF2, EF2, EEF-2 3.6.1.48 12.3 Aminoacyl-tRNA biosynthesisPATH:hsa00970 13. Sorting and Degradation (condensed) 13.1 Proteinexport PATH:hsa03060 23478 SPC18 3.4.21.89 13.4 Proteasome PATH:hsa030505687 PSMA6, IOTA, PROS27 3.4.99.46 5683 PSMA2, HC3, MU, PMSA2, PSC23.4.99.46 5685 PSMA4, HC9 3.4.99.46 5688 PSMA7, XAPC7 3.4.99.46 5686PSMA5, ZETA, PSC5 3.4.99.46 5682 PSMA1, HC2, NU, PROS30 3.4.99.46 5684PSMA3, HC8 3.4.99.46 5698 PSMB9, LMP2, RING12 3.4.99.46 5695 PSMB7, Z3.4.99.46 5691 PSMB3, HC10-II 3.4.99.46 5690 PSMB2, HC7-I 3.4.99.46 5693PSMB5, LMPX, MB1 3.4.99.46 5689 PSMB1, HCS, PMSB1 3.4.99.46 5692 PSMB4,HN3, PROS26 3.4.99.46 14. Replication and Repair 14.1 DNA polymerasePATH:hsa03030 14.2 Replication Complex PATH:hsa03032 23626 SPO115.99.1.3 7153 TOP2A, TOP2 5.99.1.3 7155 TOP2B 5.99.1.3 7156 TOP3A, TOP35.99.1.2 8940 TOP3B 5.99.1.2 22. Enzyme Complex 22.1 Electron TransportSystem, Complex I PATH:hsa03100 22.2 Electron Transport System, ComplexII PATH:hsa03150 22.3 Electron Transport System, Complex IIIPATH:hsa03140 22.4 Electron Transport System, Complex IV PATH:hsa0313022.5 ATP Synthase PATH:hsa03110 22.8 ATPases PATH:hsa03230 23.Unassigned 23.1 Enzymes 5538 PPT1, CLN1, PPT, INCL C160ACP + H2O −>C160 + ACP 3.1.2.22 23.2 Non-enzymes 22934 RPIA, RPI RL5P <−> R5P5.3.1.6 5250 SLC25A3, PHC PI + H <−> Hm + Plm 6576 CIT + MALm <−> CITm +MAL 51166 LOC51168 AADP + AKG −> GLU + KADP 2.6.1.39 5625 PRODH PRO +FAD −> P5C + FADH2 1.5.3.— 6517 SLC2A4, GLUT4 GLCxt −> GLC 6513 SLC2A1,GLUT1, GLUT GLCxt −> GIG 26275 HIBCH, HIBYL-COA-H HIBCOAm + H2Om −>HIBm + COAm 3.1.2.4 23305 KIAA0837, ACS2, LACS5, IACS2 C160 + COA + ATP−> AMP + PPI + C160COA 8611 PPAP2A, PAP-2A PA + H2O −> DAGLY + PI 8612PPAP2C, PAP-2C PA + H2O −> DAGLY + PI 8613 PPAP2B, PAP-28 PA + H2O −>DAGLY + PI 56994 LOC56994 CDPCHO + DAGLY −> PC + CMP 10400 PEMT, PEMT2SAM + PE −> SAH + PMME 5833 PCYT2, ET PETHM + CTP −> CDPETN + PPI 10390CEPT1 CDPETN + DAGLY <−> CMP + PE 8394 PIP5K1A PINS4P + ATP −> D45PI +ADP 8395 P1P5K1B, STMT, MSS4 PINS4P + ATP −> D45PI + ADP 8396 PIP5K2BPINS4P + ATP −> D45PI + ADP 23396 PIP5K1C, KIAA0589, PIP5K-GAMMAPINS4P + ATP −> D45PI + ADP 24. Our own reactions which need to be foundin KEGG GL3P <−> GL3Pm T3P2 <−> T3P2m PYR <−> PYRm + Hm ADP + ATPm +PI + H −> Hm + ADPm + ATP + Plm AKG + MALm <−> AKGm + MAL ASPm + GLU + H−> Hm + GLUm + ASP GDP + GTPm + PI + H −> Hm + GDPm + GTP + PlmC160Axt + FABP −> C160FP + ALBxt C160FP −> C160 + FABP C180Axt + FABP −>C180FP + ALBxt C180FP −> C180 + FABP C161Axt + FABP −> C161FP + ALBxtC161FP −> C161 + FABP C181Axt + FABP −> C181FP + ALBxt C181FP −> C181 +FABP C182Ax1 + FABP −> C182FP + ALBxt C182FP −> C182 + FABP C204Axt +FABP −> C204FP + ALBxt C204FP −> C204 + FABP O2xt −> O2 O2 <−> O2mACTACm + SUCCOAm −> SUCCm + AACCOAm 3HB −> 3HBm MGCOAm + H2Om −> H3MCOAm4.2.1.18 OMVAL −> OMVALm OIVAL −> OIVALm OICAP −> OICAPm Cl60CAR <−>Cl60CARm CAR <−> CARm DMMCOAm −> LMMCOAm 5.1.99.1 amino acid metabolismTHR −> NH3 + H2O + OBUT 4.2.1.16 THR + NAD −> CO2 + NADH + AMA 1.1.1.103THR + NAD + COA −> NADH + ACCOA + GLY AASA + NAD −> NADH + AADP1.2.1.3.1 FKYN + H2O −> FOR + KYN 3.5.1.9 CMUSA −> CO2 + AM6SA 4.1.1.45AM6SA + NAD −> AMUCO + NADH 1.2.1.32 AMUCO + NADPH −> KADP + NADP + NH41.5.1.— CYSS + AKG <−> GLU + SPYR URO + H2O −> 4I5P 4.2.1.49 4I5P + H2O−> FIGLU 3.5.2.7 GLU <−> GLUm + Hm ORN + Hm −> ORNm ORN + Hm + CITRm <−>CITR + ORNm GLU + ATP + NADPH −> NADP + ADP + PI + GLUGSAL GLYAm + ATPm−> ADPm + 2PGm AM6SA −> PIC SPYR + H2O −> H2S03 + PYR P5C <−> GLUGSALfatty acid synthesis MALCOA + ACP <−> MALACP + COA 2.3.1.39 ACCOA + ACP<−> AC ACP + COA ACACP + 4 MALACP + 8 NADPH −> 8 NADP + C100ACP + 4CO2 + 4 ACP ACACP + 5 MALACP + 10 NADPH −> 10 NADP + C120ACP + 5 CO2 + 5ACP ACACP + 6 MALACP + 12 NADPH −> 12 NADP + C140ACP + 6 CO2 + 6 ACPACACP + 6 MALACP + 11 NADPH −> 11 NADP + C141ACP + 6 CO2 + 6 ACP ACACP +7 MALACP + 14 NADPH −> 14 NADP + C160ACP + 7 CO2 + 7 ACP ACACP + 7MALACP + 13 NADPH −> 13 NADP + C181ACP + 7 CO2 + 7 ACP ACACP + 8MALACP + 16 NADPH −> 16 NADP + C180ACP + 8 CO2 + 8 ACP ACACP + 8MALACP + 15 NADPH −> 15 NADP + C181ACP + 8 CO2 + 8 ACP ACACP + 8MALACP + 14 NADPH −> 14 NADP + C182ACP + 8 CO2 + 8 ACP C160COA + CAR −>C160CAR + COA C160CARm + COAm −> C160COAm + CARm fatty acid depredationGL3P + 0.017 C100ACP + 0.062 C120ACP + 0.1 C140ACP + 0.27 C160ACP +0.169 C161ACP + 0.055 C180ACP + 0.235 C181ACP + 0.093 C182ACP −> AGL3P +ACP TAGLYm + 3 H2Om −> GLm + 3 C160m Phospholipid metabolism SAM + PMME−> SAH + PDME PDME + SAM −> PC + SAH PE + SER <−> PS + ETHM Musclecontraction MYOACT + ATP −> MYOATP + ACTIN MYOATP + ACTIN −> MYOADPACMYOADPAC −> ADP + PI + MYOACT + CONTRACT

TABLE 2 // Homo Sapiens Core Metabolic Network // // Glycolysis // −1GLC −1 ATP +1 G6P +1 ADP 0 HK1 −1 G6P −1 H2O +1 GLC +1 PI 0 G6PC −1 G6P+1 F6P 0 GPIR −1 F6P −1 ATP +1 FDP +1 ADP 0 PFKL −1 FDP −1 H2O +1 F6P +1PI 0 FBP1 −1 FDP +1 T3P2 +1 T3P1 0 ALDOAR −1 T3P2 +1 T3P1 0 TPI1R −1T3P1 −1 PI −1 NAD +1 NADH +1 13PDG 0 GAPDR −1 13PDG −1 ADP +1 3PG +1 ATP0 PGK1R −1 13PDG +1 23PDG 0 PGAM1 −1 23PDG −1 H2O +1 3PG +1 PI 0 PGAM2−1 3PG +1 2PG 0 PGAM3R −1 2PG +1 PEP +1 H2O 0 ENO1R −1 PEP −1 ADP +1 PYR+1 ATP 0 PKLR −1 PYRm −1 COAm −1 NADm +1 NADHm +1 CO2m +1 ACCOAm 0 PDHA1−1 NAD −1 LAC +1 PYR +1 NADH 0 LDHAR −1 GIP +1 G6P 0 PGM1R // TCA // −1ACCOAm −1 OAm −1 H2Om +1 COAm +1 CITm 0 CS −1 CIT +1 ICIT 0 ACO1R −1CITm +1 ICITm 0 ACO2R −1 ICIT −1 NADP +1 NADPH +1 CO2 +1 AKG 0 IDH1 −1ICITm −1 NADPm +1 NADPHm +1 CO2m +1 AKGm 0 IDH2 −1 ICITm −1 NADm +1 CO2m+1 NADHm +1 AKGm 0 IDH3A −1 AKGm −1 NADm −1 COAm +1 CO2m +1 NADHm +1SUCCOAm 0 OGDH −1 GTPm −1 SUCCm −1 COAm +1 GDPm +1 Pim +1 SUCCOAm 0SUCLG1R −1 ATPm −1 SUCCm −1 COAm +1 ADPm +1 Pim +1 SUCCOAm 0 SUCLA2R −1FUMm −1 H2Om +1 MALm 0 FHR −1 MAL −1 NAD +1 NADH +1 OA 0 MDH1R −1 MALm−1 NADm +1 NADHm +1 OAm 0 MDH2R −1 PYRm −1 ATPm −1 CO2m +1 ADPm +1 OAm+1 Pim 0 PC −1 OA −1 GTP +1 PEP +1 GDP +1 CO2 0 PCK1 −1 OAm −1 GTPm +1PEPm +1 GDPm +1 CO2m 0 PCK2 −1 ATP −1 CIT −1 COA −1 H2O +1 ADP +1 PI +1ACCOA +1 OA 0 ACLY // PPP // −1 G6P −1 NADP +1 D6PGL +1 NADPH 0 G6PDR −1D6PGL −1 H2O +1 D6PGC 0 PGLS −1 D6PGC −1 NADP +1 NADPH +1 CO2 +1 RL5P 0PGD −1 RL5P +1 X5P 0 RPER −1 R5P −1 X5P +1 T3P1 +1 S7P 0 TKT1R −1 X5P −1E4P +1 F6P +1 T3P1 0 TKT2R −1 T3P1 −1 S7P +1 E4P +1 F6P 0 TALD01R −1RL5P +1 R5P 0 RPIAR // Glycogen // −1 G1P −1 UTP +1 UDPG +1 PPI 0 UGP1−1 UDPG +1 UDP +1 GLYCOGEN 0 GYSl −1 GLYCOGEN −1 PI +1 GlP 0 GBE1 // ETS// −1 MALm −1 NADPm +1 CO2m +1 NADPHm +1 PYRm 0 ME3 −1 MALm −1 NADm +1CO2m +1 NADHm +1 PYRm 0 ME2 −1 MAL −1 NADP +1 CO2 +1 NADPH +1 PYR 0 ME1−1 NADHm −1 Qm −4 Hm +1 QH2m +1 NADm +4 H 0 MTND1 −1 SUCCm −1 FADm +1FUMm +1 FADH2m 0 SDHC1R −1 FADH2m −1 Qm +1 FADm +1 QH2m 0 SDHC2R −1 O2m−4 FEROm −4 Hm +4 FERIm +2 H2Om +4 H 0 UQCRFS1 −1 QH2m −2 FERIm −4 Hm +1Qm +2 FEROm +4 H 0 COX5BL4 −1 ADPm −1 PIm −3 H +1 ATPm +3 Hm +1 H2Om 0MTAT −1 ADP −1 ATPm −1 PI −1 H +1 Hm +1 ADPm +1 ATP +1 PIm 0 ATPMC −1GDP −1 GTPm −1 PI −1 H +1 Hm +1 GDPm +1 GTP +1 PIm 0 GTPMC −1 PPI +2 PI0 PP −1 ACCOA −1 ATP −1 CO2 +1 MALCOA +1 ADP +1 PI 0 ACACAR −1 GDP −1ATP +1 GTP +1 ADP 0 GOT3R // Transporters // −1 CIT −1 MALm +1 CITm +1MAL 0 CITMCR −1 PYR −1 H +1 PYRm +1 Hm 0 PYRMCR // Glycerol PhosphateShuttle // −1 GL3Pm −1 FADm +1 T3P2m +1 FADH2m 0 GPD2 −1 T3P2 −1 NADH +1GL3P +1 NAD 0 GPD1 −1 GL3P +1 GL3Pm 0 GL3PMCR −1 T3P2 +1 T3P2m 0 T3P2MCR// Malate/Aspartate Shuttle // −1 OAm −1 GLUm +1 ASPm +1 AKGm 0 GOT1R −1ASP −1 AKG +1 OA +1 GLU 0 GOT2R −1 AKG −1 MALm +1 AKGm +1 MAL 0 MALMCR−1 ASPm −1 GLU −1 H +1 Hm +1 GLUm +1 ASP 0 ASPMC // Exchange Fluxes //+1 GLC 0 GLCexR +1 PYR 0 PYRexR +1 CO2 0 CO2exR +1 O2 0 O2exR +1 PI 0PIexR +1 H2O 0 H2OexR +1 LAC 0 LACexR +1 CO2m 0 CO2min −1 CO2m 0 CO2mout+1 O2m 0 02min −1 O2m 0 02mout +1 H2Om 0 H2Omin −1 H2Om 0 H2Omout +1 PIm0 PImin −1 PIm 0 Pimout // Output // −1 ATP +1 ADP +1 PI 0 Output 0.0end end E 0 max 1 Output 0 end 0 GLCexR 1 −1000 PYRexR0 −1000 LACexR 0 0end 0 rev. rxn 33 nonrev. rxn 31 total rxn 64 matrix columns 97 uniqueenzymes 52

TABLE 3 Abbrev. Reaction Rxn Name Glycolysis HK1 GLC + ATP −> G6P + ADPHK1 G6PC, G6PT G6P + H2O −> GLC + PI G6PC GPI G6P <−> F6P GPI PFKL F6P +ATP −> FDP + ADP PFKL FBP1, FBP FDP + H2O −> F6P + PI FBP1 ALDOA FDP <−>T3P2 + T3P1 ALDOA TPI1 T3P2 <−> T3P1 TPI1 GAPD, GAPDH T3P1 + PI + NAD<−> NADH + 13PDG GAPD PGK1, PGKA 13PDG + ADP <−> 3PG + ATP PGK1 PGAM1,PGAMA 13PDG <−> 23PDG PGAM1 23PDG + H2O −> 3PG + PI PGAM2 3PG <−> 2PGPGAM3 EN01, PPH, EN01L1 2PG <−> PEP + H2O EN01 PKLR, PK1 PEP + ADP −>PYR + ATP PKLR PDHA1, PHE1A, PDHA PYRm COAm + NADm −> + NADHm + CO2m +ACCOAm PDHA1 LDHA, LDH1 NAD + LAC <−> PYR + NADH LDHA PGM1 G1P <−> G6PPGM1 TCA CS ACCOAm + OAm + H2Om −> COAm + CITm CS ACO1, IREB1, IRP1 CIT<−> ICIT ACO1 ACO2 CITm <−> ICITm ACO2 IDH1 ICIT + NADP −> NADPH + CO2 +AKG IDH1 IDH2 ICITm + NADPm −> NADPHm + CO2m + AKGm IDH2 IDH3A ICITm +NADm −> CO2m + NADHm + AKGm IDH3A OGDH AKGm + NADm + COAm −> CO2m +NADHm + SUCCOAm OGDH SUCLG1, SUCLA1 GTPm + SUCCm + COAm <−> GDPm + PIm +SUCCOAm SUCLG1 SUCLA2 ATPm + SUCCm + COAm <−> ADPm + Pim + SUCCOAmSUCLA2 FH FUMm + H2Om <−> MALm FH MDH1 MAL + NAD <−> NADH + OA MDH1 MDH2MALm + NADm <−> NADHm + OAm MDH2 PC, PCB PYRm + ATPm + CO2m −> ADPm +OAm + PIm PC ACLY, ATPCL, CLATP ATP + CIT + COA + H2O −> ADP + PI +ACCOA + OA ACLY PCK1 OA + GTP −> PEP + GDP + CO2 PCK1 PPP G6PD, G6PD1G6P + NADP <−> D6PGL + NADPH G6PD PGLS, 6PGL D6PGL + H2O −> D6PGC PGLSPGD D6PGC + NADP −> NADPH + CO2 + RL5P PGD RPE RL5P <−> X5P RPE TKTR5P + X5P <−> T3P1 + S7P TKT1 X5P + E4P <−> F6P + T3P1 TKT2 TALDO1T3P1 + S7P <−> E4P + F6P TALDO1 UGP1 G1P + UTP −> UDPG + PPI UGP1 ACACA,ACAC, ACC ACCOA + ATP + CO2 <−> MALCOA + ADP + PI + H ACACA ETS ME3MALm + NADPm −> CO2m + NADPHm + PYRm ME3 MTND1 NADHm + Qm + 4 Hm −>QH2m + NADm + 4 H MTND1 SDHC SUCCm + FADm <−> FUMm + FADH2m SDHC1FADH2m + Qm <−> FADm + QH2m SDHC2 UQCRFS1, RIS1 O2m + 4 FEROm + 4 Hm −>4 FERIm + 2 H2Om + 4 H UQCRFS1 COX5BL4 QH2m + 2 FERIm + 4 Hm −> Qm + 2FEROm + 4 H COX5BL4 MTATP6 ADPm + PIm + 3 H −> ATPm + 3 Hm + H2Om MTATPP, SID6-8061 PPI −> 2 PI PP Malate Aspartate shunttle GOT1 OAm + GLUm<−> ASPm + AKGm GOT1 GOT2 OA + GLU <−> ASP + AKG GOT2 GDP + ATP <−>GTP + ADP GOT3 Glycogen GBE1 GLYCOGEN + PI −> G1P GBE1 GYS1, GYS UDPG −>UDP + GLYCOGEN GYS1 Glycerol Phosphate Shunttle GPD2 GL3Pm + FADm −>T3P2m + FADH2m GPD2 GPD1 T3P2 + NADH −> GL3P + NAD GPD1 RPIA, RPI RL5P<−> R5P RPIA Mitochondria Transport CIT + MALm <−> CITm + MAL CITMC GL3P<−> GL3Pm GL3PMC T3P2 <−> T3P2m T3P2MC PYR <−> PYRm + Hm PYRMC ADP +ATPm + PI + H −> Hm + ADPm + ATP + PIm ATPMC AKG + MALm <−> AKGm + MALMALMC ASPm + GLU + H −> Hm + GLUm + ASP ASPMC GDP + GTPm + PI + H −>Hm + GDPm + GTP + PIm GTPMC

TABLE 4 Metabolic Reaction for Muscle Cells Reaction Rxt Name GLC + ATP−> G6P + ADP 0 HK1 G6P <-> F6P 0 GPI F6P + ATP −> FDP + ADP 0 PFKL1FDP + H2O −> F6P + PI 0 FBP1 FDP <-> T3P2 + T3P1 0 ALDOA T3P2 <-> T3P1 0TPI1 T3P1 + PI + NAD <-> NADH + 13PDG 0 GAPD 13PDG + ADP <-> 3PG + ATP 0PGK1 3PG <-> 2PG 0 PGAM3 2PG <-> PEP + H2O 0 ENO1 PEP + ADP −> PYR + ATP0 PK1 PYRm + COAm + NADm −> + NADHm + CO2m + ACCOAm 0 PDHA1 NAD + LAC<-> PYR + NADH 0 LDHA G1P <-> G6P 0 PGM1 ACCOAm + OAm + H2Om −> COAm +CITm 0 CS CIT <-> ICIT 0 ACO1 CITm <-> ICITm 0 ACO2 ICIT + NADP −>NADPH + CO2 + AKG 0 IDH1 ICITm + NADPm −> NADPHm + CO2m + AKGm 0 IDH2ICITm + NADm −> CO2m + NADHm + AKGm 0 IDH3A AKGm + NADm + COAm −> CO2m +NADHm + SUCCOAm 0 OGDH GTPm + SUCCm + COAm <-> GDPm + PIm + SUCCOAm 0SUCLG1 ATPm + SUCCm + COAm <-> ADPm + PIm + SUCCOAm 0 SUCLA2 FUMm + H2Om<-> MALm 0 FH MAL + NAD <-> NADH + OA 0 MDH1 MALm + NADm <-> NADHm + OAm0 MDH2 PYRm + ATPm + CO2m −> ADPm + OAm + PIm 0 PC ATP + CIT + COA + H2O−> ADP + PI + ACCOA + OA 0 ACLY OA + GTP −> PEP + GDP + CO2 0 PCK1 OAm +GTPm −> PEPm + GDPm + CO2m 0 PCK2 G6P + NADP <-> D6PGL + NADPH 0 G6PDD6PGL + H2O −> D6PGC 0 H6PD D6PGC + NADP −> NADPH + CO2 + RL5P 0 PGDRL5P <-> X5P 0 RPE R5P + X5P <-> T3P1 + S7P 0 TKT1 X5P + E4P <-> F6P +T3P1 0 TKT2 T3P1 + S7P <-> E4P + F6P 0 TALDO1 RL5P <-> R5P 0 RPIA G1P +UTP −> UDPG + PPI 0 UGP1 GLYCOGEN + PI −> G1P 0 GBE1 UDPG −> UDP +GLYCOGEN 0 GYS1 MALm + NADm −> CO2m + NADHm + PYRm 0 ME2 MALm + NADPm −>CO2m + NADPHm + PYRm 0 ME3 MAL + NADP −> CO2 + NADPH + PYR 0 HUMNDMENADHm + Qm + 4 Hm −> QH2m + NADm + 4 H 0 MTND1 SUCCm + FADm <-> FUMm +FADH2m 0 SDHC1 FADH2m + Qm <-> FADm + QH2m 0 SDHC2 O2m + 4 FEROm + 4 Hm−> 4 FERIm + 2 H2Om + 4 H 0 UQCRFS1 QH2m + 2 FERIm + 4 Hm −> Qm + 2FEROm + 4 H 0 COX5BL4 ADPm + PIm + 3 H −> ATPm + 3 Hm + H2Om 0 MTAT1ADP + ATPm + PI + H −> Hm + ADPm + ATP + PIm 0 ATPMC GDP + GTPm + PI + H−> Hm + GDPm + GTP + PIm 0 GTPMC PPI −> 2 PI 0 PP GDP + ATP <-> GTP +ADP 0 NME1 ACCOA + ATP + CO2 <-> MALCOA + ADP + PI + H 0 ACACA MALCOA +ACP <-> MALACP + COA 0 FAS1_1 ACCOA + ACP <-> ACACP + COA 0 FAS1_2ACACP + 4 MALACP + 8 NADPH −> 8 NADP + C100ACP + 4 CO2 + 4 ACP 0 C100SYACACP + 5 MALACP + 10 NADPH −> 10 NADP + C120ACP + 5 CO2 + 5 0 C120SYACP ACACP + 6 MALACP + 12 NADPH −> 12 NADP + C140ACP + 6 CO2 + 6 0C140SY ACP ACACP + 6 MALACP + 11 NADPH −> 11 NADP + C141ACP + 6 CO2 + 60 C141SY ACP ACACP + 7 MALACP + 14 NADPH −> 14 NADP + C160ACP + 7 CO2 +7 0 C160SY ACP ACACP + 7 MALACP + 13 NADPH −> 13 NADP + C161ACP + 7CO2 + 7 0 C161SY ACP ACACP + 8 MALACP + 16 NADPH −> 16 NADP + C180ACP +8 CO2 + 8 0 C180SY ACP ACACP + 8 MALACP + 15 NADPH −> 15 NADP +C181ACP + 8 CO2 + 8 0 C181SY ACP ACACP + 8 MALACP + 14 NADPH −> 14NADP + C182ACP + 8 CO2 + 8 0 C182SY ACP C160ACP + H2O −> C160 + ACP 0PPT1 C160 + COA + ATP −> AMP + PPI + C160COA 0 KIAA C160COA + CAR −>C160CAR + COA 0 C160CA C160CARm + COAm −> C160COAm + CARm 0 C160CBC160CARm + COAm + FADm + NADm −> FADH2m + NADHm + 0 HADHA C140COAm +ACCOAm C140COAm + 7 COAm + 7 FADm + 7 NADm −> 7 FADH2m + 7 NADHm + 7 0HADH2 ACCOAm TAGLYm + 3 H2Om −> GLm + 3 C160m 0 TAGRXN GL3P + 0.017C100ACP + 0.062 C120ACP + 0.1 C140ACP + 0.27 0 GAT1 C160ACP + 0.169C161ACP + 0.055 C180ACP + 0.235 C181ACP + 0.093 C182ACP −> AGL3P + ACPAGL3P + 0.017 C100ACP + 0.062 C120ACP + 0.100 C140ACP + 0.270 0 AGPAT1C160ACP + 0.169 C161ACP + 0.055 C180ACP + 0.235 C181ACP + 0.093 C182ACP−> PA + ACP ATP + CHO −> ADP + PCHO 0 CHKLT1 PCHO + CTP −> CDPCHO + PPI0 PCYT1A CDPCHO + DAGLY −> PC + CMP 0 LOC SAM + PE −> SAH + PMME 0 PEMTSAM + PMME −> SAH + PDME 0 MFPS PDME + SAM −> PC + SAH 0 PNMNM G6P −>MI1P 0 ISYNA1 MI1P −> MYOI + PI 0 IMPA1 PA + CTP <-> CDPDG + PPI 0 CDS1CDPDG + MYOI −> CMP + PINS 0 PIS ATP + PINS −> ADP + PINSP 0 PIK3CAATP + PINS −> ADP + PINS4P 0 PIK4CA PINS4P + ATP −> D45PI + ADP 0 PIP5K1D45PI −> TPI + DAGLY 0 PLCB2 PA + H2O −> DAGLY + PI 0 PPAP2A DAGLY +0.017 C100ACP + 0.062 C120ACP + 0.100 C140ACP + 0.270 0 DGAT C160ACP +0.169 C161ACP + 0.055 C180ACP + 0.235 C181ACP + 0.093 C182ACP −> TAGLY +ACP CDPDG + SER <-> CMP + PS 0 PTDS CDPETN + DAGLY <-> CMP + PE 0 CEPT1PE + SER <-> PS + ETHM 0 PESER ATP + ETHM −> ADP + PETHM 0 EKI1 PETHM +CTP −> CDPETN + PPI 0 PCYT2 PS −> PE + CO2 0 PISD 3HBm + NADm −> NADHm +Hm + ACTACm 0 BDH ACTACm + SUCCOAm −> SUCCm + AACOAm 0 3OCT THF + SER<-> GLY + METTHF 0 SHMT1 THFm + SERm <-> GLYm + METTHFm 0 SHMT2 SERm +PYRm <-> ALAm + 3HPm 0 AGXT 3PG + NAD <-> NADH + PHP 0 PHGDH PHP + GLU<-> AKG + 3PSER 0 PSA 3PSER + H2O −> PI + SER 0 PSPH 3HPm + NADHm −>NADm + GLYAm 0 GLYD SER −> PYR + NH3 + H2O 0 SDS GLYAm + ATPm −> ADPm +2PGm 0 GLTK PYR + GLU <-> AKG + ALA 0 GPT GLUm + CO2m + 2 ATPm −> 2ADPm + 2 PIm + CAPm 0 CPS1 AKGm + NADHm + NH3m <-> NADm + H2Om + GLUm 0GLUD1 AKGm + NADPHm + NH3m <-> NADPm + H2Om + GLUm 0 GLUD2 GLUm + NH3m +ATPm −> GLNm + ADPm + PIm 0 GLUL ASPm + ATPm + GLNm −> GLUm + ASNm +AMPm + PPIm 0 ASNS ORN + AKG <-> GLUGSAL + GLU 0 OAT GLU <-> GLUm + Hm 0GLUMT GLU + ATP + NADPH −> NADP + ADP + PI + GLUGSAL 0 P5CS GLUP + NADH−> NAD + PI + GLUGSAL 0 PYCS P5C <-> GLUGSAL 0 SPTC HIS −> NH3 + URO 0HAL URO + H2O −> 4I5P 0 UROH 4I5P + H2O −> FIGLU 0 IMPR FIGLU + THF −>NFTHF + GLU 0 FTCD MET + ATP + H2O −> PPI + PI + SAM 0 MAT1A SAM + DNA−> SAH + DNA5MC 0 DNMT1 SAH + H2O −> HCYS + ADN 0 AHCYL1 HCYS + MTHF −>THF + MET 0 MTR SER + HCYS −> LLCT + H2O 0 CBS LLCT + H2O −> CYS + HSER0 CTH1 OBUT + NH3 <-> HSER 0 CTH2 CYS + O2 <-> CYSS 0 CDO1 CYSS + AKG<-> GLU + SPYR 0 CYSAT SPYR + H2O −> H2SO3 + PYR 0 SPTB LYS + NADPH +AKG −> NADP + H2O + SAC 0 LKR1 SAC + H2O + NAD −> GLU + NADH + AASA 0LKR2 AASA + NAD −> NADH + AADP 0 2ASD AADP + AKG −> GLU + KADP 0 LOC5TRP + O2 −> FKYN 0 TDO2 FKYN + H2O −> FOR + KYN 0 KYNF KYN + NADPH + O2−> HKYN + NADP + H2O 0 KMO HKYN + H2O −> HAN + ALA 0 KYNU2 HAN + O2 −>CMUSA 0 HAAO CMUSA −> CO2 + AM6SA 0 ACSD AM6SA −> PIC 0 SPTA AM6SA + NAD−> AMUCO + NADH 0 AMSD AMUCO + NADPH −> KADP + NADP + NH4 0 2AMR ARG −>ORN + UREA 0 ARG2 ORN + Hm −> ORNm 0 ORNMT ORN + Hm + CITRm <-> CITR +ORNm 0 ORNCITT ORNm + CAPm −> CITRm + PIm + Hm 0 OTC CITR + ASP + ATP<-> AMP + PPI + ARGSUCC 0 ASS ARGSUCC −> FUM + ARG 0 ASL PRO + FAD −>P5C + FADH2 0 PRODH P5C + NADPH −> PRO + NADP 0 PYCR1 THR −> NH3 + H2O +OBUT 0 WTDH THR + NAD −> CO2 + NADH + AMA 0 TDH AMA + H2O + FAD −> NH3 +FADH2 + MTHGXL 0 MAOA GLYm + THFm + NADm <-> METTHFm + NADHm + CO2m +NH3m 0 AMT PHE + THBP + O2 −> TYR + DHBP + H2O 0 PAH NADPH + DHBP −>NADP + THBP 0 QDPR AKG + TYR −> HPHPYR + GLU 0 TAT HPHPYR + O2 −> HGTS +CO2 0 HPD HGTS + O2 −> MACA 0 HGD MACA −> FACA 0 GSTZ1 FACA + H2O −>FUM + ACA 0 FAH AKG + ILE −> OMVAL + GLU 0 BCAT1A OMVALm + COAm + NADm−> MBCOAm + NADHm + CO2m 0 BCKDHAA MBCOAm + FADm −> MCCOAm + FADH2m 0ACADMA MCCOAm + H2Om −> MHVCOAm 0 ECHS1B MHVCOAm + NADm −> MAACOAm +NADHm 0 EHHADHA MAACOAm −> ACCOAm + PROPCOAm 0 ACAA2 2 ACCOAm <-> COAm +AACCOAm 0 ACATm1 AKG + VAL −> OIVAL + GLU 0 BCAT1B OIVALm + COAm + NADm−> IBCOAm + NADHm + CO2m 0 BCKDHAB IBCOAm + FADm −> MACOAm + FADH2m 0ACADSB MACOAm + H2Om −> HIBCOAm 0 EHHADHC HIBCOAm + H2Om −> HIBm + COAm0 HIBCHA HIBm + NADm −> MMAm + NADHm 0 EHHADHB MMAm + COAm + NADm −>NADHm + CO2m + PROPCOAm 0 MMSDH PROPCOAm + CO2m + ATPm −> ADPm + PIm +DMMCOAm 0 PCCA DMMCOAm −> LMMCOAm 0 HIBCHF LMMCOAm −> SUCCOAm 0 MUTAKG + LEU −> OICAP + GLU 0 BCAT1C OICAPm + COAm + NADm −> IVCOAm +NADHm + CO2m 0 BCKDHAC OICAPm + COAm + NADH −> IVCOAm + NADHm + CO2m 0BCKDHBC OICAPm + COAm + NADHm −> IVCOAm + NADHm + CO2m 0 DBTC IVCOAm +FADm −> MCRCOAm + FADH2m 0 IVD MCRCOAm + ATPm + CO2m + H2Om −> MGCOAm +ADPm + PIm 0 MCCC1 MGCOAm + H2Om −> H3MCOAm 0 HIBCHB H3MCOAm −> ACCOAm +ACTACm 0 HMGCL MYOACT + ATP −> MYOATP + ACTIN 0 MYOSA MYOATP + ACTIN −>MYOADPAC 0 MYOSB MYOADPAC −> ADP + PI + MYOACT + CONTRACT 0 MYOSC PCRE +ADP −> CRE + ATP 0 CREATA AMP + H2O −> PI + ADN 0 CREATB ATP + AMP <-> 2ADP 0 CREATC O2 <-> O2m 0 O2MT 3HB −> 3HBm 0 HBMT CIT + MALm <-> CITm +MAL 0 CITMC PYR <-> PYRm + Hm 0 PYRMC C160CAR + COAm −> C160COAm + CAR 0C160CM OMVAL −> OMVALm 0 HIBCHC OIVAL −> OIVALm 0 HIBCHD OICAP −> OICAPm0 HIBCHE GL <-> GLm 0 GLMT GL3Pm + FADm −> T3P2m + FADH2m 0 GPD2 T3P2 +NADH <-> GL3P + NAD 0 GPD1 GL3P <-> GL3Pm 0 GL3PMC T3P2 <-> T3P2m 0T3P2MC OAm + GLUm <-> ASPm + AKGm 0 GOT1 OA + GLU <-> ASP + AKG 0 GOT2AKG + MALm <-> AKGm + MAL 0 MALMC ASPm + GLU + H −> Hm + GLUm + ASP 0ASPMC GLCxt −> GLC 0 GLUT4 O2xt −> O2 0 O2UP C160Axt + FABP −> C160FP +ALBxt 0 FAT1 C160FP −> C160 + FABP 0 FAT2 C180Axt + FABP −> C180FP +ALBxt 0 FAT3 C180FP −> C180 + FABP 0 FAT4 C161Axt + FABP −> C161FP +ALBxt 0 FAT5 C161FP −> C161 + FABP 0 FAT6 C181Axt + FABP −> C181FP +ALBxt 0 FAT7 C181FP −> C181 + FABP 0 FAT8 C182Axt + FABP −> C182FP +ALBxt 0 FAT9 C182FP −> C182 + FABP 0 FAT10 C204Axt + FABP −> C204FP +ALBxt 0 FAT11 C204FP −> C204 + FABP 0 FAT12 PYRxt + HEXT <-> PYR + H 0PYRUP LACxt + HEXT <-> LAC + HEXT 0 LACUP H <-> HEXT 0 HextUP CO2 <->CO2m 0 CO2MT H2O <-> H2Om 0 H2OMT ATP + AC + COA −> AMP + PPI + ACCOA 0FLJ2 C160CAR <-> C160CARm 0 C160MT CARm <-> CAR 0 CARMT CO2xt <-> CO2 0CO2UP H2Oxt <-> H2O 0 H2OUP PIxt + HEXT <-> HEXT + PI 0 PIUP <-> GLCxt 0GLCexR <-> PYRxt 0 PYRexR <-> CO2xt 0 CO2exR <-> O2xt 0 O2exR <-> PIxt 0PlexR <-> H2Oxt 0 H2OexR <-> LACxt 0 LACexR <-> C160Axt 0 C160AexR <->C161Axt 0 C161AexR <-> C180Axt 0 C180AexR <-> C181Axt 0 C181AexR <->C182Axt 0 C182AexR <-> C204Axt 0 C204AexR <-> ALBxt 0 ALBexR <-> 3HB 0HBexR <-> GLYCOGEN 0 GLYex <-> PCRE 0 PCREex <-> TAGLYm 0 TAGmex <-> ILE0 ILEex <-> VAL 0 VALex <-> CRE 0 CREex <-> ADN 0 ADNex <-> PI 0 PIex

TABLE 5 Human Cell Types Keratinizing epithelial cells Epidermalkeratinocyte (differentiating epidermal cell) Epidermal basal cell (stemcell) Keratinocyte of fingernails and toenails Nail bed basal cell (stemcell) Medullary hair shaft cell Cortical hair shaft cell Cuticular hairshaft cell Cuticular hair root sheath cell Hair root sheath cell ofHuxley's layer Hair root sheath cell of Henle's layer External hair rootsheath cell Hair matrix cell (stem cell) Wet stratified barrierepithelial cells Surface epithelial cell of stratified squamousepithelium of cornea, tongue, oral cavity, esophagus, anal canal, distalurethra and vagina basal cell (stem cell) of epithelia of cornea,tongue, oral cavity, esophagus, anal canal, distal urethra and vaginaUrinary epithelium cell (lining urinary bladder and urinary ducts)Exocrine secretory epithelial cells Salivary gland mucous cell(polysaccharide-rich secretion) Salivary gland serous cell (glycoproteinenzyme-rich secretion) Von Ebner's gland cell in tongue (washes tastebuds) Mammary gland cell (milk secretion) Lacrimal gland cell (tearsecretion) Ceruminous gland cell in ear (wax secretion) Eccrine sweatgland dark cell (glycoprotein secretion) Eccrine sweat gland clear cell(small molecule secretion) Apocrine sweat gland cell (odoriferoussecretion, sex-hormone sensitive) Gland of Moll cell in eyelid(specialized sweat gland) Sebaceous gland cell (lipid-rich sebumsecretion) Bowman's gland cell in nose (washes olfactory epithelium)Brunner's gland cell in duodenum (enzymes and alkaline mucus) Seminalvesicle cell (secretes seminal fluid components, including fructose forswimming sperm) Prostate gland cell (secretes seminal fluid components)Bulbourethral gland cell (mucus secretion) Bartholin's gland cell(vaginal lubricant secretion) Gland of Littre cell (mucus secretion)Uterus endometrium cell (carbohydrate secretion) Isolated goblet cell ofrespiratory and digestive tracts (mucus secretion) Stomach lining mucouscell (mucus secretion) Gastric gland zymogenic cell (pepsinogensecretion) Gastric gland oxyntic cell (hydrogen chloride secretion)Pancreatic acinar cell (bicarbonate and digestive enzyme secretion)Paneth cell of small intestine (lysozyme secretion) Type II pneumocyteof lung (surfactant secretion) Clara cell of lung Hormone secretingcells Anterior pituitary cells Somatotropes Lactotropes ThyrotropesGonadotropes Corticotropes Intermediate pituitary cell, secretingmelanocyte-stimulating hormone Magnocellular neurosecretory cellssecreting oxytocin secreting vasopressin Gut and respiratory tract cellssecreting serotonin secreting endorphin secreting somatostatin secretinggastrin secreting secretin secreting cholecystokinin secreting insulinsecreting glucagon secreting bombesin Thyroid gland cells thyroidepithelial cell parafollicular cell Parathyroid gland cells Parathyroidchief cell oxyphil cell Adrenal gland cells chromaffin cells secretingsteroid hormones (mineralcorticoids and gluco corticoids) Leydig cell oftestes secreting testosterone Theca interna cell of ovarian folliclesecreting estrogen Corpus luteum cell of ruptured ovarian folliclesecreting progesterone Kidney juxtaglomerular apparatus cell (reninsecretion) Macula densa cell of kidney Peripolar cell of kidneyMesangial cell of kidney Epithelial absorptive cells (Gut, ExocrineGlands and Urogenital Tract) Intestinal brush border cell (withmicrovilli) Exocrine gland striated duct cell Gall bladder epithelialcell Kidney proximal tubule brush border cell Kidney distal tubule cellDuctulus efferens nonciliated cell Epididymal principal cell Epididymalbasal cell Metabolism and storage cells Hepatocyte (liver cell) Whitefat cell Brown fat cell Liver lipocyte Barrier function cells (Lung,Gut, Exocrine Glands and Urogenital Tract) Type I pneumocyte (lining airspace of lung) Pancreatic duct cell (centroacinar cell) Nonstriated ductcell (of sweat gland, salivary gland, mammary gland, etc.) Kidneyglomerulus parietal cell Kidney glomerulus podocyte Loop of Henle thinsegment cell (in kidney) Kidney collecting duct cell Duct cell (ofseminal vesicle, prostate gland, etc.) Epithelial cells lining closedinternal body cavities Blood vessel and lymphatic vascular endothelialfenestrated cell Blood vessel and lymphatic vascular endothelialcontinuous cell Blood vessel and lymphatic vascular endothelial spleniccell Synovial cell (lining joint cavities, hyaluronic acid secretion)Serosal cell (lining peritoneal, pleural, and pericardial cavities)Squamous cell (lining perilymphatic space of ear) Squamous cell (liningendolymphatic space of ear) Columnar cell of endolymphatic sac withmicrovilli (lining endolymphatic space of ear) Columnar cell ofendolymphatic sac without microvilli (lining endolymphatic space of ear)Dark cell (lining endolymphatic space of ear) Vestibular membrane cell(lining endolymphatic space of ear) Stria vascularis basal cell (liningendolymphatic space of ear) Stria vascularis marginal cell (liningendolymphatic space of ear) Cell of Claudius (lining endolymphatic spaceof ear) Cell of Boettcher (lining endolymphatic space of ear) Choroidplexus cell (cerebrospinal fluid secretion) Pia-arachnoid squamous cellPigmented ciliary epithelium cell of eye Nonpigmented ciliary epitheliumcell of eye Corneal endothelial cell Ciliated cells with propulsivefunction Respiratory tract ciliated cell Oviduct ciliated cell (infemale) Uterine endometrial ciliated cell (in female) Rete testiscilated cell (in male) Ductulus efferens ciliated cell (in male)Ciliated ependymal cell of central nervous system (lining braincavities) Extracellular matrix secretion cells Ameloblast epithelialcell (tooth enamel secretion) Planum semilunatum epithelial cell ofvestibular apparatus of ear (proteoglycan secretion) Organ of Cortiinterdental epithelial cell (secreting tectorial membrane covering haircells) Loose connective tissue fibroblasts Corneal fibroblasts Tendonfibroblasts Bone marrow reticular tissue fibroblasts Other nonepithelialfibroblasts Blood capillary pericyte Nucleus pulposus cell ofintervertebral disc Cementoblast/cementocyte (tooth root bonelikecementum secretion) Odontoblast/odontocyte (tooth dentin secretion)Hyaline cartilage chondrocyte Fibrocartilage chondrocyte Elasticcartilage chondrocyte Osteoblast/osteocyte Osteoprogenitor cell (stemcell of osteoblasts) Hyalocyte of vitreous body of eye Stellate cell ofperilymphatic space of ear Contractile cells Red skeletal muscle cell(slow) White skeletal muscle cell (fast) Intermediate skeletal musclecell nuclear bag cell of Muscle spindle nuclear chain cell of Musclespindle Satellite cell (stem cell) Ordinary heart muscle cell Nodalheart muscle cell Purkinje fiber cell Smooth muscle cell (various types)Myoepithelial cell of iris Myoepithelial cell of exocrine glands RedBlood Cell Blood and Immune system cells Erythrocyte (red blood cell)Megakaryocyte (platelet precursor) Monocyte Connective tissue macrophage(various types) Epidermal Langerhans cell Osteoclast (in bone) Dendriticcell (in lymphoid tissues) Microglial cell (in central nervous system)Neutrophil granulocyte Eosinophil granulocyte Basophil granulocyte Mastcell Helper T cell Suppressor T cell Cytotoxic T cell B cells Naturalkiller cell Reticulocyte Stem cells and committed progenitors for theblood and immune system (various types) Sensory transducer cellsPhotoreceptor rod cell of eye Photoreceptor blue-sensitive cone cell ofeye Photoreceptor green-sensitive cone cell of eye Photoreceptorred-sensitive cone cell of eye Auditory inner hair cell of organ ofCorti Auditory outer hair cell of organ of Corti Type I hair cell ofvestibular apparatus of ear (acceleration and gravity) Type II hair cellof vestibular apparatus of ear (acceleration and gravity) Type I tastebud cell Olfactory receptor neuron Basal cell of olfactory epithelium(stem cell for olfactory neurons) Type I carotid body cell (blood pHsensor) Type II carotid body cell (blood pH sensor) Merkel cell ofepidermis (touch sensor) Touch-sensitive primary sensory neurons(various types) Cold-sensitive primary sensory neurons Heat-sensitiveprimary sensory neurons Pain-sensitive primary sensory neurons (varioustypes) Proprioceptive primary sensory neurons (various types) Autonomicneuron cells Cholinergic neural cell (various types) Adrenergic neuralcell (various types) Peptidergic neural cell (various types) Sense organand peripheral neuron supporting cells Inner pillar cell of organ ofCorti Outer pillar cell of organ of Corti Inner phalangeal cell of organof Corti Outer phalangeal cell of organ of Corti Border cell of organ ofCorti Hensen cell of organ of Corti Vestibular apparatus supporting cellType I taste bud supporting cell Olfactory epithelium supporting cellSchwann cell Satellite cell (encapsulating peripheral nerve cell bodies)Enteric glial cell Central nervous system neurons and glial cells Neuroncells (large variety of types, still poorly classified) Astrocyte(various types) Oligodendrocyte Lens cells Anterior lens epithelial cellCrystallin-containing lens fiber cell Pigment cells Melanocyte Retinalpigmented epithelial cell Germ cells Oogonium/Oocyte SpermatidSpermatocyte Spermatogonium cell (stem cell for spermatocyte)Spermatozoon Nurse cells Ovarian follicle cell Sertoli cell (in testis)Thymus epithelial cell

TABLE 6 Human Tissues Epithelial Tissue Connective Tissues Unilaminar(simple) epithelia Fluid Connective Tissues Squamous Lymph CuboidalBlood Columnar Connective Tissues Proper Sensory Loose ConnectiveTissues Myoepitheliocyte Areolar Multilaminar eipithelia LooseConnective Tissues and Inflammation Replacing or stratified squamousepithelia Adipose Stratified cuboidal and columnar eipithelia ReticularUrothelium (transitional epithelium) Dense Connective TissuesSeminiferous eipthelium Regular(collagen) Glands Irregular(collagen)Exocrine glands Regular(elastic) Ducts and Tubules Supportive ConnectiveTissues Endocrine glands Osseous Tissue Nervous Tissue Compact NeuronsCancellous Multipolar Neurons in CNS Cartilage Nerves Hyaline Nerves ofthe PNS Elastic Receptors Fibrocartilage Miessner's and PacinianCorpuscles Muscle Tissue Non-striated Smooth Muscle Striated SkeletalMuscle Cardiac Muscle Systems Major Structures Skeletal Bones,cartilage, tendons, ligaments, and joints Muscular Muscles (skeletal,cardiac, and smooth) Integumentary Skin, hair nails, breast CirculatoryHeart, blood vessels, blood Respiratory Trachea, air passages, lungsImmune Lymph nodes and vessels, white blood cells Digestive Mouth,esophagus, stomach, liver, pancreas, duodenum, jejunum, ileum, caecum,rectum, gallbladder, pancreas, small and large intestines Excretory andUrinary Kidneys, ureters, bladder, urethra Nervous Brain, spinal cord,nerves, sense organs, receptors, dorsal root ganglion EndocrineEndocrine glands, pineal gland, pituitary gland, adrenal gland, thyroidgland, and hormones Lymphatic Lymph nodes, spleen, lymph vesselsReproductive Ovaries, uterus, fallopian tube, mammary glands (infemales), vas deferens, prostate, testes (in males), umbilical cord,placenta Functions provides structure; supports and protects internalorgans provides structure; supports and moves trunk and limbs; movessubstances through body protects against pathogens; helps regulate bodytemperature transports nutrients and wastes to and from all body tissuescarries air into and out of lungs, where gases (oxygen and carbondioxide) are exchanged provides protection against infection and diseasestores and digests food; absorbs nutrients; eliminates waste eliminatewaste; maintains water and chemical balance controls and coordinatesbody movements and senses; controls consciousness and creativity; helpsmonitor and maintain other body systems maintain homeostasis; regulatesmetabolism, water and mineral balance, growth and sexual development,and reproduction cleans and returns tissue fluid to the blood anddestroys pathogens that enter the body produce gametes and offspring

TABLE 7 Cells of the Liver Hepatocytes Perisinusoidal (Ito) cellsEndotheliocytes Macrophages (Kupffer cells) Lymphocytes (pit cells)Cells of the biliary tree Cuboldal epitheliocytes Columnarepitheliocytes Connective tissue cells

TABLE 15 Adipocyte-myocyte reactions Reaction Protein AbbreviationReaction Name Equation Subsystem Classification G6PASEer_acglucose-6-phosphatase [f]: g6p + h2o --> glc-D + piGlycolysis/Gluconeogenesis EC-3.1.3.9 G6PASEer_mc glucose-6-phosphatase[u]: g6p + h2o --> glc-D + pi Glycolysis/Gluconeogenesis EC-3.1.3.9PFK26_ac 6-phosphofructo-2-kinase [a]: atp + f6p --> adp + f26bp + hGlycolysis/Gluconeogenesis EC-2.7.1.105 PGI_ac glucose-6-phosphate [a]:g6p <==> f6p Glycolysis/Gluconeogenesis EC-5.3.1.9 isomerase PGK_acphosphoglycerate kinase [a]: 13dpg + adp <==> 3pg + atpGlycolysis/Gluconeogenesis EC-2.7.2.3 PGM_ac phosphoglycerate mutase[a]: 3pg <==> 2pg Glycolysis/Gluconeogenesis EC-5.4.2.1 PYK_ac pyruvatekinase [a]: adp + h + pep --> atp + pyr Glycolysis/GluconeogenesisEC-2.7.1.40 TPI_ac triose-phosphate [a]: dhap <==> g3pGlycolysis/Gluconeogenesis EC-5.3.1.1 isomerase ACONTm_ac Aconitatehydratase [b]: cit <==> icit Central Metabolism EC-4.2.1.3 ACONTm_mcAconitate hydratase [z]: cit <==> icit Central Metabolism EC-4.2.1.3AKGDm_ac 2-oxoglutarate [b]: akg + coa + nad --> co2 + CentralMetabolism dehydrogenase, nadh + succoa mitochondrial AKGDm_mc2-oxoglutarate [z]: akg + coa + nad --> co2 + Central Metabolismdehydrogenase, nadh + succoa mitochondrial CITL2_ac Citrate lyase (ATP-[a]: atp + cit + coa --> accoa + adp + Central Metabolism EC-4.1.3.8requiring) oaa + pi CITL2_mc Citrate lyase (ATP- [y]: atp + cit + coa--> accoa + adp + Central Metabolism EC-4.1.3.8 requiring) oaa + piCSm_ac citrate synthase [b]: accoa + h2o + oaa --> cit + CentralMetabolism EC-4.1.3.7 coa + h CSm_mc citrate synthase [z]: accoa + h2o +oaa --> cit + Central Metabolism EC-4.1.3.7 coa + h ENO_ac enolase [a]:2pg <==> h2o + pep Central Metabolism EC-4.2.1.11 ENO_mc enolase [y]:2pg <==> h2o + pep Central Metabolism EC-4.2.1.11 FBA_acfructose-bisphosphate [a]: fdp <==> dhap + g3p Central MetabolismEC-4.1.2.13 aldolase FBA_mc fructose-bisphosphate [y]: fdp <==> dhap +g3p Central Metabolism EC-4.1.2.13 aldolase FBP26_acFructose-2,6-bisphosphate [a]: f26bp + h2o --> f6p + pi CentralMetabolism EC-3.1.3.46 2-phosphatase FBP26_mc Fructose-2,6-bisphosphate[y]: f26bp + h2o --> f6p + pi Central Metabolism EC-3.1.3.462-phosphatase FBP_ac fructose-bisphosphatase [a]: fdp + h2o --> f6p + piCentral Metabolism EC-3.1.3.11 FBP_mc fructose-bisphosphatase [y]: fdp +h2o --> f6p + pi Central Metabolism EC-3.1.3.11 FUMm_ac fumarase,mitochondrial [b]: fum + h2o <==> mal-L Central Metabolism EC-4.2.1.2FUMm_mc fumarase, mitochondrial [z]: fum + h2o <==> mal-L CentralMetabolism EC-4.2.1.2 G3PD1_ac glycerol-3-phosphate [a]: glyc3p + nad<==> dhap + h + Central Metabolism EC-1.1.1.94 dehydrogenase (NAD), nadhadipocyte G3PD_mc Glycerol-3-phosphate [y]: dhap + h + nadh --> glyc3p +Central Metabolism EC-1.1.1.8 dehydrogenase (NAD) nad G3PDm_acglycerol-3-phosphate [b]: fad + glyc3p --> dhap + fadh2 CentralMetabolism EC-1.1.99.5 dehydrogenase G3PDm_mc glycerol-3-phosphate [z]:fad + glyc3p --> dhap + fadh2 Central Metabolism EC-1.1.99.5dehydrogenase G6PDH_ac glucose 6-phosphate [a]: g6p + nadp --> 6pgl +h + Central Metabolism EC-1.1.1.49 dehydrogenase nadph G6PDH_mc glucose6-phosphate [y]: g6p + nadp --> 6pgl + h + Central MetabolismEC-1.1.1.49 dehydrogenase nadph GAPD_ac glyceraldehyde-3- [a]: g3p +nad + pi <==> 13dpg + Central Metabolism EC-1.2.1.12 phosphatedehydrogenase h + nadh (NAD) GAPD_mc glyceraldehyde-3- [y]: g3p + nad +pi <==> 13dpg + Central Metabolism EC-1.2.1.12 phosphate dehydrogenaseh + nadh (NAD) GL3Ptm_ac glycerol-3-phosphate glyc3p[a] <==> glyc3p[b]Central Metabolism transport, adipocyte mitochondrial GLCP_ac glycogenphosphorylase [a]: glycogen + pi --> g1p Central Metabolism EC-2.4.1.1HCO3Em_ac HCO3 equilibration [b]: co2 + h2o <==> h + hco3 CentralMetabolism EC-4.2.1.1 reaction, mitochondrial HCO3Em_mc HCO3equilibration [z]: co2 + h2o <==> h + hco3 Central Metabolism EC-4.2.1.1reaction, mitochondrial HEX1_ac hexokinase (D- [a]: atp + glc-D -->adp + g6p + h Central Metabolism EC-2.7.1.2 glucose:ATP) HEX1_mchexokinase (D- [y]: atp + glc-D --> adp + g6p + h Central MetabolismEC-2.7.1.2 glucose:ATP) ICDHxm_ac Isocitrate dehydrogenase [b]: icit +nad --> akg + co2 + nadh Central Metabolism EC-1.1.1.41 (NAD+) ICDHxm_mcIsocitrate dehydrogenase [z]: icit + nad --> akg + co2 + nadh CentralMetabolism EC-1.1.1.41 (NAD+) ICDHym_ac Isocitrate dehydrogenase [b]:icit + nadp --> akg + co2 + Central Metabolism EC-1.1.1.42 (NADP+) nadphICDHym_mc Isocitrate dehydrogenase [z]: icit + nadp --> akg + co2 +Central Metabolism EC-1.1.1.42 (NADP+) nadph LDH_L_mc L-lactatedehydrogenase [y]: lac-L + nad <==> h + nadh + Central MetabolismEC-1.1.1.27 pyr MDH_ac malate dehydrogenase [a]: mal-L + nad <==> h +nadh + Central Metabolism EC-1.1.1.37 oaa MDH_mc malate dehydrogenase[y]: mal-L + nad <==> h + nadh + Central Metabolism EC-1.1.1.37 oaaMDHm_ac malate dehydrogenase, [b]: mal-L + nad <==> h + nadh + CentralMetabolism EC-1.1.1.37 mitochondrial oaa MDHm_mc malate dehydrogenase,[z]: mal-L + nad <==> h + nadh + Central Metabolism EC-1.1.1.37mitochondrial oaa ME1m_ac malic enzyme (NAD), [b]: mal-L + nad --> co2 +nadh + Central Metabolism EC-1.1.1.38 mitochondrial pyr ME1m_mc malicenzyme (NAD), [z]: mal-L + nad --> co2 + nadh + Central MetabolismEC-1.1.1.38 mitochondrial pyr ME2_ac malic enzyme (NADP) [a]: mal-L +nadp --> co2 + nadph + Central Metabolism EC-1.1.1.40 pyr ME2_mc malicenzyme (NADP) [y]: mal-L + nadp --> co2 + nadph + Central MetabolismEC-1.1.1.40 pyr ME2m_ac malic enzyme (NADP), [b]: mal-L + nadp --> co2 +nadph + Central Metabolism EC-1.1.1.40 mitochondrial pyr ME2m_mc malicenzyme (NADP), [z]: mal-L + nadp --> co2 + nadph + Central MetabolismEC-1.1.1.40 mitochondrial pyr PCm_mc pyruvate carboxylase, [z]: atp +hco3 + pyr --> adp + h + Central Metabolism EC-6.4.1.1 mitochondrialoaa + pi PDHm_mc pyruvate dehydrogenase, [z]: coa + nad + pyr -->accoa + Central Metabolism EC-1.2.1.51 mitochondrial co2 + nadh PFK26_mc6-phosphofructo-2-kinase [y]: atp + f6p --> adp + f26bp + h CentralMetabolism EC-2.7.1.105 PFK_ac phosphofructokinase [a]: atp + f6p -->adp + fdp + h Central Metabolism EC-2.7.1.11 PFK_mc phosphofructokinase[y]: atp + f6p --> adp + fdp + h Central Metabolism EC-2.7.1.11 PGDH_mcphosphogluconate [y]: 6pgc + nadp --> co2 + nadph + Central MetabolismEC-1.1.1.44 dehydrogenase ru5p-D PGI_mc glucose-6-phosphate [y]: g6p<==> f6p Central Metabolism EC-5.3.1.9 isomerase PGK_mc phosphoglyceratekinase [y]: 13dpg + adp <==> 3pg + atp Central Metabolism EC-2.7.2.3PGL_mc 6- [y]: 6pgl + h2o --> 6pgc + h Central Metabolism EC-3.1.1.31phosphogluconolactonase PGM_mc phosphoglycerate mutase [y]: 3pg <==> 2pgCentral Metabolism EC-5.4.2.1 PPA_ac inorganic diphosphatase [a]: h2o +ppi --> h + (2) pi Central Metabolism EC-3.6.1.1 PPA_mc inorganicdiphosphatase [y]: h2o + ppi --> h + (2) pi Central MetabolismEC-3.6.1.1 PPCKG_ac phosphoenolpyruvate [a]: gtp + oaa --> co2 + gdp +pep Central Metabolism EC-4.1.1.32 carboxykinase (GTP) PPCKG_mcphosphoenolpyruvate [y]: gtp + oaa --> co2 + gdp + pep CentralMetabolism EC-4.1.1.32 carboxykinase (GTP) PYK_mc pyruvate kinase [y]:adp + h + pep --> atp + pyr Central Metabolism EC-2.7.1.40 RPE_mcribulose 5-phosphate 3- [y]: ru5p-D <==> xu5p-D Central MetabolismEC-5.1.3.1 epimerase RPI_mc ribose-5-phosphate [y]: r5p <==> ru5p-DCentral Metabolism EC-5.3.1.6 isomerase SUCD1m_mc succinatedehydrogenase [z]: succ + ubq <==> fum + qh2 Central MetabolismEC-1.3.5.1 SUCD3m_mc succinate dehydrogenase [z]: fadh2 + ubq <==> fad +qh2 Central Metabolism cytochrome b SUCOASAm_mc Succinate--CoA ligase[z]: atp + coa + succ <==> adp + Central Metabolism EC-6.2.1.4(ADP-forming) pi + succoa SUCOASGm_mc Succinate--CoA ligase [z]: coa +gtp + succ <==> gdp + Central Metabolism EC-6.2.1.4 (GDP-forming) pi +succoa TAL_mc transaldolase [y]: g3p + s7p <==> e4p + f6p CentralMetabolism EC-2.2.1.2 TKT1_mc transketolase [y]: r5p + xu5p-D <==> g3p +s7p Central Metabolism EC-2.2.1.1 TKT2_mc transketolase [y]: e4p +xu5p-D <==> f6p + g3p Central Metabolism EC-2.2.1.1 TPI_mctriose-phosphate [y]: dhap <==> g3p Central Metabolism EC-5.3.1.1isomerase SUCOASAm_ac Succinate--CoA ligase [b]: atp + coa + succ <==>adp + Citrate Cycle (TCA) EC-6.2.1.4 (ADP-forming) pi + succoaSUCOASGm_ac Succinate--CoA ligase [b]: coa + gtp + succ <==> gdp +Citrate Cycle (TCA) EC-6.2.1.4 (GDP-forming) pi + succoa PGDH_acphosphogluconate [a]: 6pgc + nadp --> co2 + nadph + Pentose PhosphateEC-1.1.1.44 dehydrogenase ru5p-D Cycle PGL_ac 6- [a]: 6pgl + h2o -->6pgc + h Pentose Phosphate EC-3.1.1.31 phosphogluconolactonase CycleRPE_ac ribulose 5-phosphate 3- [a]: ru5p-D <==> xu5p-D Pentose PhosphateEC-5.1.3.1 epimerase Cycle RPI_ac ribose-5-phosphate [a]: r5p <==>ru5p-D Pentose Phosphate EC-5.3.1.6 isomerase Cycle TAL_ac transaldolase[a]: g3p + s7p <==> e4p + f6p Pentose Phosphate EC-2.2.1.2 Cycle TKT1_actransketolase [a]: r5p + xu5p-D <==> g3p + s7p Pentose PhosphateEC-2.2.1.1 Cycle TKT2_ac transketolase [a]: e4p + xu5p-D <==> f6p + g3pPentose Phosphate EC-2.2.1.1 Cycle PCm_ac pyruvate carboxylase, [b]:atp + hco3 + pyr --> adp + h + Pyruvate metabolism EC-6.4.1.1mitochondrial oaa + pi PDHm_ac pyruvate dehydrogenase, [b]: coa + nad +pyr --> accoa + Pyruvate metabolism EC-1.2.1.51 mitochondrial co2 + nadhATPM_ac ATP maintenance [a]: atp + h2o --> adp + h + pi EnergyMetabolism requirment ATPM_mc ATP maintenance [y]: atp + h2o --> adp +h + pi Energy Metabolism requirment ATPS4m_ac ATP synthase, adipocyteadp[b] + (4) h[a] + pi[b] --> atp[b] + Energy Metabolism EC-3.6.1.14,mitochondrial (3) h[b] + h2o[b] ATPS4m_mc ATP synthase, myocyte adp[z] +(4) h[y] + pi[z] --> atp[z] + Energy Metabolism EC-3.6.1.14,mitochondrial (3) h[z] + h2o[y] ATPSis_ac ATPase, adipocyte atp[a] +h2o[a] --> adp[a] + h[i] + Energy Metabolism EC-3.6.3.6, cytosolic pi[a]ATPSis_mc ATPase, myocyte atp[y] + h2o[y] --> adp[y] + h[c] + EnergyMetabolism EC-3.6.3.6, cytosolic pi[y] CREATK_mc creatine kinase,myocyte [y]: atp + creat <==> adp + creatp Energy Metabolism EC-2.7.3.2cytosol CREATPD_mc creatine phosphate [y]: creatp --> crtn + h + piEnergy Metabolism dephosphorylation, spontaneous CYOO4m_ac cytochrome coxidase (4) focytc[b] + (8) h[b] + o2[b] --> Energy MetabolismEC-1.9.3.1, (adipocyte mitochondrial 4 (4) ficytc[b] + (4) h[a] + (2)h2o[b] protons) CYOO4m_mc cytochrome c oxidase (4) focytc[z] + (8)h[z] + o2[z] --> Energy Metabolism EC-1.9.3.1, (myocyte mitochondrial 4(4) ficytc[z] + (4) h[y] + (2) h2o[z] protons) CYOR4m_ac ubiquinolcytochrome c (2) ficytc[b] + (2) h[b] + qh2[b] --> Energy MetabolismEC-1.10.2.2, reductase, adipocyte (2) focytc[b] + (4) h[a] + ubq[b]CYOR4m_mc ubiquinol cytochrome c (2) ficytc[z] + (2) h[z] + qh2[z] -->Energy Metabolism EC-1.10.2.2, reductase, myocyte (2) focytc[z] + (4)h[y] + ubq[z] NADH4m_mc NADH dehydrogenase, (5) h[z] + nadh[z] + ubq[z]--> (4) Energy Metabolism EC-1.6.99.3, mitochondrial h[y] + nad[z] +qh2[z] NADH4m_ac NADH dehydrogenase, (5) h[b] + nadh[b] + ubq[b] --> (4)Oxidative EC-1.6.99.3, adipocyte mitochondrial h[a] + nad[b] + qh2[b]phosphorylation SUCD1m_ac succinate dehydrogenase [b]: succ + ubq <==>fum + qh2 Oxidative EC-1.3.5.1 phosphorylation SUCD3m_ac succinatedehydrogenase [b]: fadh2 + ubq <==> fad + qh2 Oxidative cytochrome bphosphorylation GALUi_ac UTP-glucose-1-phosphate [a]: g1p + h + utp -->ppi + udpg Galactose metabolism EC-2.7.7.9 uridylyltransferase(irreversible) PGMT_ac phosphoglucomutase [a]: g1p <==> g6p Galactosemetabolism EC-5.4.2.2 GALUi_mc UTP-glucose-1-phosphate [y]: g1p + h +utp --> ppi + udpg Carbohydrate EC-2.7.7.9 uridylyltransferaseMetabolism (irreversible) GLCP_mc glycogen phosphorylase [y]: glycogen +pi --> g1p Carbohydrate EC-2.4.1.1 Metabolism GLYGS_ac glycogen synthase[a]: udpg --> glycogen + h + udp Carbohydrate EC-2.4.1.11 (UDPGlc)Metabolism GLYGS_mc glycogen synthase [y]: udpg --> glycogen + h + udpCarbohydrate EC-2.4.1.11 (UDPGlc) Metabolism PGMT_mc phosphoglucomutase[y]: g1p <==> g6p Carbohydrate EC-5.4.2.2 Metabolism ACACT10m_acacetyl-CoA C- [b]: 2maacoa + coa --> accoa + Amino Acid MetabolismEC-2.3.1.16 acyltransferase, adipocyte ppcoa mitochondrial ACOAD3m_acacyl-CoA dehydrogenase, [b]: 2mbcoa + fad <==> 2mb2coa + Amino AcidMetabolism EC-1.3.99.3 adipocyte mitochondrial fadh2 ASPO_D_acD-aspartate oxidase [a]: asp-D + h2o + o2 --> h + h2o2 + Amino AcidMetabolism EC-1.4.3.16 nh3 + oaa ASPR_ac aspartase racemase, [a]: asp-D<==> asp-L Amino Acid Metabolism EC-5.1.1.13 adipocyte cytosolicASPTA1_ac aspartate transaminase [a]: akg + asp-L <==> glu-L + oaa AminoAcid Metabolism EC-2.6.1.1 ASPTA1_mc aspartate transaminase [y]: akg +asp-L <==> glu-L + oaa Amino Acid Metabolism EC-2.6.1.1 ASPTA1m_acaspartate transaminase, [b]: akg + asp-L <==> glu-L + oaa Amino AcidMetabolism EC-2.6.1.1 mitochondrial ASPTA1m_mc aspartate transaminase,[z]: akg + asp-L <==> glu-L + oaa Amino Acid Metabolism EC-2.6.1.1mitochondrial ECOAH3m_ac enoyl-CoA hydratase, [b]: 2mb2coa + h2o <==>Amino Acid Metabolism EC-4.2.1.17 adipocyte mitochondrial 3hmbcoaHACD8m_ac 3-hydroxyacyl-CoA [b]: 3hmbcoa + nad <==> Amino AcidMetabolism EC-1.1.1.35 dehydrogenase (2- 2maacoa + h + nadhMethylacetoacetyl-CoA), adipocyte mitochondrial ILETA_ac isoleucinetransaminase, [a]: akg + ile-L <==> 3mop + glu-L Amino Acid MetabolismEC-2.6.1.42 adipocyte cytosolic MOBD3m_ac 3-Methyl-2-oxobutanoate [b]:3mop + coa + nad --> 2mbcoa + Amino Acid Metabolism dehydrogenase,adipocyte co2 + nadh mitochondrial CSNAT_mc carnitine O- [y]: accoa +crn --> acrn + coa Carnitine Shuttle EC-2.3.1.7 acetyltransferase,myocyte cytosol CSNATifm_mc carnitine O- [z]: acrn + coa --> accoa + crnCarnitine Shuttle EC-2.3.1.7 aceyltransferase, forward reaction, myocytemitochondrial PPS_ac propionyl-CoA synthetase, [a]: atp + coa + ppa <==>amp + Propanoate EC-6.2.1.1 adipocyte cytosolic ppcoa + ppi MetabolismPPSm_ac propionyl-CoA synthetase, [b]: atp + coa + ppa <==> amp +Propanoate EC-6.2.1.1 adipocyte mitochondrial ppcoa + ppi MetabolismACACT10m_mc acetyl-CoA C- [z]: accoa + occoa <==> 3odcoa + Fatty AcidDegradation EC-2.3.1.16 acyltransferase (octanoyl- coa CoA) ACACT11m_mcacetyl-CoA C- [z]: accoa + nncoa <==> 3oedcoa + Fatty Acid DegradationEC-2.3.1.16 acyltransferase (nonanoyl- coa CoA) ACACT12m_mc acetyl-CoAC- [z]: accoa + dccoa <==> 3oddcoa + Fatty Acid Degradation EC-2.3.1.16acyltransferase (decanoyl- coa CoA) ACACT13m_mc acetyl-CoA C- [z]:accoa + edcoa <==> 3otrdcoa + Fatty Acid Degradation EC-2.3.1.16acyltransferase coa (endecanoyl-CoA) ACACT145m_mc acetyl-CoA C- [z]:accoa + cis-dd2coa <==> Fatty Acid Degradation EC-2.3.1.16acyltransferase 3otdecoa5 + coa (dodecenoyl-CoA C12:1CoA, n-3)ACACT14m_mc acetyl-CoA C- [z]: accoa + ddcoa <==> 3otdcoa + Fatty AcidDegradation EC-2.3.1.16 acyltransferase coa (dodecanoyl-CoA) ACACT15m_mcacetyl-CoA C- [z]: accoa + trdcoa <==> 3opdcoa + Fatty Acid DegradationEC-2.3.1.16 acyltransferase coa (tridecanoyl-CoA) ACACT167m_mcacetyl-CoA C- [z]: accoa + tdecoa5 <==> Fatty Acid DegradationEC-2.3.1.16 acyltransferase 3ohdecoa7 + coa (tetradecenoyl-CoA C14:1CoA,n-5) ACACT16m_mc acetyl-CoA C- [z]: accoa + tdcoa <==> 3ohdcoa + FattyAcid Degradation EC-2.3.1.16 acyltransferase coa (tetradecanoyl-CoA)ACACT189m_mc acetyl-CoA C- [z]: accoa + hdcoa7 <==> Fatty AcidDegradation EC-2.3.1.16 acyltransferase 3oodcecoa9 + coa(hexadecenoyl-CoA C16:1CoA, n-7) ACACT18m_mc acetyl-CoA C- [z]: accoa +pmtcoa <==> Fatty Acid Degradation EC-2.3.1.16 acyltransferase(palmitoyl- 3oodcoa + coa CoA C16:0CoA) ACACT20m_mc acetyl-CoA C- [z]:accoa + strcoa <==> 3oescoa + Fatty Acid Degradation EC-2.3.1.16acyltransferase coa (octadecanoyl-CoA C18:0CoA) ACACT22p_mc acetyl-CoAC- [w]: accoa + ecsacoa <==> Fatty Acid Degradation EC-2.3.1.16acyltransferase 3odscoa + coa (eicosanoyl-CoA C20:0CoA) ACACT4m_mcacetyl-CoA C- [z]: (2) accoa <==> aacoa + coa Fatty Acid DegradationEC-2.3.1.16 acyltransferase (acetyl- CoA) ACACT5m_mc acetyl-CoA C- [z]:accoa + ppcoa <==> 3optcoa + Fatty Acid Degradation EC-2.3.1.16acyltransferase (propanoyl- coa CoA) ACACT6m_mc acetyl-CoA C- [z]:accoa + btcoa <==> 3ohcoa + Fatty Acid Degradation EC-2.3.1.16acyltransferase (butanoyl- coa CoA) ACACT7m_mc acetyl-CoA C- [z]:accoa + ptcoa <==> 3ohpcoa + Fatty Acid Degradation EC-2.3.1.16acyltransferase (pentanoyl- coa CoA) ACACT8m_mc acetyl-CoA C- [z]:accoa + hxcoa <==> 3oocoa + Fatty Acid Degradation EC-2.3.1.16acyltransferase (hexanoyl- coa CoA) ACACT9m_mc acetyl-CoA C- [z]:accoa + hpcoa <==> 3onncoa + Fatty Acid Degradation EC-2.3.1.16acyltransferase (heptanoyl- coa CoA) ACOAD10m_mc acyl-CoA dehydrogenase[z]: dccoa + fad <==> dc2coa + Fatty Acid Degradation EC-1.3.99.13(decanoyl-CoA C10:0CoA) fadh2 ACOAD11m_mc acyl-CoA dehydrogenase [z]:edcoa + fad <==> ed2coa + Fatty Acid Degradation EC-1.3.99.13(endecanoyl-CoA) fadh2 ACOAD12m_mc acyl-CoA dehydrogenase [z]: ddcoa +fad <==> fadh2 + Fatty Acid Degradation EC-1.3.99.13 (dodecanoyl-CoAtrans-dd2coa C12:0CoA) ACOAD13m_mc acyl-CoA dehydrogenase [z]: fad +trdcoa <==> fadh2 + Fatty Acid Degradation EC-1.3.99.13(tridecanoyl-CoA) trd2coa ACOAD145m_mc acyl-CoA dehydrogenase [z]: fad +tdecoa5 <==> fadh2 + Fatty Acid Degradation EC-1.3.99.13(tetradecenoyl-CoA, tde2coa5 C14:1CoA, n-5) ACOAD14m_mc acyl-CoAdehydrogenase [z]: fad + tdcoa <==> fadh2 + Fatty Acid DegradationEC-1.3.99.13 (tetradecanoyl-CoA) td2coa ACOAD15m_mc acyl-CoAdehydrogenase [z]: fad + pdcoa <==> fadh2 + Fatty Acid DegradationEC-1.3.99.13 (pentadecanoyl-CoA) pd2coa ACOAD167m_mc acyl-CoAdehydrogenase [z]: fad + hdcoa7 <==> fadh2 + Fatty Acid DegradationEC-1.3.99.13 (hexadecenoyl-CoA, hde2coa7 C16:1CoA, n-7) ACOAD16m_mcacyl-CoA dehydrogenase [z]: fad + pmtcoa <==> fadh2 + Fatty AcidDegradation EC-1.3.99.13 (hexadecanoyl-CoA hdd2coa C16:0CoA)ACOAD189m_mc acyl-CoA dehydrogenase [z]: fad + odecoa9 <==> fadh2 +Fatty Acid Degradation EC-1.3.99.13 (octadecenoyl-CoA, ode2coa9C18:1CoA, n-9) ACOAD18m_mc acyl-CoA dehydrogenase [z]: fad + strcoa <==>fadh2 + Fatty Acid Degradation EC-1.3.99.13 (Stearyl-CoA, C18:0CoA)od2coa ACOAD20m_mc acyl-CoA dehydrogenase [z]: ecsacoa + fad <==>es2coa + Fatty Acid Degradation EC-1.3.99.13 (eicosanoyl-CoA, fadh2C20:0CoA) ACOAD22p_mc acyl-CoA dehydrogenase [w]: dcsacoa + fad <==>ds2coa + Fatty Acid Degradation EC-1.3.99.13 (docosanoyl-CoA, fadh2C22:0CoA) ACOAD4m_mc acyl-CoA dehydrogenase [z]: btcoa + fad <==>b2coa + Fatty Acid Degradation EC-1.3.99.13 (butanoyl-CoA C4:0CoA) fadh2ACOAD5m_mc acyl-CoA dehydrogenase [z]: fad + ptcoa <==> fadh2 + FattyAcid Degradation EC-1.3.99.13 (pentanoyl-CoA) pt2coa ACOAD6m_mc acyl-CoAdehydrogenase [z]: fad + hxcoa <==> fadh2 + Fatty Acid DegradationEC-1.3.99.13 (hexanoyl-CoA C8:0CoA) hx2coa ACOAD7m_mc acyl-CoAdehydrogenase [z]: fad + hpcoa <==> fadh2 + Fatty Acid DegradationEC-1.3.99.13 (heptanoyl-CoA) hp2coa ACOAD8m_mc acyl-CoA dehydrogenase[z]: fad + occoa <==> fadh2 + Fatty Acid Degradation EC-1.3.99.13(octanoyl-CoA C8:0CoA) oc2coa ACOAD9m_mc acyl-CoA dehydrogenase [z]:fad + nncoa <==> fadh2 + Fatty Acid Degradation EC-1.3.99.13(nonanoyl-CoA) nn2coa CRNDST_mc carnitine [y]: crn + dcsacoa --> coa +Fatty Acid Degradation EC-2.3.1.21 docosanoyltransferase, dcsacrnmyocyte CRNDSTp_mc carnitine coa[w] + dcsacrn[y] <==> crn[y] + FattyAcid Degradation docosanoyltransferase II, dcsacoa[w] myocyte CRNDT_mccarnitine [y]: crn + ddcoa <==> coa + ddcrn Fatty Acid DegradationEC-2.3.1.21 dodecanoyltransferase, myocyte CRNDTm_mc carnitine coa[z] +ddcrn[y] <==> crn[y] + Fatty Acid Degradation dodecanoyltransferase II,ddcoa[z] myocyte CRNET_mc carnitine [y]: crn + ecsacoa <==> coa + FattyAcid Degradation EC-2.3.1.21 eicosanoyltransferase, ecsacrn myocyteCRNETm_mc carnitine coa[z] + ecsacrn[y] <==> crn[y] + Fatty AcidDegradation eicosanoyltransferase II, ecsacoa[z] myocyte CRNETp_mccarnitine coa[w] + ecsacrn[y] <==> crn[y] + Fatty Acid Degradationeicosanoyltransferase II, ecsacoa[w] myocyte CRNODET_mc carnitine 9-cis-[y]: crn + odecoa9 <==> coa + Fatty Acid Degradation EC-2.3.1.21octadecenoyltransferase, odecrn9 myocyte CRNOT_mc carnitine [y]: crn +strcoa <==> coa + strcrn Fatty Acid Degradation EC-2.3.1.21octadecanoyltransferase, myocyte CRNOTm_mc carnitine coa[z] + strcrn[y]<==> crn[y] + Fatty Acid Degradation octadecanoyltransferase strcoa[z]II, myocyte CRNPTDT_mc carnitine [y]: crn + pdcoa <==> coa + pdcrn FattyAcid Degradation EC-2.3.1.21 pentadecanoyltransferase, myocyte CRNPT_mccarnitine O- [y]: crn + pmtcoa --> coa + pmtcrn Fatty Acid DegradationEC-2.3.1.21 palmitoyltransferase, myocyte CRNPTm_mc carnitine O-coa[z] + pmtcrn[y] --> crn[y] + Fatty Acid Degradationpalmitoyltransferase II, pmtcoa[z] myocyte CRNTT_mc carnitine [y]: crn +tdcoa <==> coa + tdcrn Fatty Acid Degradation EC-2.3.1.21tetradecanoyltransferase, myocyte CRNTTm_mc carnitine coa[z] + tdcrn[y]<==> crn[y] + Fatty Acid Degradation tetradecanoyltransferase tdcoa[z]II, myocyte DDCIm_mc dodecenoyl-CoA D- [z]: cis-dd2coa <==> trans-dd2coaFatty Acid Degradation EC-5.3.3.8 isomerase, myocyte mitochondrialECOAH10m_mc 3-hydroxyacyl-CoA [z]: 3hdcoa <==> dc2coa + h2o Fatty AcidDegradation EC-4.2.1.17 dehydratase (3- hydroxydecanoyl-CoA) ECOAH11m_mc3-hydroxyacyl-CoA [z]: 3hedcoa <==> ed2coa + h2o Fatty Acid DegradationEC-4.2.1.17 dehydratase (3- hydroxyendecanoyl-CoA) ECOAH12m_mc3-hydroxyacyl-CoA [z]: 3hddcoa <==> h2o + trans- Fatty Acid DegradationEC-4.2.1.17 dehydratase (3- dd2coa hydroxydodecanoyl-CoA) ECOAH13m_mc3-hydroxyacyl-CoA [z]: 3htrdcoa <==> h2o + trd2coa Fatty AcidDegradation EC-4.2.1.17 dehydratase (3- hydroxytridecanoyl-CoA)ECOAH145m_mc 3-hydroxyacyl-CoA [z]: 3htdecoa5 <==> h2o + Fatty AcidDegradation EC-4.2.1.17 dehydratase (3- tde2coa5 hydroxytetradecenoyl-CoA, C14:1CoA, n-5) ECOAH14m_mc 3-hydroxyacyl-CoA [z]: 3htdcoa <==>h2o + td2coa Fatty Acid Degradation EC-4.2.1.17 dehydratase (3-hydroxytetradecanoyl- CoA) ECOAH15m_mc 3-hydroxyacyl-CoA [z]: 3hpdcoa<==> h2o + pd2coa Fatty Acid Degradation EC-4.2.1.17 dehydratase (3-hydroxypentadecanoyl- CoA) ECOAH167m_mc 3-hydroxyacyl-CoA [z]: 3hhdecoa7<==> h2o + Fatty Acid Degradation EC-4.2.1.17 dehydratase (3- hde2coa7hydroxyhexadecenoyl- CoA, C16:1CoA, n-7) ECOAH16m_mc 3-hydroxyacyl-CoA[z]: 3hhdcoa <==> h2o + hdd2coa Fatty Acid Degradation EC-4.2.1.17dehydratase (3- hydroxyhexadecanoyl- CoA) ECOAH189m_mc 3-hydroxyacyl-CoA[z]: 3hodecoa9 <==> h2o + Fatty Acid Degradation EC-4.2.1.17 dehydratase(3- ode2coa9 hydroxyoctadecenoyl-CoA, C18:1CoA, n-9) ECOAH18m_mc3-hydroxyacyl-CoA [z]: 3hodcoa <==> h2o + od2coa Fatty Acid DegradationEC-4.2.1.17 dehydratase (3- hydroxyoctadecanoyl-CoA, C18:0CoA)ECOAH20m_mc 3-hydroxyacyl-CoA [z]: 3hescoa <==> es2coa + h2o Fatty AcidDegradation EC-4.2.1.17 dehydratase (3- hydroxyeicosanoyl-CoA, C18:0CoA)ECOAH22p_mc 3-hydroxyacyl-CoA [w]: 3hdscoa <==> ds2coa + h2o Fatty AcidDegradation EC-4.2.1.17 dehydratase (3- hydroxydocosanoyl-CoA, C18:0CoA)ECOAH4m_mc 3-hydroxyacyl-CoA [z]: 3hbycoa <==> b2coa + h2o Fatty AcidDegradation EC-4.2.1.17 dehydratase (3- hydroxybutanoyl-CoA) ECOAH5m_mc3-hydroxyacyl-CoA [z]: 3hptcoa <==> h2o + pt2coa Fatty Acid DegradationEC-4.2.1.17 dehydratase (3- hydroxypentanoyl-CoA) ECOAH6m_mc3-hydroxyacyl-CoA [z]: 3hhcoa <==> h2o + hx2coa Fatty Acid DegradationEC-4.2.1.17 dehydratase (3- hydroxyhexanoyl-CoA) ECOAH7m_mc3-hydroxyacyl-CoA [z]: 3hhpcoa <==> h2o + hp2coa Fatty Acid DegradationEC-4.2.1.17 dehydratase (3- hydroxyheptanoyl-CoA) ECOAH8m_mc3-hydroxyacyl-CoA [z]: 3hocoa <==> h2o + oc2coa Fatty Acid DegradationEC-4.2.1.17 dehydratase (3- hydroxyoctanoyl-CoA) ECOAH9m_mc3-hydroxyacyl-CoA [z]: 3hnncoa <==> h2o + nn2coa Fatty Acid DegradationEC-4.2.1.17 dehydratase (3- hydroxynonanoyl-CoA) HACD10m_mc3-hydroxyacyl-CoA [z]: 3odcoa + h + nadh <==> Fatty Acid DegradationEC-1.1.1.35 dehydrogenase (3- 3hdcoa + nad oxodecanoyl-CoA) HACD11m_mc3-hydroxyacyl-CoA [z]: 3oedcoa + h + nadh <==> Fatty Acid DegradationEC-1.1.1.35 dehydrogenase (3- 3hedcoa + nad oxoendecanoyl-CoA)HACD12m_mc 3-hydroxyacyl-CoA [z]: 3oddcoa + h + nadh <==> Fatty AcidDegradation EC-1.1.1.35 dehydrogenase (3- 3hddcoa + nadoxododecanoyl-CoA) HACD13m_mc 3-hydroxyacyl-CoA [z]: 3otrdcoa + h + nadh<==> Fatty Acid Degradation EC-1.1.1.35 dehydrogenase (3- 3htrdcoa + nadoxotridecanoyl-CoA) HACD145m_mc 3-hydroxyacyl-CoA [z]: 3otdecoa5 + h +nadh <==> Fatty Acid Degradation EC-1.1.1.35 dehydrogenase (3-3htdecoa5 + nad oxotetradecenoyl-CoA C14:1CoA, n-5) HACD14m_mc3-hydroxyacyl-CoA [z]: 3otdcoa + h + nadh <==> Fatty Acid DegradationEC-1.1.1.35 dehydrogenase (3- 3htdcoa + nad oxotetradecanoyl-CoA)HACD15m_mc 3-hydroxyacyl-CoA [z]: 3opdcoa + h + nadh <==> Fatty AcidDegradation EC-1.1.1.35 dehydrogenase (3- 3hpdcoa + nadoxopentadecanoyl-CoA) HACD167m_mc 3-hydroxyacyl-CoA [z]: 3ohdecoa7 + h +nadh <==> Fatty Acid Degradation EC-1.1.1.35 dehydrogenase (3-3hhdecoa7 + nad oxohexadecenoyl-CoA C16:1CoA, n-7) HACD16m_mc3-hydroxyacyl-CoA [z]: 3ohdcoa + h + nadh <==> Fatty Acid DegradationEC-1.1.1.35 dehydrogenase (3- 3hhdcoa + nad oxohexadecanoyl-CoA)HACD189m_mc 3-hydroxyacyl-CoA [z]: 3oodcecoa9 + h + nadh <==> Fatty AcidDegradation EC-1.1.1.35 dehydrogenase (3- 3hodecoa9 + nadoxooctadecenoyl-CoA C18:1CoA, n-9) HACD18m_mc 3-hydroxyacyl-CoA [z]:3oodcoa + h + nadh <==> Fatty Acid Degradation EC-1.1.1.35 dehydrogenase(3- 3hodcoa + nad oxooctadecanoyl-CoA C18:0CoA) HACD20m_mc3-hydroxyacyl-CoA [z]: 3oescoa + h + nadh <==> Fatty Acid DegradationEC-1.1.1.35 dehydrogenase (3- 3hescoa + nad oxoeicosanoyl-CoA C18:0CoA)HACD22p_mc 3-hydroxyacyl-CoA [z]: 3odscoa + h + nadh <==> Fatty AcidDegradation EC-1.1.1.35 dehydrogenase (3- 3hdscoa + nadoxodocosanoyl-CoA C18:0CoA) HACD4m_mc 3-hydroxyacyl-CoA [z]: aacoa + h +nadh <==> Fatty Acid Degradation EC-1.1.1.35 dehydrogenase (3- 3hbycoa +nad oxobutanoyl-CoA) HACD5m_mc 3-hydroxyacyl-CoA [z]: 3optcoa + h + nadh<==> Fatty Acid Degradation EC-1.1.1.35 dehydrogenase (3- 3hptcoa + nadoxopentanoyl-CoA) HACD6m_mc 3-hydroxyacyl-CoA [z]: 3ohcoa + h + nadh<==> Fatty Acid Degradation EC-1.1.1.35 dehydrogenase (3- 3hhcoa + nadoxohexanoyl-CoA) HACD7m_mc 3-hydroxyacyl-CoA [z]: 3ohpcoa + h + nadh<==> Fatty Acid Degradation EC-1.1.1.35 dehydrogenase (3- 3hhpcoa + nadoxoheptanoyl-CoA) HACD8m_mc 3-hydroxyacyl-CoA [z]: 3oocoa + h + nadh<==> Fatty Acid Degradation EC-1.1.1.35 dehydrogenase (3- 3hocoa + nadoxooctanoyl-CoA) HACD9m_mc 3-hydroxyacyl-CoA [z]: 3onncoa + h + nadh<==> Fatty Acid Degradation EC-1.1.1.35 dehydrogenase (3- 3hnncoa + nadoxononanoyl-CoA) MMEm_mc methylmalonyl-CoA [z]: mmcoa-S <==> mmcoa-RFatty Acid Degradation EC-5.1.99.1 epimerase, myocyte mitochondrialMMMm_mc R-methylmalonyl-CoA [z]: mmcoa-R --> succoa Fatty AcidDegradation EC-5.4.99.2 mutase, myocyte mitochondrial PPCOACm_mcPropionyl-CoA [z]: atp + hco3 + ppcoa --> adp + h + Fatty AcidDegradation EC-6.4.1.3 carboxylase, myocyte mmcoa-S + pi mitochondrialFACOAL120_mc fatty-acid--CoA ligase [y]: atp + coa + ddca <==> amp +Fatty Acid Metabolism EC-6.2.1.3 (dodecanoate, C12:0), ddcoa + ppimyocyte FACOAL140_mc fatty-acid--CoA ligase [y]: atp + coa + ttdca <==>amp + Fatty Acid Metabolism EC-6.2.1.3 (tetradecanoate, C14:0), ppi +tdcoa myocyte FACOAL150_mc fatty-acid--CoA ligase [y]: atp + coa + ptdca<==> amp + Fatty Acid Metabolism EC-6.2.1.3 (pentadecanoate, C15:0),pdcoa + ppi myocyte FACOAL160_mc fatty-acid--CoA ligase [y]: atp + coa +hdca <==> amp + Fatty Acid Metabolism EC-6.2.1.3 (hexadecanoate, C16:0),pmtcoa + ppi myocyte FACOAL180_mc fatty-acid--CoA ligase [y]: atp +coa + ocdca <==> amp + Fatty Acid Metabolism EC-6.2.1.3 (octadecanoate,C28:0), ppi + strcoa myocyte FACOAL181_9_mc fatty-acid--CoA ligase [y]:atp + coa + ocdcea9 <==> Fatty Acid Metabolism EC-6.2.1.3(octadecenoate, C18:1 n- amp + odecoa9 + ppi 9), myocyte FACOAL200_mcfatty-acid--CoA ligase [y]: atp + coa + ecsa <==> amp + Fatty AcidMetabolism EC-6.2.1.3 (eicosanoate, C20:0), ecsacoa + ppi myocyteACCOAC_ac acetyl-CoA carboxylase [a]: accoa + atp + hco3 --> adp + h +Fatty Acid Synthesis EC-6.4.1.2 malcoa + pi AGAT_ac_HS_ub unbalanced1-Acyl- [a]: 1ag3p_HS + (0.00032) Fatty Acid Synthesisglycerol-3-phosphate dcsacoa + (0.00698) ddcoa + acyltransferase,adipocyte (0.00024) dsecoa11 + (0.00056) cytosol, Homo sapiens dsecoa9 +(0.00172) dshcoa3 + specific (0.00163) dspcoa3 + (0.00016) dspcoa6 +(0.00182) ecsacoa + (0.00272) esdcoa6 + (0.00035) esdcoa9 + (0.00148)esecoa11 + (0.00026) esecoa7 + (0.00732) esecoa9 + (0.00036) espcoa3 +(0.00027) estcoa3 + (0.0023) estcoa6 + (0.00027) ettcoa3 + (0.00311)ettcoa6 + (0.02985) hdcoa7 + (0.00582) hdcoa9 + (0.00295) hpdcoa8 +(0.15761) ocdycacoa6 + (0.00499) odcoa3 + (0.00039) odcoa6 + (0.0026)odecoa5 + (0.01831) odecoa7 + (0.39309) odecoa9 + (0.00138) osttcoa6 +(0.00375) pdcoa + (0.24351) pmtcoa + (0.06379) strcoa + (0.03728)tdcoa + (0.00244) tdecoa5 + (0.00037) tdecoa7 --> coa + pa_HSDESAT141_5_ac Myristicoyl-CoA [a]: h + nadph + o2 + tdcoa --> (2) FattyAcid Synthesis EC-1.14.19.1 desaturase (n-C14:0CoA −> h2o + nadp +tdecoa5 C14:1CoA, n-5), adipocyte DESAT141_7_ac Myristicoyl-CoA [a]: h +nadph + o2 + tdcoa --> (2) Fatty Acid Synthesis EC-1.14.19.1 desaturase(n-C14:0CoA −> h2o + nadp + tdecoa7 C14:1CoA, n-7), adipocyteDESAT161_7_ac Palmitoyl-CoA desaturase [a]: h + nadph + o2 + pmtcoa -->Fatty Acid Synthesis EC-1.14.19.1 (n-C16:0CoA −> (2) h2o + hdcoa7 + nadpC16:1CoA, n-7), adipocyte DESAT161_9_ac Palmitoyl-CoA desaturase [a]:h + nadph + o2 + pmtcoa --> Fatty Acid Synthesis EC-1.14.19.1(n-C16:0CoA −> (2) h2o + hdcoa9 + nadp C16:1CoA, n-9), adipocyteDESAT171_8_ac Palmitoyl-CoA desaturase [a]: h + hpdcoa + nadph + o2 -->Fatty Acid Synthesis EC-1.14.19.1 (n-C17:0CoA −> (2) h2o + hpdcoa8 +nadp C17:1CoA, n-8), adipocyte DESAT181_5_ac stearoyl-CoA desaturase[a]: h + nadph + o2 + strcoa --> (2) Fatty Acid Synthesis EC-1.14.19.1(n-C18:0CoA −> h2o + nadp + odecoa5 C18:1CoA, n-5), adipocyteDESAT181_7_ac stearoyl-CoA desaturase [a]: h + nadph + o2 + strcoa -->(2) Fatty Acid Synthesis EC-1.14.19.1 (n-C18:0CoA −> h2o + nadp +odecoa7 C18:1CoA, n-7), adipocyte DESAT181_9_ac stearoyl-CoA desaturase[a]: h + nadph + o2 + strcoa --> (2) Fatty Acid Synthesis EC-1.14.19.1(n-C18:0CoA −> h2o + nadp + odecoa9 C18:1CoA, n-9), adipocyteDESAT201_11_ac stearoyl-CoA desaturase [a]: ecsacoa + h + nadph + o2 -->Fatty Acid Synthesis EC-1.14.19.1 (n-C20:0CoA −> esecoa11 + (2) h2o +nadp C20:1CoA, n-11), adipocyte DESAT201_7_ac stearoyl-CoA desaturase[a]: ecsacoa + h + nadph + o2 --> Fatty Acid Synthesis EC-1.14.19.1(n-C20:0CoA −> esecoa7 + (2) h2o + nadp C20:1CoA, n-7), adipocyteDESAT201_9_ac stearoyl-CoA desaturase [a]: ecsacoa + h + nadph + o2 -->Fatty Acid Synthesis EC-1.14.19.1 (n-C20:0CoA −> esecoa9 + (2) h2o +nadp C20:1CoA, n-9), adipocyte DESAT202_9_ac stearoyl-CoA desaturase[a]: ecsacoa + (2) h + (2) nadph + Fatty Acid Synthesis EC-1.14.19.1(lumped: n-C20:0CoA −> (2) o2 --> esdcoa9 + (4) h2o + (2) C20:2CoA,n-9), adipocyte nadp DESAT221_11_ac stearoyl-CoA desaturase [a]:dcsacoa + h + nadph + o2 --> Fatty Acid Synthesis EC-1.14.19.1(n-C22:0CoA −> dsecoa11 + (2) h2o + nadp C22:1CoA, n-11), adipocyteDESAT221_9_ac stearoyl-CoA desaturase [a]: dcsacoa + h + nadph + o2 -->Fatty Acid Synthesis EC-1.14.19.1 (n-C22:0CoA −> dsecoa9 + (2) h2o +nadp C22:1CoA, n-9), adipocyte FACOAL120_ac fatty-acid--CoA ligase [a]:atp + coa + ddca <==> amp + Fatty Acid Synthesis EC-6.2.1.3(dodecanoate, C12:0), ddcoa + ppi adipocyte FACOAL140_ac fatty-acid--CoAligase [a]: atp + coa + ttdca <==> amp + Fatty Acid Synthesis EC-6.2.1.3(tetradecanoate, C14:0), ppi + tdcoa adipocyte FACOAL141_5_acfatty-acid--CoA ligase [a]: atp + coa + ttdcea5 <==> amp + Fatty AcidSynthesis EC-6.2.1.3 (tetradecenoate, C14:1 n- ppi + tdecoa5 5),adipocyte FACOAL141_7_ac fatty-acid--CoA ligase [a]: atp + coa + ttdcea7<==> amp + Fatty Acid Synthesis EC-6.2.1.3 (tetradecenoate, C14:1 n-ppi + tdecoa7 7), adipocyte FACOAL150_ac fatty-acid--CoA ligase [a]:atp + coa + ptdca <==> amp + Fatty Acid Synthesis EC-6.2.1.3(heptadecanoate, C15:0), pdcoa + ppi adipocyte FACOAL160_acfatty-acid--CoA ligase [a]: atp + coa + hdca <==> amp + Fatty AcidSynthesis EC-6.2.1.3 (hexadecanoate, C16:0), pmtcoa + ppi adipocyteFACOAL161_7_ac fatty-acid--CoA ligase [a]: atp + coa + hdcea7 <==> amp +Fatty Acid Synthesis EC-6.2.1.3 (hexadecenoate, C16:1 n- hdcoa7 + ppi7), adipocyte FACOAL161_9_ac fatty-acid--CoA ligase [a]: atp + coa +hdcea9 <==> amp + Fatty Acid Synthesis EC-6.2.1.3 (hexadecenoate, C16:1n- hdcoa9 + ppi 9), adipocyte FACOAL170_ac fatty-acid--CoA ligase [a]:atp + coa + hpdca <==> amp + Fatty Acid Synthesis EC-6.2.1.3(heptadecanoate, C17:0), hpdcoa + ppi adipocyte FACOAL171_8_acfatty-acid--CoA ligase [a]: atp + coa + hpdcea8 <==> Fatty AcidSynthesis EC-6.2.1.3 (heptadecenoate, C17:1 n- amp + hpdcoa8 + ppi 8),adipocyte FACOAL180_ac fatty-acid--CoA ligase [a]: atp + coa + ocdca<==> amp + Fatty Acid Synthesis EC-6.2.1.3 (octadecanoate, C18:0), ppi +strcoa adipocyte FACOAL181_5_ac fatty-acid--CoA ligase [a]: atp + coa +ocdcea5 <==> Fatty Acid Synthesis EC-6.2.1.3 (octadecenoate, C18:1 n-amp + odecoa5 + ppi 5), adipocyte FACOAL181_7_ac fatty-acid--CoA ligase[a]: atp + coa + ocdcea7 <==> Fatty Acid Synthesis EC-6.2.1.3(octadecenoate, C18:1 n- amp + odecoa7 + ppi 7), adipocyteFACOAL181_9_ac fatty-acid--CoA ligase [a]: atp + coa + ocdcea9 <==>Fatty Acid Synthesis EC-6.2.1.3 (octadecenoate, C18:1 n- amp + odecoa9 +ppi 9), adipocyte FACOAL182_6_ac fatty-acid--CoA ligase [a]: atp + coa +ocddea6 <==> Fatty Acid Synthesis EC-6.2.1.3 (octadecadienoate, C18:2amp + ocdycacoa6 + ppi n-6), adipocyte FACOAL183_3_ac fatty-acid--CoAligase [a]: atp + coa + ocdctra3 <==> Fatty Acid Synthesis EC-6.2.1.3(octadecadienoate, C18:3 amp + odcoa3 + ppi n-3), adipocyteFACOAL183_6_ac fatty-acid--CoA ligase [a]: atp + coa + ocdctra6 <==>Fatty Acid Synthesis EC-6.2.1.3 (octadecadienoate, C18:3 amp + odcoa6 +ppi n-6), adipocyte FACOAL200_ac fatty-acid--CoA ligase [a]: atp + coa +ecsa <==> amp + Fatty Acid Synthesis EC-6.2.1.3 (eicosanoate, C20:0),ecsacoa + ppi adipocyte FACOAL201_11_ac fatty-acid--CoA ligase [a]:atp + coa + ecsea11 <==> Fatty Acid Synthesis EC-6.2.1.3 (eicosenoate,C20:1 n-11), amp + esecoa11 + ppi adipocyte FACOAL201_7_acfatty-acid--CoA ligase [a]: atp + coa + ecsea7 <==> amp + Fatty AcidSynthesis EC-6.2.1.3 (eicosenoate, C20:1 n-7), esecoa7 + ppi adipocyteFACOAL201_9_ac fatty-acid--CoA ligase [a]: atp + coa + ecsea9 <==> amp +Fatty Acid Synthesis EC-6.2.1.3 (eicosenoate, C20:1 n-9), esecoa9 + ppiadipocyte FACOAL202_6_ac fatty-acid--CoA ligase [a]: atp + coa + ecsdea6<==> Fatty Acid Synthesis EC-6.2.1.3 (eicosadienoate, C20:2 n- amp +esdcoa6 + ppi 6), adipocyte FACOAL202_9_ac fatty-acid--CoA ligase [a]:atp + coa + ecsdea9 <==> Fatty Acid Synthesis EC-6.2.1.3(eicosadienoate, C20:2 n- amp + esdcoa9 + ppi 9), adipocyteFACOAL203_3_ac fatty-acid--CoA ligase [a]: atp + coa + ecstea3 <==>amp + Fatty Acid Synthesis EC-6.2.1.3 (eicosatrienoate, C20:3 n-estcoa3 + ppi 6), adipocyte FACOAL203_6_ac fatty-acid--CoA ligase [a]:atp + coa + ecstea6 <==> amp + Fatty Acid Synthesis EC-6.2.1.3(eicosatrienoate, C20:3 n- estcoa6 + ppi 6), adipocyte FACOAL204_3_acfatty-acid--CoA ligase [a]: atp + coa + ecsttea3 <==> Fatty AcidSynthesis EC-6.2.1.3 (eicosatetraenoate, C20:4 amp + ettcoa3 + ppi n-3),adipocyte FACOAL204_6_ac fatty-acid--CoA ligase [a]: atp + coa +ecsttea6 <==> Fatty Acid Synthesis EC-6.2.1.3 (eicosatetraenoate, C20:4amp + ettcoa6 + ppi n-6), adipocyte FACOAL205_3_ac fatty-acid--CoAligase [a]: atp + coa + ecspea3 <==> Fatty Acid Synthesis EC-6.2.1.3(eicosapentaenoate, amp + espcoa3 + ppi C20:5 n-3), adipocyteFACOAL220_ac fatty-acid--CoA ligase [a]: atp + coa + dcsa <==> amp +Fatty Acid Synthesis EC-6.2.1.3 (docosanoate, C22:0), dcsacoa + ppiadipocyte FACOAL221_11_ac fatty-acid--CoA ligase [a]: atp + coa +dcsea11 <==> Fatty Acid Synthesis EC-6.2.1.3 (docosenoate, C22:1 n-amp + dsecoa11 + ppi 11), adipocyte FACOAL221_9_ac fatty-acid--CoAligase [a]: atp + coa + dcsea9 <==> amp + Fatty Acid SynthesisEC-6.2.1.3 (docosenoate, C22:1 n-9), dsecoa9 + ppi adipocyteFACOAL224_6_ac fatty-acid--CoA ligase [a]: atp + coa + ocsttea6 <==>Fatty Acid Synthesis EC-6.2.1.3 (ocosatetraenoate, C22:4 amp +osttcoa6 + ppi n-6), adipocyte FACOAL225_3_ac fatty-acid--CoA ligase[a]: atp + coa + dcspea3 <==> Fatty Acid Synthesis EC-6.2.1.3(docosapentaenoate, amp + dspcoa3 + ppi C22:5 n-3), adipocyteFACOAL225_6_ac fatty-acid--CoA ligase [a]: atp + coa + dcspea6 <==>Fatty Acid Synthesis EC-6.2.1.3 (docosapentaenoate, amp + dspcoa6 + ppiC22:5 n-6), adipocyte FACOAL226_6_ac fatty-acid--CoA ligase [a]: atp +coa + dcshea3 <==> Fatty Acid Synthesis EC-6.2.1.3 (docosahexaenoate,amp + dshcoa3 + ppi C22:6 n-6), adipocyte FAS100_ac fatty acid synthase(n- [a]: (3) h + malcoa + (2) nadph + Fatty Acid Synthesis EC-2.3.1.85C10:0), adipocyte octa --> co2 + coa + dca + h2o + (2) nadp FAS120_acfatty acid synthase (n- [a]: dca + (3) h + malcoa + (2) Fatty AcidSynthesis EC-2.3.1.85 C12:0), adipocyte nadph --> co2 + coa + ddca +h2o + (2) nadp FAS140_ac fatty acid synthase (n- [a]: ddca + (3) h +malcoa + (2) Fatty Acid Synthesis EC-2.3.1.85 C14:0), adipocyte nadph--> co2 + coa + h2o + (2) nadp + ttdca FAS150_ac fatty acid synthase[a]: (17) h + (6) malcoa + (12) Fatty Acid Synthesis (C15:0), adipocytecytosol nadph + ppcoa --> (6) co2 + (7) coa + (5) h2o + (12) nadp +ptdca FAS160_ac fatty acid synthase (n- [a]: (3) h + malcoa + (2)nadph + Fatty Acid Synthesis EC-2.3.1.85 C16:0), adipocyte ttdca -->co2 + coa + h2o + hdca + (2) nadp FAS170_ac fatty acid synthase [a]: (3)h + malcoa + (2) nadph + Fatty Acid Synthesis (C17:0), adipocyte cytosolptdca --> co2 + coa + h2o + hpdca + (2) nadp FAS180_ac fatty acidsynthase (n- [a]: (3) h + hdca + malcoa + (2) Fatty Acid SynthesisEC-2.3.1.85 C18:0), adipocyte nadph --> co2 + coa + h2o + (2) nadp +ocdca FAS200_ac fatty acid synthase (n- [a]: (3) h + malcoa + (2)nadph + Fatty Acid Synthesis EC-2.3.1.85 C20:0), adipocyte ocdca -->co2 + coa + ecsa + h2o + (2) nadp FAS220_ac fatty acid synthase (n- [a]:ecsa + (3) h + malcoa + (2) Fatty Acid Synthesis EC-2.3.1.85 C22:0),adipocyte nadph --> co2 + coa + dcsa + h2o + (2) nadp FAS80_L_ac fattyacid synthase (n- [a]: accoa + (8) h + (3) malcoa + Fatty Acid SynthesisEC-2.3.1.85 C8:0), lumped reaction, (6) nadph --> (3) co2 + (4) coa +adipocyte (2) h2o + (6) nadp + octa GAT1_ac_HS_ub unbalanced glycerol 3-[a]: (0.00032) dcsacoa + Fatty Acid Synthesis phosphate acyltransferase(0.00698) ddcoa + (0.00024) (glycerol 3-phosphate), dsecoa11 + (0.00056)dsecoa9 + adipocyte cytosol, Homo (0.00172) dshcoa3 + (0.00163) sapiensspecific dspcoa3 + (0.00016) dspcoa6 + (0.00182) ecsacoa + (0.00272)esdcoa6 + (0.00035) esdcoa9 + (0.00148) esecoa11 + (0.00026) esecoa7 +(0.00732) esecoa9 + (0.00036) espcoa3 + (0.00027) estcoa3 + (0.0023)estcoa6 + (0.00027) ettcoa3 + (0.00311) ettcoa6 + glyc3p + (0.02985)hdcoa7 + (0.00582) hdcoa9 + (0.00295) hpdcoa8 + (0.15761) ocdycacoa6 +(0.00499) odcoa3 + (0.00039) odcoa6 + (0.0026) odecoa5 + (0.01831)odecoa7 + (0.39309) odecoa9 + (0.00138) osttcoa6 + (0.00375) pdcoa +(0.24351) pmtcoa + (0.06379) strcoa + (0.03728) tdcoa + (0.00244)tdecoa5 + (0.00037) tdecoa7 --> 1ag3p_HS + coa 12DGRH_ac_HS_ubunbalanced diacylglycerol [a]: 12dgr_HS + h2o --> (0.00032) TriglycerolDegradation EC-3.1.1.3 hydrolase, adipocyte dcsa + (0.00024) dcsea11 +cytosol, Homo sapiens (0.00056) dcsea9 + (0.00172) specific dcshea3 +(0.00163) dcspea3 + (0.00016) dcspea6 + (0.00698) ddca + (0.00182)ecsa + (0.00272) ecsdea6 + (0.00035) ecsdea9 + (0.00148) ecsea11 +(0.00026) ecsea7 + (0.00732) ecsea9 + (0.00036) ecspea3 + (0.00027)ecstea3 + (0.0023) ecstea6 + (0.00027) ecsttea3 + (0.00311) ecsttea6 +h + (0.24351) hdca + (0.02985) hdcea7 + (0.00582) hdcea9 + (0.00295)hpdcea8 + mglyc_HS + (0.06379) ocdca + (0.0026) ocdcea5 + (0.01831)ocdcea7 + (0.39309) ocdcea9 + (0.00499) ocdctra3 + (0.00039) ocdctra6 +(0.15761) ocddea6 + (0.00138) ocsttea6 + (0.00375) ptdca + (0.03728)ttdca + (0.00244) ttdcea5 + (0.00037) ttdcea7 MGLYCH_ac_HS_ub unbalancedmonoglycerol [a]: h2o + mglyc_HS --> (0.00032) Triglycerol DegradationEC-3.1.1.3 hydrolase, adipocyte dcsa + (0.00024) dcsea11 + cytosol, Homosapiens (0.00056) dcsea9 + (0.00172) specific dcshea3 + (0.00163)dcspea3 + (0.00016) dcspea6 + (0.00698) ddca + (0.00182) ecsa +(0.00272) ecsdea6 + (0.00035) ecsdea9 + (0.00148) ecsea11 + (0.00026)ecsea7 + (0.00732) ecsea9 + (0.00036) ecspea3 + (0.00027) ecstea3 +(0.0023) ecstea6 + (0.00027) ecsttea3 + (0.00311) ecsttea6 + glyc + h +(0.24351) hdca + (0.02985) hdcea7 + (0.00582) hdcea9 + (0.00295)hpdcea8 + (0.06379) ocdca + (0.0026) ocdcea5 + (0.01831) ocdcea7 +(0.39309) ocdcea9 + (0.00499) ocdctra3 + (0.00039) ocdctra6 + (0.15761)ocddea6 + (0.00138) ocsttea6 + (0.00375) ptdca + (0.03728) ttdca +(0.00244) ttdcea5 + (0.00037) ttdcea7 TRIGH_ac_HS_ub unbalancedtriacylglycerol [a]: h2o + triglyc_HS --> Triglycerol DegradationEC-3.1.1.3 hydrolase, adipocyte 12dgr_HS + cytosol, Homo sapiens(0.00032) dcsa + (0.00024) specific dcsea11 + (0.00056) dcsea9 +(0.00172) dcshea3 + (0.00163) dcspea3 + (0.00016) dcspea6 + (0.00698)ddca + (0.00182) ecsa + (0.00272) ecsdea6 + (0.00035) ecsdea9 +(0.00148) ecsea11 + (0.00026) ecsea7 + (0.00732) ecsea9 + (0.00036)ecspea3 + (0.00027) ecstea3 + (0.0023) ecstea6 + (0.00027) ecsttea3 +(0.00311) ecsttea6 + h + (0.24351) hdca + (0.02985) hdcea7 + (0.00582)hdcea9 + (0.00295) hpdcea8 + (0.06379) ocdca + (0.0026) ocdcea5 +(0.01831) ocdcea7 + (0.39309) ocdcea9 + (0.00499) ocdctra3 + (0.00039)ocdctra6 + (0.15761) ocddea6 + (0.00138) ocsttea6 + (0.00375) ptdca +(0.03728) ttdca + (0.00244) ttdcea5 + (0.00037) ttdcea7 DAGPYP_ac_HS_ubunbalanced diacylglycerol [a]: h2o + pa_HS --> 12dgr_HS + TriglycerolSynthesis EC-3.1.3.4 pyrophosphate pi phosphatase, adipocyte cytosol,Homo sapiens specific TRIGS_ac_HS_ub unbalanced triglycerol [a]:12dgr_HS + (0.00032) Triglycerol Synthesis synthesis, adipocytedcsacoa + (0.00698) ddcoa + cytosol, Homo sapiens (0.00024) dsecoa11 +(0.00056) specific dsecoa9 + (0.00172) dshcoa3 + (0.00163) dspcoa3 +(0.00016) dspcoa6 + (0.00182) ecsacoa + (0.00272) esdcoa6 + (0.00035)esdcoa9 + (0.00148) esecoa11 + (0.00026) esecoa7 + (0.00732) esecoa9 +(0.00036) espcoa3 + (0.00027) estcoa3 + (0.0023) estcoa6 + (0.00027)ettcoa3 + (0.00311) ettcoa6 + (0.02985) hdcoa7 + (0.00582) hdcoa9 +(0.00295) hpdcoa8 + (0.15761) ocdycacoa6 + (0.00499) odcoa3 + (0.00039)odcoa6 + (0.0026) odecoa5 + (0.01831) odecoa7 + (0.39309) odecoa9 +(0.00138) osttcoa6 + (0.00375) pdcoa + (0.24351) pmtcoa + (0.06379)strcoa + (0.03728) tdcoa + (0.00244) tdecoa5 + (0.00037) tdecoa7 -->coa + triglyc_HS NDPK1_ac nucleoside-diphosphate [a]: atp + gdp <==>adp + gtp Nucleotide Metabolism EC-2.7.4.6 kinase (ATP:GDP) NDPK1_mcnucleoside-diphosphate [y]: atp + gdp <==> adp + gtp NucleotideMetabolism EC-2.7.4.6 kinase (ATP:GDP) ADK1_mc adenylate kinase, myocyte[y]: amp + atp <==> (2) adp Nucleotide Salvage EC-2.7.4.3 cytosolicPathways NTPP6m_ac Nucleoside triphosphate [b]: atp + h2o --> amp + h +ppi Nucleotide Salvage pyrophosphorylase (atp), Pathways adipocytemitochondrial ADK1_ac adenylate kinase, [a]: amp + atp <==> (2) adpNucleotide Savage EC-2.7.4.3 adipocyte cytosolic Pathway CAT_accatalase, adipocyte [a]: (2) h2o2 --> (2) h2o + o2 Other EC-1.11.1.6cytosolic HCO3E_ac carbonate dehydratase [a]: co2 + h2o <==> h + hco3Other EC-4.2.1.1 (HCO3 equilibration reaction), adipocyte cytosolicHCO3E_mc carbonate dehydratase [y]: co2 + h2o <==> h + hco3 OtherEC-4.2.1.1 (HCO3 equilibration reaction), myocyte cytosolic HCO3Eicarbonate dehydratase [i]: co2 + h2o <==> h + hco3 Other EC-4.2.1.1(HCO3 equilibration reaction), intra-organism NH4DIS_ac nh4 Dissociation[a]: nh4 <==> h + nh3 Other CONTRACTION_mc muscle contraction, [y]:myoactinADPPi --> adp + Contraction myocyte cytosol myoactin + piMYOADPPIA_mc myosin-ADP-Pi [y]: actin + myosinADPPi --> Contractionattachment, myocyte myoactinADPPi cytosol MYOSINATPB_mc mysosin ATPbinding, [y]: atp + myoactin --> actin + Contraction myocyte cytosolmyosinATP MYOSINATPH_mc myosin-ATP hydrolysis, [y]: h2o + myosinATP -->h + Contraction myocyte cytosol myosinADPPi CREATt2is_mc Creatine Na+symporter, creat[i] + na1[c] <==> creat[y] + Transport myocyte cytosolna1[y] CRTNtis_mc creatinine transport, crtn[i] <==> crtn[y] Transportmyocyte cytosol Clt_xo chlorideion transport out cl[e] --> cl[i]Transport via diffusion DCSAtis_ac docosanoate (C22:0) dcsa[a] -->dcsa[i] Transport adipocyte transport DCSEA11tis_ac docosenoate (C22:1,n-11) dcsea11[a] --> dcsea11[i] Transport adipocyte transportDCSEA9tis_ac docosenoate (C22:1, n-9) dcsea9[a] --> dcsea9[i] Transportadipocyte transport DCSHEA3t docosahexaenoate dcshea3[e] <==> dcshea3[i]Transport (C22:6, n-3) transport DCSHEA3tis_ac docosahexaenoatedcshea3[i] <==> dcshea3[a] Transport (C22:6, n-3) adipocyte transportDCSPEA3t Docosapentaenoate dcspea3[e] <==> dcspea3[i] Transport (C22:5,n-3) transport DCSPEA3tis_ac Docosapentaenoate dcspea3[i] <==>dcspea3[a] Transport (C22:5, n-3) adipocyte transport DCSPEA6tDocosapentaenoate dcspea6[e] <==> dcspea6[i] Transport (C22:5, n-6)transport DCSPEA6tis_ac Docosapentaenoate dcspea6[i] <==> dcspea6[a]Transport (C22:5, n-6) adipocyte transport DDCAtis_ac dodecanoate(C12:0) ddca[a] --> ddca[i] Transport adipocyte transport DDCAtis_mcdodecanoate (C12:0) ddca[i] --> ddca[y] Transport myocyte transportECSAtis_ac eicosanoate (C20:0) ecsa[a] --> ecsa[i] Transport adipocytetransport ECSDEA6t Eicosadienoate (C20:2, n- ecsdea6[e] <==> ecsdea6[i]Transport 6) transport ECSDEA6tis_ac Eicosadienoate (C20:2, n-ecsdea6[i] <==> ecsdea6[a] Transport 6) adipocyte transportECSDEA9tis_ac eicosadienoate (C20:2, n- ecsdea9[a] --> ecsdea9[i]Transport 9) adipocyte transport ECSEA11tis_ac eicosenoate (C20:1, n-11)ecsea11[a] --> ecsea11[i] Transport adipocyte transport ECSEA7tis_aceicosenoate (C20:1, n-7) ecsea7[a] --> ecsea7[i] Transport adipocytetransport ECSEA9tis_ac eicosenoate (C20:1, n-9) ecsea9[a] --> ecsea9[i]Transport adipocyte transport ECSFAtis_mc eicosanoate transport (n-ecsa[i] <==> ecsa[y] Transport C20:0) ECSPEA3t Eicosapentaenoateecspea3[e] <==> ecspea3[i] Transport (C20:5, n-3) transportECSPEA3tis_ac Eicosapentaenoate ecspea3[i] <==> ecspea3[a] Transport(C20:5, n-3) adipocyte transport ECSTEA3t Eicosatrienoate (C20:3, n-ecstea3[e] <==> ecstea3[i] Transport 3) transport ECSTEA3tis_acEicosatrienoate (C20:3, n- ecstea3[i] <==> ecstea3[a] Transport 3)adipocyte transport ECSTEA6t Eicosatrienoate (C20:3, n- ecstea6[e] <==>ecstea6[i] Transport 6) transport ECSTEA6tis_ac Eicosatrienoate (C20:3,n- ecstea6[i] <==> ecstea6[a] Transport 6) adipocyte transport ECSTTEA3tEicosatetraenoate (C20:4, ecsttea3[e] <==> ecsttea3[i] Transport n-3)transport ECSTTEA3tis_ac Eicosatetraenoate (C20:4, ecsttea3[i] <==>ecsttea3[a] Transport n-3) adipocyte transport ECSTTEA6tEicosatetraenoate (C20:4, ecsttea6[e] <==> ecsttea6[i] Transport n-6)transport ECSTTEA6tis_ac Eicosatetraenoate (C20:4, ecsttea6[i] <==>ecsttea6[a] Transport n-6) adipocyte transport GLYCt6is_ac glyceroltransport in/out glyc[a] + h[a] <==> glyc[i] + h[i] Transport viasymporter, adipocyte HCO3t2 HCO3 transport out via hco3[e] <==> hco3[i]Transport diffusion HDCAtis_ac hexadecanoate (C16:0) hdca[a] --> hdca[i]Transport adipocyte transport HDCAtis_mc hexadecanoate (C16:0) hdca[i]--> hdca[y] Transport myocyte transport HDCEA7tis_ac hexadecenoate(C16:1, n- hdcea7[a] --> hdcea7[i] Transport 7) adipocyte transportHDCEA9tis_ac hexadecenoate (C16:1, n- hdcea9[a] --> hdcea9[i] Transport9) adipocyte transport HPDCEA8tis_ac heptadecenoate (C17:1, n-hpdcea8[a] --> hpdcea8[i] Transport 8) adipocyte transport ILEtis_acL-isoeucine transport h[i] + ile-L[i] <==> h[a] + ile-L[a] TransportTC-2.A.26 in/out via proton symport, adipocyte NAt sodium transportin/out via h[i] + na1[e] <==> h[e] + na1[i] Transport TC-2.A.36 protonantiport (one H+) NAtis_mc sodium transport in/out via na1[i] <==>na1[y] Transport TC-1.A.15 the non-selective cation channel NH4CLt_xoammonium chloride cl[i] + nh4[i] <==> cl[e] + nh4[e] Transport transportNH4tis_ac ammonia transport via nh4[i] <==> nh4[a] Transport diffusion,adipocyte cytosolic OCDCAtis_ac octadecanoate (C18:0) ocdca[a] -->ocdca[i] Transport adipocyte transport OCDCAtis_mc octadecanoate (C18:0)ocdca[i] --> ocdca[y] Transport myocyte transport OCDCEA5tis_acoctadecenoate (C18:1, n- ocdcea5[a] --> ocdcea5[i] Transport 5)adipocyte transport OCDCEA7tis_ac octadecenoate (C18:1, n- ocdcea7[a]--> ocdcea7[i] Transport 7) adipocyte transport OCDCEA9tis_acoctadecenoate (C18:1, n- ocdcea9[a] --> ocdcea9[i] Transport 9)adipocyte transport OCDCEA9tis_mc octadecenoate (C18:1, n- ocdcea9[i]--> ocdcea9[y] Transport 9) myocyte transport OCDCTRA3tOctadecatrienoate (C18:3, ocdctra3[e] <==> ocdctra3[i] Transport n-3)transport OCDCTRA3tis_ac Octadecatrienoate (C18:3, ocdctra3[i] <==>ocdctra3[a] Transport n-3) adipocyte transport OCDCTRA6tOctadecatrienoate (C18:3, ocdctra6[e] <==> ocdctra6[i] Transport n-6)transport OCDCTRA6tis_ac Octadecatrienoate (C18:3, ocdctra6[i] <==>ocdctra6[a] Transport n-6) adipocyte transport OCDDEA6t Octadecadienoate(C18:2, ocddea6[e] <==> ocddea6[i] Transport n-6) transportOCDDEA6tis_ac Octadecadienoate (C18:2, ocddea6[i] <==> ocddea6[a]Transport n-6) adipocyte transport OCSTTEA6t Ocosatetraenoate (C22:4,ocsttea6[e] <==> ocsttea6[i] Transport n-6) transport OCSTTEA6tis_acOcosatetraenoate (C22:4, ocsttea6[i] <==> ocsttea6[a] Transport n-6)adipocyte transport PIt2_xo phosphate transport in via h[e] + pi[e] <==>h[i] + pi[i] Transport proton symport PTDCAtis_ac pentadecanoate (C15:0)ptdca[a] --> ptdca[i] Transport adipocyte transport PTDCAtis_mcpentadecanoate (C15:0) ptdca[i] --> ptdca[y] Transport myocyte transportTTDCAtis_ac tetradecanoate (C14:0) ttdca[a] --> ttdca[i] Transportadipocyte transport TTDCAtis_mc tetradecanoate (C14:0) ttdca[i] -->ttdcat[y] Transport myocyte transport TTDCEA5tis_ac tetradecenoate(C14:1, n- ttdcea5[a] --> ttdcea5[i] Transport 5) adipocyte transportTTDCEA7tis_ac tetradecenoate (C14:1, n- ttdcea7[a] --> ttdcea7[i]Transport 7) adipocyte transport G6Pter_ac glucose 6-phosphate g6p[a]<==> g6p[f] Transport, adipocyte endoplasmic Endoplasmic Reticularreticular transport via diffusion G6Pter_mc glucose 6-phosphate g6p[y]<==> g6p[u] Transport, myocyte endoplasmic Endoplasmic Reticularreticular transport via diffusion GLCter_ac glucose transport, glc-D[a]<==> glc-D[f] Transport, endoplasmic reticulum Endoplasmic ReticularGLCter_mc glucose transport, glc-D[y] <==> glc-D[u] Transport,endoplasmic reticulum Endoplasmic Reticular CO2t_xo CO2 transport viadiffusion co2[e] <==> co2[i] Transport, Extracellular CO2tis_ac CO2adipocyte transport co2[i] <==> co2[a] Transport, Extracellular out viadiffusion CO2tis_mc CO2 myocyte transport co2[i] <==> co2[y] Transport,Extracellular out via diffusion CRTNt creatinine transport crtn[i] <==>crtn[e] Transport, Extracellular GLCt1_xo glucose transport (uniport:glc-D[e] <==> glc-D[i] Transport, Extracellular facilitated diffusion),intra- organism GLCt1is_ac glucose transport into glc-D[i] <==> glc-D[a]Transport, Extracellular adipocyte (uniport: facilitated diffusion)GLCt1is_mc glucose transport into glc-D[i] <==> glc-D[y] Transport,Extracellular myocyte (uniport: facilitated diffusion) H2Ot5_xo H2Otransport via diffusion h2o[e] <==> h2o[i] Transport, ExtracellularH2Ot5is_ac H2O transport into h2o[i] <==> h2o[a] Transport,Extracellular adipocyte via diffusion H2Ot5is_mc H2O transport intoh2o[i] <==> h2o[y] Transport, Extracellular myocyte via diffusion ILEtL-isoeucine transport h[e] + ile-L[e] <==> h[i] + ile-L[i] Transport,Extracellular TC-2.A.26 in/out via proton symport L-LACt2_xo L-lactatetransport via h[e] + lac-L[e] <==> h[i] + lac-L[i] Transport,Extracellular proton symport L-LACt2is_mc L-lactate reversible h[i] +lac-L[i] <==> h[y] + lac-L[y] Transport, Extracellular transport intomyocyte via proton symport O2t_xo O2 transport via diffusion o2[e] <==>o2[i] Transport, Extracellular O2tis_ac O2 transport into o2[i] <==>o2[a] Transport, Extracellular adipocyte via diffusion O2tis_mc O2transport into myocyte o2[i] <==> o2[y] Transport, Extracellular viadiffusion Plt2_xo [deleted phosphate transport in via h[e] + pi[e] -->h[i] + pi[i] Transport, Extracellular Aug. 26, 2004 proton symport01:34:57 PM] Plt6is_ac phosphate transport in/out h[i] + pi[i] <==>h[a] + pi[a] Transport, Extracellular TC-2.A.20 of adipocyte via protonsymporter PIt6is_mc phosphate transport in/out h[i] + pi[i] <==> h[y] +pi[y] Transport, Extracellular TC-2.A.20 of myocyte via proton symporter3MOPtm_ac 3-Methyl-2-oxopentanoate 3mop[a] <==> 3mop[b] Transport,transport, diffusion, Mitochondrial adipocyte mitochondrial ATP/ADPtm_acATP/ADP transport, adp[a] + atp[b] <==> adp[b] + Transport, adipocytemitochondrial atp[a] Mitochondrial ATP/ADPtm_mc ATP/ADP transport,adp[y] + atp[z] <==> adp[z] + atp[y] Transport, myocyte mitochondrialMitochondrial CITtam_ac citrate transport, adipocyte cit[a] + mal-L[b]<==> cit[b] + mal- Transport, mitochondrial L[a] Mitochondrial CITtam_mccitrate transport, myocyte cit[y] + mal-L[z] <==> cit[z] + mal-Transport, mitochondrial L[y] Mitochondrial CO2tm_ac CO2 transport(diffusion), co2[a] <==> co2[b] Transport, adipocyte mitochondrialMitochondrial CO2tm_mc CO2 transport (diffusion), co2[y] <==> co2[z]Transport, myocyte mitochondrial Mitochondrial CRNCARtm_mccarnithine-acetylcarnithine acrn[y] + crn[z] --> acrn[z] + crn[y]Transport, carrier, myocyte Mitochondrial mitochondrial CRNODETm_mccarnitine 9-cis- coa[z] + odecrn9[y] <==> crn[y] + Transport,octadecenoyltransferase odecoa9[z] Mitochondrial II, myocyte CRNPTDTm_mccarnitine coa[z] + pdcrn[y] <==> crn[y] + Transport,pentadecanoyltransferase pdcoa[z] Mitochondrial II, myocyte DHAP1tm_acdihydroxyacetone dhap[a] <==> dhap[b] Transport, phosphate transport,Mitochondrial adipocyte mitochondrial DHAP1tm_mc dihydroxyacetonedhap[y] <==> dhap[z] Transport, phosphate transport, Mitochondrialmyocyte mitochondrial GACm_ac glutamate aspartate asp-L[b] + glu-L[a] +h[a] --> asp- Transport, carrier, adipocyte L[a] + glu-L[b] + h[b]Mitochondrial cytosolic/mitochondrial GACm_mc glutamate aspartateasp-L[z] + glu-L[y] + h[y] --> asp- Transport, carrier, myocyte L[y] +glu-L[z] + h[z] Mitochondrial cytosolic/mitochondrial GL3Ptm_mcglycerol-3-phosphate glyc3p[y] <==> glyc3p[z] Transport, transport,myocyte Mitochondrial mitochondrial GTPt3m_ac GTP/GDP transporter,gdp[b] + gtp[a] + h[a] --> gdp[a] + Transport, adipocyte mitochondrialgtp[b] + h[b] Mitochondrial GTPt3m_mc GTP/GDP transporter, gdp[z] +gtp[y] + h[y] --> gdp[y] + Transport, myocyte mitochondrial gtp[z] +h[z] Mitochondrial H2Otm_ac H2O transport, adipocyte h2o[a] <==> h2o[b]Transport, mitochondrial Mitochondrial H2Otm_mc H2O transport, myocyteh2o[y] <==> h2o[z] Transport, mitochondrial Mitochondrial MALAKGtm_acmalate-alphaketoglutarate akg[b] + mal-L[a] --> akg[a] + mal- Transport,transporter, adipocyte L[b] Mitochondrial mitochondria MALAKGtm_mcmalate-alphaketoglutarate akg[z] + mal-L[y] --> akg[y] + mal- Transport,transporter, myocyte L[z] Mitochondrial mitochondria O2trm_ac O2transport into o2[a] <==> o2[b] Transport, adipocyte mitochondriaMitochondrial (diffusion) O2trm_mc O2 transport into myocyte o2[y] <==>o2[z] Transport, mitochondria (diffusion) Mitochondrial Pltm_acphosphate transporter, h[a] + pi[a] <==> h[b] + pi[b] Transport,adipocyte mitochondrial Mitochondrial Pltm_mc phosphate transporter,h[y] + pi[y] <==> h[z] + pi[z] Transport, myocyte mitochondrialMitochondrial PPAtm_ac propionate transport in/out h[a] + ppa[a] <==>h[b] + ppa[b] Transport, TC-2.A.20 via proton symport, Mitochondrialadipocyte PYRtm_ac pyruvate transport, h[a] + pyr[a] <==> h[b] + pyr[b]Transport, adipocyte mitochondrial Mitochondrial PYRtm_mc pyruvatetransport, h[y] + pyr[y] <==> h[z] + pyr[z] Transport, myocytemitochondrial Mitochondrial CRNCARtp_mc carnithine-acetylcarnithineacrn[y] + crn[w] <==> acrn[w] + Transport, Peroxisomal carrier, myocytecrn[y] peroxixome

1-60. (canceled)
 61. A computer-implemented method for predicting aphysiological function of single-celled organisms, comprising: (a)providing on a computer a first data structure comprising a firststoichiometric matrix having rows and columns of elements thatcorrespond to stoichiometric coefficients of a plurality of firstreactions from a first single-celled organism, each of said reactionscomprising a reactant identified as a substrate of the reaction and areactant identified as a product of the reaction, stoichiometriccoefficients of the first stoichiometric matrix relating said substrateand said product, wherein at least one reactant in said plurality ofreactants or at least one reaction in said plurality of reactions isannotated with an assignment to a subsystem or compartment; (b)providing on the computer a second data structure comprising a secondstoichiometric matrix having rows and columns of elements thatcorrespond to stoichiometric coefficients of a plurality of secondreactions from a second single-celled organism, each of said reactionscomprising a reactant identified as a substrate of the reaction and areactant identified as a product of the reaction, stoichiometriccoefficients of the second stoichiometric matrix relating said substrateand said product, wherein at least one reactant in said plurality ofreactants or at least one reaction in said plurality of reactions isannotated with an assignment to a subsystem or compartment; (c)providing on the computer a third data structure comprising a thirdstoichiometric matrix or elements in the first or second stoichiometricmatrices having rows and columns of elements that correspond tostoichiometric coefficients of a plurality of intra-system reactionsbetween said first and second single-celled organisms and anintra-cellular system of said first or second single-celled organisms,each of said intra-system reactions comprising a reactant identified asa substrate of the reaction located in one of the first or secondsingle-celled organisms or in the intra-cellular system and a reactantidentified as a product of the reaction located in another of the firstand second single-celled organisms or in the intra-cellular system,stoichiometric coefficients of the third stoichiometric matrix relatingsaid substrate and said product; (d) providing on the computer aconstraint set for said plurality of reactions for said first, secondand third data structures, the constraint set specifying an upper orlower boundary of flux through each of the reactions described in thefirst, second, and third stoichiometric matrices; (e) defining on thecomputer an objective function to be a linear combination of fluxesthrough the reactions described in the first, second, and thirdstoichiometric matrices that optimizes cell growth, reproduction,apoptosis, energy production, production of a hormone or extracellularcomponent, a mechanical property, or maintenance of biomass compositionand growth rate; (f) determining on the computer at least one fluxdistribution for said plurality of first, second and intra-systemreactions across said first single-celled organism, said secondsingle-celled organism, and said intra-cellular system by (i)identifying a plurality of flux vectors that each satisfy thestoichiometric matrix and satisfy the constraint set and (ii)identifying at least one linear combination of the flux vectors thatminimizes or maximizes the objective function; and (g) providing outputto a user of said at least one flux distribution determined in step (f),wherein said at least one flux distribution is predictive of aphysiological function of said first and second single-celled organisms.62. The method of claim 61, wherein said first data structure comprisesa first reaction network.
 63. The method of claim 61, wherein saidsecond data structure comprises a second reaction network.
 64. Themethod of claim 61, wherein said first or second data structurescomprise a plurality of reaction networks.
 65. The method of claim 61,further comprising providing on the computer one or more fourth datastructures comprising one or more fourth stoichiometric matrices and oneor more fourth constraint sets, each fourth data structure relating aplurality of reactants to a plurality of one or more third reactionsfrom one or more third single-celled organisms, each of said reactionscomprising a reactant identified as a substrate of the reaction, areactant identified as a product of the reaction and a stoichiometriccoefficient relating said substrate and said product.
 66. The method ofclaim 65, wherein said one or more fourth data structures comprises aplurality of data structures.
 67. The method of claim 66, wherein saidplurality of data structures comprise a data structure for a pluralityof different single-celled organisms.
 68. The method of 65, wherein saidone or more third single-celled organism comprises at least 4single-celled organisms, 5 single-celled organisms, 6 single-celledorganisms, 7 single-celled organisms, 8 single-celled organisms, 9single-celled organisms, 10 single-celled organisms, 100 single-celledorganisms, 1000 single-celled organisms, 5000 single-celled organisms,10,000 single-celled organisms or more.
 69. The method of claim 61,wherein said first and second single-celled organisms compriseeukaryotic cells.
 70. The method of claim 61, wherein said first andsecond single-celled organisms comprise prokaryotic cells.
 71. Themethod of claim 61, further comprising accessing with the computer agene database having information characterizing an associated gene. 72.The method of claim 61, wherein at least one of said reactions is aregulated reaction.
 73. The method of claim 72, wherein said constraintset includes a variable constraint for said regulated reaction.
 74. Themethod of claim 61, wherein said intra-system reactions comprise areactant or reactions selected from the group consisting of abicarbonate buffer system, an ammonia buffer system, a hormone, asignaling molecule, a vitamin, a mineral or a combination thereof. 75.The method of claim 61, wherein a plurality of reactions is annotated toindicate a plurality of associated genes and wherein said gene databasecomprises information characterizing said plurality of associated genes.